---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Clinical evidence. Covers ONWARD1, ONWARD2, ONWARD3, STRIDE, STRIDE open-label extension, ACTRN12621000011886, and 6 further headings. 396 evidence topics quoted from 52 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 ONWARD1

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Objective and questions in the ClinicalTrials.gov record

> “The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis.”
> “Does ESK-001 reduce the severity of people's psoriasis?”
> “How safe is ESK-001 in people with moderate to severe plaque psoriasis?”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.1-2"></a>

###### Objective of the ONWARD1 and ONWARD2 congress presentation

> “To evaluate the efficacy, safety, onset of action, and patient-reported outcomes of envudeucitinib vs placebo and apremilast in adults with moderate-to-severe plaque psoriasis through Week 24”

Source: [Blauvelt et al. (2026d)](https://www.alumis.com/file.cfm/613/docs/esk2507192m_eadv-2026-onward-topline-encore-poster_14sep2026-2.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2024-07-25”
> “Primary Completion (Actual) 2025-09-19”
> “Study Completion (Actual) 2025-11-20”
> “First Posted 2024-09-19”
> “Last Update Posted 2026-10-28”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.2-2"></a>

###### Completion dates estimated at registration, September 2024, superseded in June 2025

> “Primary Completion 2026-05 [Estimated]”
> “Study Completion 2026-06 [Estimated]”

Source: [ClinicalTrials.gov NCT06586112 version 1](https://clinicaltrials.gov/study/NCT06586112?tab=history&a=1)

<a id="topic-3.1.1.2-3"></a>

###### Results posting status and certification date in the ClinicalTrials.gov record

> “No Results Posted”
> “Certification/Extension First Submitted 2026-08-06”
> “Certification/Extension First Posted 2026-08-10”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.2-4"></a>

###### Countries of trial sites in the ClinicalTrials.gov record

> “This study has 156 locations”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

| Country | First site listed for the country in the record |
| --- | --- |
| United States | “Phoenix, Arizona, United States, 85032” |
| Australia | “Kogarah, New South Wales, Australia, 2217” |
| Bulgaria | “Gabrovo, Bulgaria, 5300” |
| Canada | “Edmonton, Alberta, Canada, T5J 3S9” |
| Czechia | “Kutná Hora, Czechia, 28401” |
| Germany | “Tübingen, Baden-Wurttemberg, Germany, 72070” |
| Japan | “Fukuoka, Fukuoka-shi, Japan, 814-0180” |
| Poland | “Gdansk, Poland, 80-546” |
| Portugal | “Lisbon, Portugal, 1998-018” |
| South Korea | “Busan, South Korea, 49241” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.2-5"></a>

###### Country removed from the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Removed location countries (`removedCountries`) | “Belgium” |

Source: [ClinicalTrials.gov NCT06586112 API record](https://clinicaltrials.gov/api/v2/studies/NCT06586112)

<a id="topic-3.1.1.2-6"></a>

###### Countries listed for ESK-001-016 and enrollment from Japan in the topline webcast presentation

> “(ESK - 001 - 016) Canada Belgium Bulgaria Australia Portugal Japan Germany Czech Republic United States South Korea Poland”
> “6.1% (56 patients) enrolled from Japan in ESK - 001 - 016 study only”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

<a id="topic-3.1.1.2-7"></a>

###### Enrollment period and number of sites across ONWARD1 and ONWARD2

> “1700+ patients enrolled at >270 study sites in 10 months”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

> “Completed patient enrollment in the pivotal Phase 3 global ONWARD clinical program of envu for the treatment of moderate-to-severe plaque psoriasis”

Source: [Alumis press release, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)”
> “Primary Purpose : Treatment”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Quadruple”
> “The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis).”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.3-2"></a>

###### Parallel 24-week design of ONWARD1 and ONWARD2

> “The Phase 3 ONWARD clinical program includes two parallel global, multicenter, randomized, double-blind, placebo- and active-comparator-controlled 24-week trials—ONWARD1 (NCT06586112) and ONWARD2 (NCT06588738)—evaluating the efficacy and safety of envudeucitinib in adults with moderate-to-severe plaque psoriasis.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-3.1.1.3-3"></a>

###### Replicate design of ONWARD1 and ONWARD2

> “Replicate design; actual enrollment is reported as ONWARD1 (NCT06586112); ONWARD2 (NCT06588738).”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.3-4"></a>

###### Placebo rollover to envudeucitinib at week 16 and treatment periods in the design schematic

> “Placebo (N= 210 ) Wk 16 : Rollover to envudeucitinib”
> “ONWARD1 and ONWARD2: 24 - week duration, placebo and active comparator (apremilast) controlled”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

<a id="topic-3.1.1.3-5"></a>

###### Eligibility for the ONWARD3 long-term extension after week 24

> “Patients completing Week 24 were eligible to enter ONWARD3 (NCT06846541), an ongoing long-term extension study assessing durability, greater maintenance of response, and long-term safety.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Age and sex | “Males or females, age ≥18 years” |
| Disease duration | “Diagnosis of plaque psoriasis for ≥6 months” |
| Body surface area | “Plaques covering ≥10% of BSA” |
| PASI | “PASI ≥12” |
| sPGA | “sPGA ≥3” |
| Contraception | “Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.4-2"></a>

###### Exclusion criteria on psoriasis type, associated conditions, and pregnancy in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Psoriasis type | “Nonplaque psoriasis or other inflammatory skin conditions” |
| Associated immune-mediated conditions | “immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Participants with psoriatic arthritis may participate” |
| Pregnancy | “Pregnant, lactating, or planning to get pregnant during the study” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.4-3"></a>

###### Washout periods and prior treatment response in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Topical therapy | “Topical within 2 weeks” |
| Phototherapy or systemic therapy | “Phototherapy or any systemic treatments within 4 weeks” |
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months” |
| Systemic immunosuppressants | “Systemic immunosuppressants or immunomodulatory drugs within 4 weeks” |
| B-cell and T-cell modulators | “Modulators of B cells within 6 months, or T cells within 3 months” |
| JAK and TYK2 inhibitors | “JAK inhibitors or TYK2 inhibitors within 4 weeks” |
| PDE4 inhibitors | “PDE4 inhibitor within 2 months” |
| Investigational agents | “Any investigational agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study” |
| Prior treatment response | “Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.4-4"></a>

###### Washout for IL-12 and IL-23 agents at registration, September 2024, superseded in November 2024

> “Any biologic or oral agent targeted to IL-12 or IL-23 within 6 months or any TNFα inhibitor within 2 months or IL-17 within 4 months”

Source: [ClinicalTrials.gov NCT06586112 version 1](https://clinicaltrials.gov/study/NCT06586112?tab=history&a=1)

<a id="topic-3.1.1.4-5"></a>

###### Cardiac, infection, and laboratory exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| QTcF | “Participants with QTcF >450 msec (males) or >470 msec (females) at Screening” |
| Cardiovascular disease | “Unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within the last 3 months” |
| Herpes zoster and herpes simplex | “Evidence of recent or recurrent herpes zoster or herpes simplex viral infection” |
| Active or chronic infection | “Evidence of active infection or positive test result for hepatitis B, hepatitis C, HIV or TB” |
| Serious infection history | “History of serious bacterial, fungal, or viral infections that led to hospitalization, or any recent serious infection requiring antibiotic treatment” |
| Immunodeficiency | “Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status” |
| Laboratory abnormalities | “Lab abnormalities indicating significant renal, hepatic or bone marrow dysfunction” |
| Systemic corticosteroids | “History of any immune-mediated or inflammatory medical condition for which participants requires current systemic corticosteroids” |
| Inhaled corticosteroids | “Stable doses of inhaled corticosteroids for treatment of asthma are allowed” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.4-6"></a>

###### Malignancy, vaccination, surgery, and psychiatric exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Malignancy | “Known current malignancy or current evaluation for a potential malignancy or history of malignancy within the past 5 years prior to screening, except for adequately treated basal cell or squamous cell skin carcinoma or carcinoma in situ of the cervix” |
| Live vaccines | “Live vaccines within 4 weeks prior to Study Day 1” |
| Planned surgery | “Participant has planned surgery during the study period” |
| Unstable clinical condition | “Any acute or chronic illness/condition or evidence of an unstable clinical condition that, in the opinion of the Investigator, will substantially increase the risk to the participant if he or she participates in the study” |
| Mental illness | “History of mental illness within the last 5 years, unless receiving a fixed regimen of psychiatric medications for at least 6 months before screening or has not required or been prescribed any psychiatric medication within 12 months before screening” |
| Depression and suicidality | “Evidence of severe depressive symptoms or active suicidal ideation or behavior” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.4-7"></a>

###### Key inclusion and exclusion criteria for ONWARD1 and ONWARD2 in the topline webcast presentation

> “Total body weight >40 kg (88 lb )”
> “Diagnosis of plaque psoriasis for ≥6 months prior to the Screening Visit”
> “Plaques covering ≥10% of BSA at Screening and Day 1”
> “PASI ≥12 at Screening and Day 1”
> “sPGA ≥3 at Screening and Day 1”
> “Deemed by the Investigator to be a candidate for phototherapy or systemic therapy”
> “Non - plaque psoriasis​ (e.g., guttate, inverse, pustular, erythrodermic or other inflammatory skin conditions that may interfere with the study assessments)”
> “Unstable cardiovascular disease, defined as a recent clinical deterioration (e.g., unstable angina, rapid atrial fibrillation) or a cardiac hospitalization within the last 3 months”
> “Entry criteria reflects a moderate - to - severe plaque psoriasis adult population”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Quoted record |
| --- | --- |
| Experimental: ESK-001 | “ESK-001 administered as an oral tablet” |
| Placebo comparator | “Matching oral placebo” |
| Active comparator: apremilast | “Apremilast administered as an oral capsule” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.5-2"></a>

###### Dose and randomization ratio across ONWARD1 and ONWARD2

> “More than 1,700 patients were enrolled and randomized 2:1:1 to receive envudeucitinib 40 mg twice daily, placebo, or apremilast.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-3.1.1.5-3"></a>

###### No fasting requirement in ONWARD1 and ONWARD2

> “The ONWARD clinical trials did not have a fasting requirement.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using PASI 75 and sPGA 0/1 Response as the Co-primary Endpoints

<a id="topic-3.1.1.6.1-1"></a>

###### Primary outcome in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary outcome measure | “To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo” |
| Measure description | “Proportion of participants achieving ≥75% reduction in PASI score. Proportion of participants achieving a score of 0 or 1 on sPGA.” |
| Time frame | “16 weeks” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.6.1-2"></a>

###### Secondary outcomes in the ClinicalTrials.gov record

| Secondary outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast” | “Proportion of participants achieving of ≥90% or 100% reduction in PASI” | “24 weeks” |
| “To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast” | “Proportion of participants achieving of ≥75% reduction in PASI” | “24 weeks” |
| “To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast” | “Proportion of participants achieving a score of 0 or 1 on sPGA” | “24 weeks” |
| “To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast” | “Change from baseline in %BSA” | “24 weeks” |
| “To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast.” | “Proportion of participants achieving a score of 0 or 1 on ssPGA” | “24 weeks” |
| “To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast” | “Proportion of participants achieving a score of 0” | “24 weeks” |
| “To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast” | “Proportion of participants achieving a score of 0 or 1” | “24 weeks” |
| “To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo” | “Change from baseline in Pruritus NRS” | “24 weeks” |
| “Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)” | “Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)” | “24 weeks” |
| “To characterize the pharmacokinetics of ESK-001” | “Maximum [Cmax] and minimum [Cmin] plasma concentration” | “24 weeks” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.6.1-3"></a>

###### Planned co-primary endpoints of ONWARD1 and ONWARD2

> “The co-primary efficacy endpoints will be the proportion of patients with moderate-to-severe plaque psoriasis achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) and sPGA score 0/1 of ESK-001 compared to placebo at Week 16.”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

<a id="topic-3.1.1.6.1-4"></a>

###### Co-primary, key secondary, and safety endpoints of ONWARD1 and ONWARD2 in the congress poster

> “Coprimary endpoints (vs placebo; PASI 75 and sPGA-0/1), key secondary endpoints (vs placebo or apremilast; PASI 75/90/100, sPGA-0/1, change from baseline in itch [NRS], ss-PGA-0/1 [baseline ≥3], and DLQI-0/1 [baseline ≥2]), and safety endpoints were assessed.”

Source: [Blauvelt et al. (2026d)](https://www.alumis.com/file.cfm/613/docs/esk2507192m_eadv-2026-onward-topline-encore-poster_14sep2026-2.pdf)

<a id="topic-3.1.1.6.1-5"></a>

###### Definitions of PASI and sPGA response thresholds in the congress presentation

> “PASI 75/90/100, ≥75%/≥90%/100% improvement in PASI; PGA, Physician’s Global Assessment; sPGA, static PGA; sPGA-0/1, sPGA 0 (clear) or 1 (almost clear); ss-PGA-0/1, scalp-specific PGA 0 (clear) or 1 (almost clear)”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.6.1-6"></a>

###### Regulatory guidance on PASI as a primary endpoint and its pairing with a global score

> “PASI score has been the most frequently used primary endpoint in therapeutic confirmatory trials both for topical and systemic agents.”
> “It is considered that PASI alone is not sufficient to evaluate psoriasis severity at baseline and on treatment.”
> “Therefore, it is strongly recommended to use two endpoints to assess efficacy: a validated, standardised global score (e.g. PGA) in conjunction with PASI.”

Source: [EMA psoriasis clinical investigation guideline (2004)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 912”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment at registration

> “Enrollment 840 [Estimated]”

Source: [ClinicalTrials.gov NCT06586112 version 1](https://clinicaltrials.gov/study/NCT06586112?tab=history&a=1)

<a id="topic-3.1.1.7.1-3"></a>

###### Planned enrollment of approximately 840 participants per trial

> “Each trial will enroll approximately 840 patients randomized 2:1:1 to receive either ESK-001 40 mg twice-daily, placebo or apremilast.”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants by arm in ONWARD1 and ONWARD2

> “Envudeucitinib 40 mg BID (n = 459; 433)”
> “Placebo (n = 230; 211)”
> “Apremilast 30 mg BID (n = 223; 215)”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

> “ONWARD1/2: N=1771 (envudeucitinib n=459, 433; placebo n=230, 211, apremilast n=223, 215, respectively).”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Intention-to-treat analysis of response endpoints in ONWARD1 and ONWARD2

> “Intention-to-treat population. The 95% CIs and P-values of the treatment differences were based on the Cochran-Mantel-Haenszel test adjusted for stratification factors. Nonresponder imputation was applied for missing data.”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Mixed model for repeated measures for itch in ONWARD1 and ONWARD2

> “Intention-to-treat population. LSMs, CIs, and P-values are based on MMRM.”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Pooled safety analysis population of ONWARD1 and ONWARD2

> “Safety analysis population; pooled ONWARD1 and ONWARD2 data.”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Baseline demographics and disease characteristics by arm in ONWARD1

| Characteristic | Envudeucitinib 40 mg BID, n = 459 | Placebo, n = 230 | Apremilast 30 mg BID, n = 223 |
| --- | --- | --- | --- |
| Age, years, mean (SD) | “49.1 (13.4)” | “49.2 (13.3)” | “47.7 (11.8)” |
| Age group, ≥65 years, n (%) | “61 (13.3)” | “27 (11.7)” | “15 (6.7)” |
| Sex, male, n (%) | “300 (65.4)” | “156 (67.8)” | “152 (68.2)” |
| Race, White, n (%) | “358 (78.0)” | “182 (79.1)” | “177 (79.4)” |
| Race, Asian, n (%) | “68 (14.8)” | “28 (12.2)” | “30 (13.5)” |
| Race, other, n (%) | “33 (7.2)” | “20 (8.7)” | “16 (7.2)” |
| Weight, kg, mean (SD) | “90.4 (24.0)” | “91.0 (24.3)” | “88.9 (21.0)” |
| BMI, kg/m2, mean (SD) | “30.6 (7.2)” | “30.6 (7.2)” | “29.8 (6.5)” |
| Duration of disease, years, mean (SD) | “19.9 (13.5)” | “19.5 (13.3)” | “17.2 (11.8)” |
| PASI, mean (SD) | “20.4 (8.0)” | “19.9 (7.5)” | “20.3 (6.9)” |
| sPGA of 4, n (%) | “129 (28.1)” | “57 (24.8)” | “61 (27.4)” |
| BSA % affected, mean (SD) | “25.8 (15.8)” | “26.2 (16.0)” | “25.2 (14.9)” |
| DLQI, mean (SD) | “10.6 (6.5)” | “10.1 (6.7)” | “10.8 (6.8)” |
| Worst pruritus NRS, mean (SD) | “6.1 (2.7)” | “6.0 (2.7)” | “6.3 (2.6)” |
| Prior systemic psoriasis treatment, n (%) | “221 (48.1)” | “113 (49.1)” | “107 (48.0)” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.2-2"></a>

###### Balance across arms and definitions of other race and prior systemic treatment in the ONWARD1 and ONWARD2 baseline table

> “Baseline Demographics and Disease Characteristics Were Balanced Across Arms and Representative of a Typical Moderate-to-Severe Population”
> “Includes Black or African American, Native Hawaiian or Other Pacific Islander, American Indian or Alaska Native, and Other or not reported.”
> “Any prior exposure to systemic therapies for psoriasis (excluded phototherapy); all patients were required to meet protocol-defined exclusion and washout criteria prior to Study Day 1.”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.2-3"></a>

###### Baseline itch and scalp involvement by arm in ONWARD1

| Characteristic | Envudeucitinib 40 mg BID, N = 459 | Placebo, N = 230 | Apremilast 30 mg BID, N = 223 |
| --- | --- | --- | --- |
| Worst pruritus NRS ≥1, n (%) | “420 (91.5)” | “210 (91.3)” | “210 (94.2)” |
| Worst pruritus NRS ≥4, n (%) | “353 (76.9)” | “175 (76.1)” | “176 (78.9)” |
| ss-PGA ≥3, n | “274” | “135” | “150” |
| Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%) | “213 (77.7)” | “102 (75.6)” | “124 (82.7)” |

Source: [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)

<a id="topic-3.1.1.8.2-4"></a>

###### Baseline characteristics averaged across ONWARD1 and ONWARD2, including prior systemic and prior biologic use

> “Data based on average from both studies”
> “64 - 67% Male”
> “79 - 89% White”
> “33 - 38% United States”
> “Duration of Psoriasis Diagnosis ~19 years”
> “Over 40% prior systemic use”
> “Approximately 25% prior biologic use”
> “Mean PASI ~20; approximately 40% of patients having a PASI score >20”
> “sPGA of 3 in 70 - 73% of patients; sPGA of 4 in 27 - 30% of patients”
> “Mean BSA of 26%”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Co-primary and secondary endpoint results of ONWARD1 and ONWARD2 at topline

> “Envudeucitinib met all primary and secondary endpoints with high statistical significance in ONWARD1 and ONWARD2.”
> “In each of these trials, envudeucitinib achieved superior skin clearance compared with placebo (p < 0.0001) on the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician’s Global Assessment (sPGA) 0/1 at Week 16.”
> “On average across both ONWARD1 and ONWARD2, 74% of patients achieved PASI 75 and 59% of patients achieved sPGA 0/1, with responses deepening over time.”
> “In addition, the placebo-adjusted response rates for the co-primary endpoints were consistent between the two trials.”
> “At Week 24, on the higher hurdle skin clearance measures, approximately 65% of patients achieved PASI 90, and more than 40% achieved PASI 100, on average across both trials.”
> “Rapid responses were observed, with clear separation from placebo on PASI 90 as early as Week 4.”
> “Envudeucitinib also achieved superior skin clearance compared with apremilast in each trial (p<0.0001) on all PASI endpoints at Week 24.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

<a id="topic-3.1.1.8.3-2"></a>

###### PASI 75, PASI 90, and PASI 100 response rates at week 16 in ONWARD1

| Week 16 response, % | Envudeucitinib 40 mg BID, n = 459 | Placebo, n = 230 | Apremilast 30 mg BID, n = 223 |
| --- | --- | --- | --- |
| PASI 75 (co-primary endpoint) | “76.5” | “18.7” | “44.4” |
| PASI 90 | “59.9” | “4.8” | “21.5” |
| PASI 100 | “29.4” | “0.9” | “4.0” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.3-3"></a>

###### PASI 75, PASI 90, and PASI 100 response rates at week 24 in ONWARD1

| Week 24 response, % | Envudeucitinib 40 mg BID, n = 459 | Apremilast 30 mg BID, n = 223 |
| --- | --- | --- |
| PASI 75 | “78.6” | “46.2” |
| PASI 90 | “68.0” | “25.6” |
| PASI 100 | “41.0” | “8.5” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.3-4"></a>

###### PASI 90 and PASI 100 response rates by trial at weeks 16 and 24 in ONWARD1 and ONWARD2

> “Psoriasis Area and Severity Index (PASI) 90 responses, which emerged as early as Week 4, were achieved by 59.9% and 53.1% of envudeucitinib patients at Week 16 (and by 4.8% and 4.3% of placebo patients), increasing to 68.0% and 62.1% at Week 24.”
> “PASI 100 responses followed a similar trajectory, with 29.4% and 27.7% of envudeucitinib patients achieving complete skin clearance at Week 16 (as compared to 0.9% and 0.9% of placebo patients), rising to 41.0% and 39.5% at Week 24.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-3.1.1.8.3-5"></a>

###### PASI, sPGA, and onset of response in ONWARD1 and ONWARD2 in the congress presentation

> “Almost 30% of patients receiving envudeucitinib achieved PASI 100 at Week 16”
> “Approximately 65% and 40% of patients achieved PASI 90 and PASI 100 with envudeucitinib at Week 24”
> “Early onset of action: separation vs placebo observed at Week 4”
> “Approximately 40% complete skin clearance at Week 24 without evidence of plateau”
> “Approximately 60% and 30% of patients receiving envudeucitinib achieved sPGA-0/1 and sPGA-0 at Week 16, and responses continued to improve through Week 24”
> “All primary and secondary efficacy endpoints met, with approximately 65% and 40% of patients receiving envudeucitinib achieving PASI 90 and PASI 100 at Week 24”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.3-6"></a>

###### Scalp psoriasis response (ss-PGA 0/1) at weeks 4 and 24 in ONWARD1 and ONWARD2

> “At Week 24, approximately three out of four envudeucitinib patients”
> “achieved clear or almost clear scalp psoriasis, measured by the Scalp Specific Physician’s Global Assessment (ss-PGA 0/1), with over 30% responding as early as Week 4.”
> “Based on patients with baseline ss-PGA ≥3”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-3.1.1.8.3-7"></a>

###### Treat-to-target PASI and BSA thresholds in a post hoc analysis of ONWARD1 and ONWARD2

> “To evaluate the achievement of clinically relevant treat-to-target thresholds for PASI and BSA in a post hoc analysis of ONWARD1 and ONWARD2”
> “Absolute PASI thresholds (0, ≤1, and ≤3) and BSA (≤3% and ≤1%) were calculated post hoc and assessed at Week 16 (vs placebo and apremilast) and Week 24 (vs apremilast)”
> “Patients who discontinued or had missing data were imputed as nonresponders”
> “Least squares (LS) means and corresponding 95% CIs for percent change from baseline in PASI total score were estimated using a mixed model with repeated measures (MMRM) with modified baseline observation carried forward (mBOCF) imputation; nominal P-values for treatment comparisons are presented at Weeks 16 and 24”
> “At Week 16, significantly more patients treated with envudeucitinib achieved clinically meaningful PASI treatment targets (Figure 3) and BSA treatment targets (Figure 4) vs placebo and apremilast”
> “Responses continued to improve through Week 24 for all thresholds”
> “Improvement in PASI from baseline with envudeucitinib was evident at Week 2 (Figure 6)”
> “Patients receiving envudeucitinib met stringent treat-to-target thresholds associated with disease control, with response rates increasing from Weeks 16 to 24”

Source: [Ehst et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-treattotarget-fall-clinical.pdf)

<a id="topic-3.1.1.8.3-8"></a>

###### Efficacy by prior biologic exposure or body weight

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Quality of life (DLQI 0/1) by week 12 in ONWARD1 and ONWARD2 among participants with baseline DLQI of 2 or more

> “Approximately 50% of patients in ONWARD 1/2 achieved a Dermatology Life Quality Index (DLQI) score of 0 or 1 by Week 12, reflecting minimal to no impact of psoriasis on daily activities.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

> “Envudeucitinib Treatment Significantly Improved Patient Quality of Life”
> “In patients with baseline DLQI ≥2.”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.4-2"></a>

###### Mean change in worst pruritus NRS by week 12 and by week 16, and timing relative to PASI 90, in ONWARD1 and ONWARD2

> “On average ˃4-point mean decrease from baseline in worst pruritus NRS by Week 12, with continued symptom improvement over time”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

> “By Week 16, envudeucitinib patients achieved an average improvement of more than 4 points from baseline on the 0–10 Worst Pruritus Numeric Rating Scale (NRS), with clinically meaningful itch relief as early as Week 2—one of the most burdensome symptoms of psoriasis.”
> “Notably, quality-of-life and itch improvements appeared before PASI 90 skin clearance responses and continued to deepen through Week 24 across both trials.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-3.1.1.8.4-3"></a>

###### Itch endpoints and methods in the ONWARD1 and ONWARD2 itch analysis

> “To evaluate the onset, magnitude, and durability of itch improvement with envudeucitinib, including among patients with scalp involvement, in ONWARD1 and ONWARD2”
> “Worst pruritus was assessed using a self-administered numeric rating scale (NRS, 0–10), reflective of the prior 24 hours”
> “Clinically meaningful improvement (≥4-point reduction from baseline) in worst pruritus NRS”
> “Among patients with baseline scalp-specific Physician’s Global Assessment (ss-PGA) ≥3 and worst pruritus NRS ≥4”
> “Worst pruritus NRS 0 with ≥1-point improvement”
> “Worst pruritus NRS 0/1 with ≥1-point improvement”
> “Confidence intervals (CIs) were obtained using Clopper–Pearson methods, and the 95% CIs and P-values of the treatment differences were calculated using the Cochran–Mantel–Haenszel test adjusted for stratification factors with nonresponder imputation. P-values are nominal”

Source: [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)

<a id="topic-3.1.1.8.4-4"></a>

###### Itch response at week 2, itch resolution at week 16, and responses through week 24 in ONWARD1 and ONWARD2

> “Approximately one-third of patients receiving envudeucitinib reported a clinically meaningful ≥4-point improvement in worst pruritus NRS at Week 2 (Figure 3)”
> “Patients transitioning from placebo to envudeucitinib at Week 16 also reported rapid improvements in their worst pruritus NRS”
> “Improvements in patients with moderate-to-severe scalp psoriasis were consistent with improvements observed in the overall population (Figure 4)”
> “By Week 16, over one-third of patients receiving envudeucitinib achieved complete itch resolution (NRS 0; Figure 5) and more than half achieved minimal itch (NRS 0/1; Figure 6)”
> “All reported itch responses continued to improve with envudeucitinib treatment through Week 24 (Figures 3–6)”

Source: [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)

> “In ONWARD 1/2, approximately one-third of patients—including those with moderate-to-severe scalp disease (ss-PGA ≥3)—achieved clinically meaningful itch reduction (≥4-point NRS improvement) as early as Week 2.”
> “By Week 16, about 40% reached complete itch resolution (NRS 0) and approximately 60% reported minimal or no itch (NRS 0/1).”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Pooled ONWARD1 and ONWARD2 adverse events through weeks 16 and 24

| Outcome, n (%) | Week 16: envudeucitinib 40 mg BID, n = 890 | Week 16: placebo, n = 441 | Week 16: apremilast 30 mg BID, n = 438 | Week 24: envudeucitinib 40 mg BID only, n = 890 | Week 24: placebo to envudeucitinib 40 mg BID, n = 390 | Week 24: overall envudeucitinib 40 mg BID, n = 1280 | Week 24: apremilast 30 mg BID, n = 438 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| At least 1 TEAE | “524 (58.9)” | “166 (37.6)” | “223 (50.9)” | “563 (63.3)” | “130 (33.3)” | “693 (54.1)” | “248 (56.6)” |
| At least 1 SAE | “19 (2.1)” | “5 (1.1)” | “5 (1.1)” | “24 (2.7)” | “1 (0.3)” | “25 (2.0)” | “6 (1.4)” |
| TEAE leading to treatment discontinuation | “30 (3.4)” | “7 (1.6)” | “9 (2.1)” | “31 (3.5)” | “4 (1.0)” | “35 (2.7)” | “12 (2.7)” |
| TEAE grade ≥3 | “42 (4.7)” | “14 (3.2)” | “18 (4.1)” | “48 (5.4)” | “7 (1.8)” | “55 (4.3)” | “23 (5.3)” |
| Nasopharyngitis | “64 (7.2)” | “21 (4.8)” | “16 (3.7)” | “92 (10.3)” | “18 (4.6)” | “110 (8.6)” | “26 (5.9)” |
| Headache | “92 (10.3)” | “11 (2.5)” | “40 (9.1)” | “97 (10.9)” | “11 (2.8)” | “108 (8.4)” | “42 (9.6)” |
| Upper respiratory tract infection | “43 (4.8)” | “7 (1.6)” | “16 (3.7)” | “57 (6.4)” | “2 (0.5)” | “59 (4.6)” | “21 (4.8)” |
| Acne | “53 (6.0)” | “3 (0.7)” | “3 (0.7)” | “60 (6.7)” | “17 (4.4)” | “77 (6.0)” | “3 (0.7)” |
| Nausea | “20 (2.2)” | “4 (0.9)” | “23 (5.3)” | “20 (2.2)” | “0” | “20 (1.6)” | “23 (5.3)” |
| Diarrhea | “14 (1.6)” | “11 (2.5)” | “36 (8.2)” | “16 (1.8)” | “1 (0.3)” | “17 (1.3)” | “36 (8.2)” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.5-2"></a>

###### Deaths, MACE, cytopenias, tuberculosis, laboratory findings, serious infections, and malignancies in pooled ONWARD1 and ONWARD2

> “TEAEs occurring in ≥5% of patients in any treatment arm through either Week 16 or Week 24.”
> “Envudeucitinib showed low rates of SAEs and AEs leading to discontinuation, with no clusters of events”
> “No deaths; no MACE or cytopenia signals; no TB reactivation”
> “Thirty-nine patients with latent or treated TB were enrolled.”
> “No clinically significant laboratory abnormalities were observed across lipid, hematologic and chemistry panels, with comparable variability across treatment arms throughout the study”
> “At Week 24, low incidence of serious infections (0.7%) and malignancies (0.2%) observed in patients treated with envudeucitinib”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.5-3"></a>

###### Tolerability and most common adverse events in ONWARD1 and ONWARD2 through week 24

> “Treatment with envudeucitinib was generally well tolerated through Week 24 in both trials, with a safety profile consistent with the Phase 2 program, including its long-term extension study.”
> “No clinically significant laboratory abnormalities or cases of tuberculosis reactivation were observed.”
> “Treatment-emergent adverse events were mostly mild, transient, self-limited, or responding to standard therapy, with the most common being headache, nasopharyngitis, upper respiratory tract infection, and acne.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-3.1.1.8.5-4"></a>

###### Similar adverse event frequency and severity between ONWARD1 and ONWARD2

> “Treatment-emergent adverse event (TEAE) frequency and severity were similar across trials, with the majority being mild to moderate, transient, and responding to standard therapy, if required.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

<a id="topic-3.1.1.8.5-5"></a>

###### Herpes zoster and creatine phosphokinase elevations

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

- ONWARD1 results are available from company press releases, a company webcast presentation, and congress materials (Blauvelt et al., Hawkes et al., Ehst et al.). The ClinicalTrials.gov record reads “No Results Posted” and records a certification/extension first submitted on 2026-08-06.
- Placebo control lasted 16 weeks, after which placebo participants rolled over to envudeucitinib; the week 24 PASI results compare envudeucitinib with apremilast alone.
- The report holds no participant disposition by arm, no efficacy by prior biologic exposure or body weight, and no herpes zoster or creatine phosphokinase data. Safety, itch, and DLQI results are reported only for ONWARD1 and ONWARD2 pooled.
- The sources differ on itch: the congress presentation places the mean decrease of more than 4 points in worst pruritus NRS by week 12 and a press release by week 16; at week 16, NRS 0 is reported as over one-third (itch poster) and about 40% (press release), and NRS 0/1 as more than half and approximately 60%.
- Prior treatment is reported on different measures: prior systemic treatment by arm in 221 (48.1%), 113 (49.1%), and 107 (48.0%) participants (congress presentation), and, averaged across both trials, “Over 40% prior systemic use” and approximately 25% prior biologic use (webcast presentation). The report holds no prior biologic use by arm.
- The itch analysis reports nominal P-values, and the PASI and BSA treat-to-target thresholds were calculated post hoc.
- Eligibility excluded participants with lack of clinical response to a TYK2, IL-12, or IL-23 targeted treatment and those with recent or recurrent herpes zoster or herpes simplex infection.
- The webcast presentation lists Belgium among the countries of study ESK-001-016, and the ClinicalTrials.gov API record for NCT06586112 lists Belgium as a removed location country.

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112); [ClinicalTrials.gov NCT06586112 API record](https://clinicaltrials.gov/api/v2/studies/NCT06586112); [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm); [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf); [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf); [Ehst et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-treattotarget-fall-clinical.pdf); [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib); [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="heading-3.1.2"></a>

#### 3.1.2 ONWARD2

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Objective in the brief title of the ClinicalTrials.gov record

> “A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001”

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study start and completion dates in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2024-08-20” |
| Primary completion (actual) | “2025-09-23” |
| Study completion (actual) | “2025-12-18” |
| First submitted | “2024-09-07” |
| Last update posted | “2026-10-28” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.2-2"></a>

###### Completion dates estimated at registration, September 2024, superseded in June 2025

| Field | Quoted record |
| --- | --- |
| Primary completion | “2026-05 [Estimated]” |
| Study completion | “2026-06 [Estimated]” |

Source: [ClinicalTrials.gov NCT06588738 version 1](https://clinicaltrials.gov/study/NCT06588738?tab=history&a=1)

<a id="topic-3.1.2.2-3"></a>

###### Results posting status and certification date in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Results | “No Results Posted” |
| Certification/extension first submitted | “2026-08-06” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.2-4"></a>

###### Countries of trial sites in the ClinicalTrials.gov record

> “This study has 124 locations”

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

| Country | First site listed for the country in the record |
| --- | --- |
| United States | “Birmingham, Alabama, United States, 35203” |
| Austria | “Vienna, Austria, 1220” |
| Canada | “Calgary, Alberta, Canada, T3E 0B2” |
| Estonia | “Tallinn, Estonia, 10128” |
| France | “Nice, France, 06000” |
| Germany | “Berlin, Germany, 10789” |
| Hungary | “Budapest, Hungary, 1152” |
| Israel | “Ramat Gan, Israel, 526200” |
| Latvia | “Riga, Latvia, LV1001” |
| Poland | “Katowice, Poland, 40-568” |
| Puerto Rico | “Caguas, Puerto Rico, 00725” |
| Spain | “Alicante, Spain, 3010” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.2-5"></a>

###### Countries listed for ESK-001-017 in the topline webcast presentation

> “(ESK - 001 - 017) Germany France Estonia Canada Austria Romania Puerto Rico Poland Latvia Hungary United Kingdom United States Israel Spain”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)”

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Age and sex | “Males or females, age ≥18 years” |
| Disease duration | “Diagnosis of plaque psoriasis for ≥6 months” |
| Body surface area | “Plaques covering ≥10% of BSA” |
| PASI | “PASI ≥12” |
| sPGA | “sPGA ≥3” |
| Contraception | “Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.4-2"></a>

###### Exclusion criteria on psoriasis type, associated conditions, and pregnancy in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Psoriasis type | “Nonplaque psoriasis or other inflammatory skin conditions” |
| Associated immune-mediated conditions | “Immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Patients with psoriatic arthritis may participate” |
| Pregnancy | “Pregnant, lactating, or planning to get pregnant during the study” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.4-3"></a>

###### Washout periods and prior treatment response in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Topical therapy | “Topical within 2 weeks” |
| Phototherapy or systemic therapy | “Phototherapy or any systemic treatments within 4 weeks” |
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months” |
| Systemic immunosuppressants | “Systemic immunosuppressants or immunomodulatory drugs within 4 weeks” |
| B-cell and T-cell modulators | “Modulators of B cells within 6 months, or T cells within 3 months” |
| JAK and TYK2 inhibitors | “JAK inhibitors or TYK2 inhibitors within 4 weeks” |
| PDE4 inhibitors | “PDE4 inhibitor within 2 months” |
| Investigational agents | “Any investigational agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study” |
| Prior treatment response | “Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.4-4"></a>

###### Washout for IL-12 and IL-23 agents at registration, September 2024, superseded in October 2024

| Criterion | Quoted record |
| --- | --- |
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic or oral agent targeted to IL-12 or IL-23 within 6 months or any TNFα inhibitor within 2 months or IL-17 within 4 months” |

Source: [ClinicalTrials.gov NCT06588738 version 1](https://clinicaltrials.gov/study/NCT06588738?tab=history&a=1)

<a id="topic-3.1.2.4-5"></a>

###### Cardiac, infection, laboratory, and corticosteroid exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| QTcF | “Patients with QTcF >450 msec (males) or >470 msec (females) at Screening” |
| Cardiovascular disease | “Unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within the last 3 months” |
| Herpes zoster and herpes simplex | “Evidence of recent or recurrent herpes zoster or herpes simplex viral infection” |
| Active or chronic infection | “Evidence of active infection or positive test result for hepatitis B, hepatitis C, HIV or TB” |
| Serious infection history | “History of serious bacterial, fungal, or viral infections that led to hospitalization, or any recent serious infection requiring antibiotic treatment” |
| Immunodeficiency | “Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the patient's immune status” |
| Laboratory abnormalities | “Lab abnormalities indicating significant renal, hepatic or bone marrow dysfunction” |
| Systemic corticosteroids | “History of any immune-mediated or inflammatory medical condition for which patient requires current systemic corticosteroids” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Quoted record |
| --- | --- |
| Experimental: ESK-001 | “ESK-001 administered as an oral tablet” |
| Placebo comparator | “Matching oral placebo” |
| Active comparator: apremilast | “Apremilast administered as an oral capsule” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using PASI 75 and sPGA 0/1 Response as the Co-primary Endpoints

<a id="topic-3.1.2.6.1-1"></a>

###### Primary outcome in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary outcome measure | “To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo” |
| Measure description | “Proportion of patients achieving ≥75% reduction in PASI score. Proportion of patients achieving a score of 0 or 1 on sPGA.” |
| Time frame | “16 weeks” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.6.1-2"></a>

###### Secondary outcomes in the ClinicalTrials.gov record

| Secondary outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast” | “Proportion of patients achieving of ≥90% or 100% reduction in PASI” | “24 weeks” |
| “To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast” | “Proportion of patients achieving of ≥75% reduction in PASI” | “24 weeks” |
| “To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast” | “Proportion of patients achieving a score of 0 or 1 on sPGA” | “24 weeks” |
| “To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast” | “Change from baseline in %BSA” | “24 weeks” |
| “To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast” | “Proportion of patients achieving a score of 0 or 1 on ssPGA” | “24 weeks” |
| “To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast” | “Proportion of patients achieving a score of 0” | “24 weeks” |
| “To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast” | “Proportion of patients achieving a score of 0 or 1” | “24 weeks” |
| “To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo” | “Change from baseline in Pruritus NRS (scale is from 0 (no pain) to 10 (severe pain)).” | “24 weeks” |
| “Proportion of patients with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)” | “Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)” | “24 weeks” |
| “To characterize the pharmacokinetics of ESK-001” | “Maximum [Cmax] and minimum [Cmin] plasma concentration” | “24 weeks” |

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.6.1-3"></a>

###### Regulatory guidance on the clinical meaning of PASI 75 response and on global assessment scales

> “Up till now, there is no generally accepted definition of what constitutes meaningful clinical improvement in psoriasis.”
> “In clinical trials using PASI, both >50% and >75% improvements compared to baseline have been considered as clinically meaningful.”
> “Physician’s global assessment of improvement (PGA or other global score if adequately validated): global assessment of the patient’s overall severity of the disease on 6 or 7-point scale”

Source: [EMA psoriasis clinical investigation guideline (2004)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 862”

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)

<a id="topic-3.1.2.7.1-2"></a>

###### Planned enrollment at registration

| Field | Quoted record |
| --- | --- |
| Enrollment | “840 [Estimated]” |

Source: [ClinicalTrials.gov NCT06588738 version 1](https://clinicaltrials.gov/study/NCT06588738?tab=history&a=1)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline demographics and disease characteristics by arm in ONWARD2

| Characteristic | Envudeucitinib 40 mg BID, n = 433 | Placebo, n = 211 | Apremilast 30 mg BID, n = 215 |
| --- | --- | --- | --- |
| Age, years, mean (SD) | “48.3 (13.1)” | “49.5 (13.3)” | “48.0 (12.8)” |
| Age group, ≥65 years, n (%) | “51 (11.8)” | “28 (13.3)” | “20 (9.3)” |
| Sex, male, n (%) | “283 (65.4)” | “135 (64.0)” | “135 (62.8)” |
| Race, White, n (%) | “388 (89.6)” | “181 (85.8)” | “193 (89.8)” |
| Race, Asian, n (%) | “10 (2.3)” | “10 (4.7)” | “7 (3.3)” |
| Race, other, n (%) | “35 (8.1)” | “20 (9.5)” | “15 (7.0)” |
| Weight, kg, mean (SD) | “92.3 (23.8)” | “91.1 (23.1)” | “90.8 (19.9)” |
| BMI, kg/m2, mean (SD) | “31.2 (7.8)” | “31.1 (7.3)” | “30.9 (5.9)” |
| Duration of disease, years, mean (SD) | “19.0 (13.5)” | “20.2 (14.5)” | “18.7 (14.5)” |
| PASI, mean (SD) | “20.6 (8.3)” | “21.8 (9.0)” | “20.4 (8.4)” |
| sPGA of 4, n (%) | “131 (30.3)” | “70 (33.2)” | “53 (24.7)” |
| BSA % affected, mean (SD) | “25.2 (14.7)” | “27.3 (16.7)” | “25.8 (14.1)” |
| DLQI, mean (SD) | “10.8 (7.0)” | “10.8 (6.8)” | “9.7 (7.1)” |
| Worst pruritus NRS, mean (SD) | “6.4 (2.6)” | “6.4 (2.4)” | “6.0 (2.7)” |
| Prior systemic psoriasis treatment, n (%) | “213 (49.2)” | “105 (49.8)” | “102 (47.4)” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.2.8.2-2"></a>

###### Baseline itch and scalp involvement by arm in ONWARD2

| Characteristic | Envudeucitinib 40 mg BID, N = 433 | Placebo, N = 211 | Apremilast 30 mg BID, N = 215 |
| --- | --- | --- | --- |
| Worst pruritus NRS ≥1, n (%) | “400 (92.4)” | “200 (94.8)” | “199 (92.6)” |
| Worst pruritus NRS ≥4, n (%) | “345 (79.7)” | “180 (85.3)” | “170 (79.1)” |
| ss-PGA ≥3, n | “285” | “140” | “134” |
| Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%) | “231 (81.1)” | “122 (87.1)” | “108 (80.6)” |

Source: [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### PASI 75, PASI 90, and PASI 100 response rates at week 16 in ONWARD2

| Week 16 response, % | Envudeucitinib 40 mg BID, n = 433 | Placebo, n = 211 | Apremilast 30 mg BID, n = 215 |
| --- | --- | --- | --- |
| PASI 75 (co-primary endpoint) | “70.4” | “13.7” | “38.6” |
| PASI 90 | “53.1” | “4.3” | “20.9” |
| PASI 100 | “27.7” | “0.9” | “7.9” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.2.8.3-2"></a>

###### PASI 75, PASI 90, and PASI 100 response rates at week 24 in ONWARD2

| Week 24 response, % | Envudeucitinib 40 mg BID, n = 433 | Apremilast 30 mg BID, n = 215 |
| --- | --- | --- |
| PASI 75 | “75.1” | “43.3” |
| PASI 90 | “62.1” | “25.6” |
| PASI 100 | “39.5” | “13.0” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

- ONWARD2-specific results are limited to baseline characteristics and PASI 75, PASI 90, and PASI 100 rates at weeks 16 and 24 in one congress presentation. The report holds no description of the ONWARD2 analysis sets, participant disposition, patient-reported outcomes, or safety for ONWARD2 alone, and no ONWARD2 sPGA 0/1 rate.
- The ClinicalTrials.gov record gives an actual enrollment of 862 participants; the congress presentation gives arm sizes of 433, 211, and 215.
- The ClinicalTrials.gov record reads “No Results Posted”, with a certification/extension first submitted on 2026-08-06.
- Asian participants made up 10 (2.3%), 10 (4.7%), and 7 (3.3%) of the envudeucitinib, placebo, and apremilast arms, and White participants 388 (89.6%), 181 (85.8%), and 193 (89.8%).
- Baseline sPGA of 4 was recorded in 131 (30.3%), 70 (33.2%), and 53 (24.7%) participants of the envudeucitinib, placebo, and apremilast arms, and mean baseline PASI was 20.6, 21.8, and 20.4.

Source: [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738); [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="heading-3.1.3"></a>

#### 3.1.3 ONWARD3

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Objective and scientific questions in the ClinicalTrials.gov record

> “The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time.”
> “How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis?”
> “Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis?”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.1-2"></a>

###### Objective of the 48-week ONWARD3 congress analysis

> “Objective: Report maintenance of efficacy and safety through 48 weeks of total treatment in patients who completed ONWARD1 or 2 and enrolled in the ONWARD3 long-term extension”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study start, completion, and record dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-01-08”
> “Primary Completion (Estimated) 2028-11”
> “Study Completion (Estimated) 2028-11”
> “First Posted 2025-02-26”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.2-2"></a>

###### Recruitment status and last update in the ClinicalTrials.gov record

> “Last Update Posted 2026-04-13 Active, not recruiting No longer looking for participants”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.2-3"></a>

###### Countries of trial sites in the ClinicalTrials.gov record

> “This study has 268 locations”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

| Country | A site listed for the country in the record |
| --- | --- |
| United States | “Chandler, Arizona, United States, 85224” |
| Australia | “Campbelltown, South Australia, Australia, 5074” |
| Bulgaria | “Pleven, Bulgaria, 5800” |
| Canada | “Edmonton, Alberta, Canada, T6H 4J8” |
| Czechia | “Brno, Czechia, 602 00” |
| Estonia | “Tartu, Estonia, 50106” |
| France | “Nice, Alpes Maritimes, France, 6000” |
| Germany | “Münster, Germany, NRW 48149” |
| Hungary | “Debrecen, Hungary, 4027” |
| Japan | “Nagoya, Aichi-ken, Japan, 467-8602” |
| Latvia | “Riga, Latvia, LV1013” |
| Poland | “Krakow, Poland, 30-033” |
| Portugal | “Porto, Portugal, 4099-001” |
| Puerto Rico | “San Juan, Puerto Rico, 00917” |
| South Korea | “Seoul, South Korea, 3080” |
| Spain | “Barcelona, Spain, 8041” |

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “An Extension Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001”
> “Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.3-2"></a>

###### Open-label period, randomized withdrawal, and return to open-label treatment in the ClinicalTrials.gov record

> “Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study.”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.3-3"></a>

###### Randomized withdrawal period and planned duration of up to 96 weeks

> “In ONWARD3, all patients received open-label envudeucitinib treatment for the first 24 weeks, regardless of their treatment assignment in ONWARD1 and 2. To assess durability and maintenance of response, the first 200 patients achieving PASI 75 at Week 24 in ONWARD3 could enter a 24-week randomized withdrawal period (RWP), in which they were randomized to receive either blinded envudeucitinib or placebo, and reassigned to open-label envudeucitinib upon loss of response or completion of the RWP, whichever occurred first.”
> “Patients not entering the randomized withdrawal period continued to receive open-label envudeucitinib treatment. ONWARD3 is designed to provide up to 96 weeks of long-term safety and efficacy data.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="topic-3.1.3.3-4"></a>

###### Phase 3 long-term extension status

> “Alumis is advancing its clinical development via ONWARD3, an ongoing Phase 3 long-term extension study in moderate-to-severe plaque psoriasis, and LUMUS, a potentially pivotal Phase 2b trial in systemic lupus erythematosus, with topline data anticipated in Q3 2026.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “Males or females, age ≥18 years Completed either of the two previous (parent) studies of ESK-001 (ESK-001-016 or ESK-001-017)”
> “ESK-001 safety and tolerability were acceptable in the parent study”
> “Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception for the entirety of the study”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Pregnant, lactating, or planning to get pregnant during the study period”
> “Any acute or chronic illness/condition or evidence of an unstable clinical condition that in the Investigator's judgment will substantially increase the risk to the patient if they continue to receive ESK-001 treatment in this extension study”
> “Deemed by the Investigator to be inappropriate for the study or unable to comply with the protocol”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.4-3"></a>

###### Ages, sexes, and healthy volunteers in the ClinicalTrials.gov record

> “Ages Eligible for Study 18 Years and older (Adult, Older Adult ) Sexes Eligible for Study All Accepts Healthy Volunteers No”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.4-4"></a>

###### Eligibility to enter ONWARD3 after week 24 of ONWARD1 or ONWARD2

> “Patients completing Week 24 of ONWARD1 or ONWARD2 were eligible to enter the ONWARD3 (NCT06846541) study, an ongoing long-term extension study assessing durability, maintenance of response, and long-term safety.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Arm and description | Intervention description |
| --- | --- | --- |
| Open-label envudeucitinib | “Experimental: Open-Label ESK-001 Open-Label ESK-001 administered as an oral tablet” | “Drug: Open-Label Envudeucitinib Open-Label ESK-001” |
| Blinded envudeucitinib | “Experimental: Blinded ESK-001 Blinded ESK-001 administered as an oral tablet” | “Blinded ESK-001 during Randomized Treatment Withdrawal Period” |
| Placebo | “Placebo Comparator: Placebo Matching placebo administered as an oral tablet” | “Placebo during Randomized Treatment Withdrawal Period” |

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.5-2"></a>

###### Open-label envudeucitinib 40 mg twice daily for 24 weeks regardless of parent-study treatment

> “All patients received open-label envudeucitinib for 24 weeks regardless of original treatment”
> “Open-label Envudeucitinib 40 mg BID (N = 1509)”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.5-3"></a>

###### Total envudeucitinib exposure by parent-study arm at week 48

> “Exposure to envudeucitinib varied based on parent-study assignment (i.e., 48, 32, and 24 weeks for the parent-envudeucitinib, -placebo, and -apremilast, respectively)”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary outcome in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary outcome measure | “To assess the long-term safety and tolerability of ESK-001 throughout the duration of the study” |
| Measure description and time frame | “Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) Approximately 4 years” |

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.6.1-2"></a>

###### Secondary outcomes in the ClinicalTrials.gov record

| Secondary outcome measure | Measure description and time frame |
| --- | --- |
| “To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-75)” | “Proportion of patients achieving ≥75% reduction in PASI 24, 48, 72, and 96 weeks” |
| “To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-90)” | “Proportion of patients achieving ≥90% reduction in PASI 24, 48, 72, and 96 weeks” |
| “To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-100)” | “Proportion of patients achieving 100% reduction in PASI 24, 48, 72, and 96 weeks” |
| “To assess the long-term efficacy of ESK-001 using the Static Physician's Global Assessment (sPGA 0/1)” | “Proportion of patients achieving a score of 0 or 1 on sPGA 24, 48, 72, and 96 weeks” |
| “To assess the long-term efficacy of ESK-001 based on change in Psoriasis Area and Severity Index (PASI)” | “Change in Psoriasis Area and Severity Index (PASI) from baseline assessments 24, 48, 72, and 96 weeks” |
| “To assess the long-term efficacy of ESK-001 based on change in Affected Body Surface Area (%BSA)” | “Change in affected body surface area (%BSA) from baseline assessments 24, 48, 72, and 96 weeks” |
| “To characterize the loss of PASI-75 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)” | “Median time to loss of PASI-75 response Week 48” |
| “To characterize the loss of PASI-90 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)” | “Median time to loss of PASI-90 response Week 48” |
| “To characterize the loss of sPGA-0/1 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)” | “Median time to loss of sPGA-0/1 response Week 48” |
| “To assess the change in quality of life (QoL) using Dermatology Life Quality Index after long-term ESK-001 administration” | “Proportion of patients achieving a DLQI-0/1 score of 0 (no effect) or 1 (minimal effect) Week 24, Week 48, and Week 72” |

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.6.1-3"></a>

###### Regulatory guidance on the size of the safety database for long-term treatment of non-life-threatening conditions

> “The objective of this guideline is to present an accepted set of principles for the safety evaluation of drugs intended for the long-term treatment (chronic or repeated intermittent use for longer than 6 months) of non-life-threatening diseases.”
> “The safety evaluation during clinical drug development is expected to characterise and quantify the safety profile of a drug over a reasonable duration of time consistent with the intended long-term use of the drug.”
> “To achieve this objective the cohort of exposed subjects should be large enough to observe whether more frequently occurring events increase or decrease over time as well as to observe delayed events of reasonable frequency (e.g., in the general range of 0.5%-5%). Usually 300-600 patients should be adequate.”

Source: [ICH E1 population exposure guideline (1995)](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-1-population-exposure-extent-population-exposure-assess-clinical-safety-step-5_en.pdf)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Estimated enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 1680”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.7.1-2"></a>

###### Participants who entered ONWARD3 from ONWARD1 or ONWARD2, all entrants

> “A total of 1,509 patients entered ONWARD3 from ONWARD1 or ONWARD2, reflecting a robust rollover rate of >85%.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="topic-3.1.3.7.1-3"></a>

###### Participants entering ONWARD3 by parent-study arm in the congress poster

> “Envudeucitinib → Envudeucitinib (n = 773)”
> “Placebo → Envudeucitinib (n = 367)”
> “Apremilast → Envudeucitinib (n = 369)”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Non-responder imputation analysis set of 773 participants from the envudeucitinib arms

> “A non-responder imputation (NRI) analysis was conducted in 773 of these patients from the envudeucitinib arms and who received up to 48 weeks of continuous treatment (24 weeks in ONWARD1/2 and up to 24 weeks in ONWARD3).”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="topic-3.1.3.7.2-2"></a>

###### Maintenance-of-response populations, restricted subgroups, imputation, and confidence intervals in the congress poster

> “Maintenance of response assessed among patients that achieved a response at entry in ONWARD3 and maintained it after 48 weeks of continuous envudeucitinib for each respective endpoint”
> “Baseline response rates for ONWARD3 encompass 24 weeks treatment duration in ONWARD1 and 2 (Figure 2); PASI 90, 100, and NRS endpoints defined as long-term improvement, and analyses of ss-PGA, NRS, and DLQI are restricted to patients with parent baseline ss-PGA ≥3, NRS ≥4, and DLQI ≥2”
> “Nonresponse imputation applied; analyses are descriptive”
> “The 95% CIs for each arm’s proportion are obtained using Clopper-Pearson methods”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Enrollment of participants who completed week 24 of ONWARD1 or ONWARD2 and consented

> “Patients who completed Week 24 of ONWARD1 or 2, and consented were enrolled in ONWARD3”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Baseline characteristics at ONWARD3 entry by parent-study arm

| Characteristic | Envudeucitinib then envudeucitinib (n = 773) | Placebo then envudeucitinib (n = 367) | Apremilast then envudeucitinib (n = 369) |
| --- | --- | --- | --- |
| Envudeucitinib exposure at start of ONWARD3, weeks | “24” | “8” | “0” |
| Age, years, mean (SD) | “49.6 (13.2)” | “50.6 (13.3)” | “49.1 (12.4)” |
| Duration of disease, years, mean (SD) | “20.2 (13.5)” | “20.1 (13.8)” | “19.0 (13.0)” |
| Prior systemic psoriasis treatment, n (%) | “395 (51.1)” | “185 (50.4)” | “186 (50.4)” |
| PASI, mean (SD) | “1.9 (3.6)” | “4.5 (5.5)” | “6.7 (7.0)” |
| ss-PGA ≥3, n (%) | “18 (2.3)” | “21 (5.7)” | “58 (15.7)” |
| BSA % affected, mean (SD) | “3.8 (7.7)” | “9.4 (12.3)” | “10.7 (13.2)” |
| Worst pruritus NRS score, mean (SD) | “1.3 (1.9)” | “2.0 (2.3)” | “3.1 (2.8)” |
| DLQI, mean (SD) | “1.8 (3.1)” | “2.9 (3.8)” | “4.0 (4.9)” |

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.2-2"></a>

###### Demographics at ONWARD3 entry compared with the parent-trial population

> “Demographics at ONWARD3 entry were consistent with the overall ONWARD1 and 2 population”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Week 48 PASI 90 and PASI 100 and maintenance among entry responders, NRI analysis of 773 participants

> “75% and 54% of patients achieved PASI 90 and PASI 100, respectively”
> “Among patients who entered ONWARD3 with PASI 90 and PASI 100 responses, approximately 90% and 80%, respectively, sustained their skin clearance for the reported duration of the extension study”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="topic-3.1.3.8.3-2"></a>

###### Week 48 PASI and sPGA responses with continuous envudeucitinib in the congress poster

> “At Week 48, 85.2% of those continuously treated with envudeucitinib achieved PASI 75”
> “At Week 48, 75.2% and 54.5% treated continuously with envudeucitinib achieved almost clear (sPGA-0/1) or clear skin (sPGA-0)”
> “Skin clearance similarly increased in patients switching from placebo or apremilast, approaching rates in continuously treated patients”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.3-3"></a>

###### Maintenance of skin and scalp response at 48 weeks among ONWARD1 and ONWARD2 responders

| Endpoint | Achieved response at the end of ONWARD1 and 2, n | Maintained response after 24 weeks in ONWARD3 (48 weeks of total exposure), % (95% CI) |
| --- | --- | --- |
| PASI 75 | “678” | “89.8 (87.3, 92.0)” |
| PASI 90 | “575” | “89.4 (86.6, 91.8)” |
| sPGA-0/1 | “584” | “87.5 (84.5, 90.1)” |
| PASI 100 | “357” | “80.1 (75.6, 84.1)” |
| sPGA-0 | “365” | “79.5 (74.9, 83.5)” |
| ss-PGA-0/1, among patients with parent baseline ss-PGA ≥3 | “418” | “89.5 (86.1, 92.2)” |

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.3-4"></a>

###### Scalp clearance at 48 weeks and response after crossover from placebo or apremilast

> “Over 80% of patients in ONWARD3 maintained clear or almost clear scalp skin (scalp-specific Physician Global Assessment [ss-PGA] 0/1) at 48 weeks.”
> “Patients switching from placebo or apremilast achieved rapid improvements across primary and key secondary endpoints, comparable to those continuously treated at Week 48”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-3.1.3.8.3-5"></a>

###### Integrated NRI analysis of 890 participants originally randomized to envudeucitinib across ONWARD1, ONWARD2, and ONWARD3

> “Results from a separate integrated NRI analysis across the ONWARD program (ONWARD1/2 and 3)—evaluating 890 patients originally randomized to envudeucitinib in ONWARD1/2, including those who did not transition into ONWARD3—demonstrated that 66% and 47% of patients who received 48 weeks of envudeucitinib achieved PASI 90 and PASI 100, respectively.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Itch and DLQI at 48 weeks, NRI analysis of 773 participants from the envudeucitinib arms

> “In ONWARD3, nearly 80% of patients sustained clinically meaningful itch reduction through Week 48.”
> “In ONWARD3, more than 70% of patients maintained DLQI 0/1 at 48 weeks.”
> “ONWARD3: N=1,509, data reported from non-responder imputation analysis in 773 patients from envudeucitinib arms who received up to 48 weeks of continuous treatment (24 weeks in ONWARD1/2 and up to 24 weeks in ONWARD3).”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-3.1.3.8.4-2"></a>

###### Maintenance of itch and DLQI response at 48 weeks among ONWARD1 and ONWARD2 responders

| Endpoint | Achieved response at the end of ONWARD1 and 2, n | Maintained response after 24 weeks in ONWARD3 (48 weeks of total exposure), % (95% CI) |
| --- | --- | --- |
| At least 4-point improvement from parent baseline in NRS worst pruritus, among patients with parent baseline NRS worst score ≥4 | “509” | “86.2 (82.9, 89.1)” |
| DLQI-0/1, among patients with parent baseline DLQI ≥2 | “497” | “86.3 (83.0, 89.2)” |

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.4-3"></a>

###### Itch and quality-of-life conclusions of the congress poster

> “Nearly 80% of patients reported clinically-meaningful improvements in itch and >70% demonstrated sustained quality of life improvements”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Adverse events with exposure-adjusted incidence rates by parent-study arm through week 48

| Event | Envudeucitinib then envudeucitinib (n = 773), n (%) | EAIR | Placebo then envudeucitinib (n = 367), n (%) | EAIR | Apremilast then envudeucitinib (n = 369), n (%) | EAIR |
| --- | --- | --- | --- | --- | --- | --- |
| At least 1 TEAE | “521 (67.4)” | “177.9” | “253 (68.9)” | “185.4” | “268 (72.6)” | “219.2” |
| At least 1 SAE | “25 (3.2)” | “4.7” | “16 (4.4)” | “6.3” | “9 (2.4)” | “3.6” |
| TEAEs grade ≥3 | “45 (5.8)” | “8.6” | “31 (8.4)” | “12.5” | “16 (4.3)” | “6.5” |
| TEAEs leading to discontinuation | “23 (3.0)” | “4.3” | “11 (3.0)” | “4.2” | “25 (6.8)” | “10.1” |
| Related TEAEs | “104 (13.5)” | “21” | “52 (14.2)” | “21.7” | “82 (22.2)” | “37.9” |
| Nasopharyngitis | “109 (14.1)” | “22.2” | “67 (18.3)” | “28.8” | “44 (11.9)” | “19” |
| Upper respiratory tract infection | “92 (11.9)” | “18.4” | “44 (12.0)” | “18.1” | “44 (11.9)” | “18.7” |
| Influenza | “34 (4.4)” | “6.5” | “19 (5.2)” | “7.5” | “17 (4.6)” | “6.9” |
| Urinary tract infection | “37 (4.8)” | “7.1” | “9 (2.5)” | “3.5” | “13 (3.5)” | “5.3” |
| Acne | “14 (1.8)” | “2.6” | “9 (2.5)” | “3.5” | “18 (4.9)” | “7.5” |

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.5-2"></a>

###### Patient-years of exposure, exposure basis of the incidence rates, deaths, MACE, laboratory abnormalities, malignancies, and tuberculosis

> “Total patient years, years 532.6 259.7 249.6”
> “EAIR is based on exposure in ONWARD 3 only.”
> “Majority of TEAEs were non-serious, grade 1 and 2, resolved and did not lead to study discontinuation”
> “There were no deaths, no MACE events, no clinically significant lab abnormalities, no lymphomas, and no tuberculosis reactivation”
> “Three positive tuberculosis tests were reported with no clinical signs or symptoms; none discontinued study treatment.”
> “Malignancies and serious infections occurred at rates consistent with expected background rates in a psoriasis population”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.5-3"></a>

###### Safety compared with ONWARD1 and ONWARD2 in the topline release

> “Treatment with envudeucitinib in ONWARD3 continued to be well tolerated, with a safety profile consistent with ONWARD1/2 and no new safety signals observed.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="topic-3.1.3.8.5-4"></a>

###### Safety with long-term exposure in the Fall Clinical release

> “No new safety signals were observed with long-term exposure in ONWARD3.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

- Results of the randomized treatment withdrawal period, which began after 24 weeks for the first 200 participants, are “data not reported” in the congress poster.
- All participants received open-label envudeucitinib during the first 24 weeks, with no concurrent control group; regulatory guidance states that the absence of a concurrent control group makes it more difficult to assess the causality relationship between adverse events and the drug.
- Entry required completion of week 24 of a parent trial, consent, and acceptable safety and tolerability of the drug in the parent study. The maintenance analyses are restricted to participants who had a response at entry, and the poster states that the analyses are descriptive.
- Envudeucitinib exposure at week 48 differed by parent-study arm (48, 32, and 24 weeks), and the exposure-adjusted incidence rates are based on exposure in ONWARD3 only.
- Week 48 PASI 90 and PASI 100 rates come from two analyses: a non-responder imputation analysis of 773 entrants (75% and 54%) and an integrated non-responder imputation analysis of 890 participants originally randomized to envudeucitinib (66% and 47%).
- Enrollment is reported as 1680 (estimated, ClinicalTrials.gov), 1,509 entrants (press release), and 773, 367, and 369 by parent-study arm (poster).
- The poster describes malignancies and serious infections as occurring at rates consistent with expected background rates without giving counts, and the report holds no ONWARD3 participant disposition beyond study entry.
- The study is ongoing, with primary completion estimated for 2028-11.

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541); [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm); [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf); [ICH E1 population exposure guideline (1995)](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-1-population-exposure-extent-population-exposure-assess-clinical-safety-step-5_en.pdf)

<a id="topic-3.1.3.9-2"></a>

###### Randomized withdrawal period results not reported in the congress poster

> “Randomized treatment withdrawal period began after 24 weeks in ONWARD3 for first 200 patients; data not reported”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.9-3"></a>

###### Regulatory guidance on causality assessment in studies without a concurrent control group

> “A study that has no concurrent control group makes it more difficult to assess the causality relationship between adverse events observed and the test drug.”

Source: [ICH E1 population exposure guideline (1995)](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-1-population-exposure-extent-population-exposure-assess-clinical-safety-step-5_en.pdf)

<a id="heading-3.1.4"></a>

#### 3.1.4 STRIDE

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Objective in the published article

> “To assess clinical efficacy, safety, and pharmacokinetics of ESK-001 compared to placebo in patients with moderate-to-severe plaque psoriasis.”
> “The phase 2 STRIDE study aimed to assess the efficacy, safety, tolerability, and PK characteristics across a range of ESK-001 doses versus placebo during 12 weeks of treatment in adults with moderate-to-severe plaque psoriasis.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.1-2"></a>

###### Main and secondary objectives in the EU Clinical Trials Register

> “E.2.1 Main objective of the trial To compare the Psoriasis Area and Severity Index (PASI-75) between doses of ESK-001 and placebo after 12 weeks of treatment”
> “1.To assess the safety and tolerability of ESK-001 dose in moderate to severe psoriasis patients.”
> “2. To characterize the pharmacokinetics (PK) of ESK-001.”
> “3.To assess the response rate in static Physician’s Global Assessment (sPGA) score after 12 weeks of treatment.”
> “4.To assess the response rate in PASI-50,90, and 100 score after 12 weeks of treatment.”
> “5.To compare the response rate in PASI-75 among ESK-001 treatments.”
> “6.To assess the effect on body surface area (%BSA) involved with psoriasis after 12 weeks of treatment.”
> “7.To assess the change in Dermatology Life Quality Index (DLQI)”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="topic-3.1.4.1-3"></a>

###### Purpose of the study in the protocol synopsis

> “The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of ESK-001 compared to placebo in patients with moderate to severe psoriasis.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-09-27”
> “Primary Completion (Actual) 2023-06-29”
> “Study Completion (Actual) 2023-07-25”
> “First Posted 2022-10-31”
> “Results First Posted 2024-07-23”

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

<a id="topic-3.1.4.2-2"></a>

###### Number of sites in the published article, the ClinicalTrials.gov record, and the protocol

> “A total of 228 patients were enrolled from 30 sites in North America and Europe beginning in September 2022.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

> “This study has 53 locations”

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

> “Study will be conducted at approximately 65 sites in North America and Europe.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.2-3"></a>

###### Countries of trial sites in the ClinicalTrials.gov record

| Country | First site listed for the country in the record |
| --- | --- |
| United States | “Birmingham, Alabama, United States, 35205” |
| Canada | “Edmonton, Alberta, Canada, T6G 1C3” |
| Czechia | “Nový Jičín, Czechia, 741 01” |

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

<a id="topic-3.1.4.2-4"></a>

###### Planned regions, planned sites, authorization dates, and end date in the EU Clinical Trials Register

> “E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned Canada United States Czechia Poland”
> “E.8.4.1 Number of sites anticipated in Member State concerned 5”
> “E.8.5.1 Number of sites anticipated in the EEA 15”
> “Date of Competent Authority Decision 2023-01-30”
> “Date of Ethics Committee Opinion 2023-02-07”
> “Date of the global end of the trial 2023-07-25”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Randomized, double-blinded, placebo-controlled 16-week design with stratified randomization in the published article

> “STRIDE (NCT05600036, EudraCT Number 2022-002633-34) was a phase 2, double-blinded, 16-week study with patients randomized to 6 treatment groups for 12 weeks of placebo or ESK-001, ranging from 10 mg QD to 40 mg BID.”
> “ESK-001-006 (STRIDE) was a randomized, double-blinded, placebo-controlled, 16-week study consisting of a screening period (up to 4 weeks), treatment period (12 weeks), and safety follow-up period (4 weeks)”
> “Randomization was stratified by prior use of biologics and geographic region.”
> “The study patients, investigators, study personnel at sites, and sponsor representatives on the clinical study team were all blinded to treatment assignments.”
> “After completing the study, patients were eligible to receive ESK-001 treatment in an open-label extension study (ESK-001-007, NCT05739435).”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.3-2"></a>

###### Design in the ClinicalTrials.gov record

> “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis”
> “This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.”
> “This study will consist of a 4 week screening period, 12 week treatment period, and a 4 week follow up period for a total of 20 weeks.”

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

| Design field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Triple (ParticipantInvestigatorOutcomes Assessor)” |

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

<a id="topic-3.1.4.3-3"></a>

###### Design fields in the EU Clinical Trials Register

> “E.7.2 Therapeutic exploratory (Phase II) Yes”
> “E.8.1.4 Double blind Yes”
> “E.8.1.5 Parallel group No”
> “E.8.2.4 Number of treatment arms in the trial 6”
> “E.8.7 Trial has a data monitoring committee Yes”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="topic-3.1.4.3-4"></a>

###### Study duration and safety monitoring committee in the protocol

> “The total duration of study participation for each patient will be approximately 20 weeks.”
> “A safety monitoring committee (SMC) comprising representatives from the Sponsor, clinical research organization (CRO), two independent physicians and a statistician will be utilized in this study.”
> “The SMC will initially convene to review all available safety data after approximately 50 patients have been randomized and completed their Week 4 visit.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Inclusion criteria in the protocol

> “1. Able and willing to provide signed informed consent to participate in this study”
> “2. Males or females, age 18-75 years, inclusive, at the Screening Visit”
> “3. Total body weight >40 kg (88 lb)”
> “4. Diagnosis of plaque psoriasis for ≥6 months”
> “5. Plaques covering ≥10% of body surface area (BSA)”
> “6. Psoriasis area severity index (PASI) score ≥12 and static Physician’s Global Assessment (sPGA) score ≥3”
> “7. Women of childbearing potential (WOCBP) must agree to adhere to highly effective methods of contraception for the entirety of the study and for 30 days after the last dose of study drug”
> “8. Males who are sexually active with WOCBP must agree to use highly effective methods of contraception for the entirety of the study and for 90 days after the last dose of study drug”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.4-2"></a>

###### Exclusion criteria on psoriasis type, associated conditions, psoriatic arthritis, and pregnancy in the protocol

> “1. Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic, drug induced)”
> “2. Diagnosis of immune-mediated conditions that are commonly associated with psoriasis (e.g., uveitis, inflammatory bowel disease) or other inflammatory skin conditions that may interfere with the study assessment”
> “3. Patients with psoriatic arthritis who are receiving systemic (oral, SC, IM or IV) immunosuppressant medications (including corticosteroids, immunosuppressant biologics) or who has or is expected, in the opinion of the investigator, to develop unstable disease.”
> “4. Pregnant, lactating, or planning to get pregnant during the study period”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.4-3"></a>

###### Exclusion criteria on prior treatment washout and lack of response to biologic therapies in the protocol

> “5. Has used topical medications/treatments that could affect psoriasis evaluation within 2 weeks of the first administration of study drug”
> “6. Has received phototherapy or any systemic medications/treatments that could affect psoriasis evaluation within 4 weeks of Study Day 1”
> “7. Has received any therapeutic agent targeted to: IL-12or IL-23 within 6 months, IL-17 within 4 months, or any TNFα inhibitor(s) within 2 months of first administration of study drug”
> “8. Is currently receiving or has received any systemic immunosuppressants or immunomodulatory drugs (e.g., methotrexate, cyclosporine) within 4 weeks of the first administration of study drug or 5 half-lives whichever is longer”
> “9. Has received agents that modulate B cells (e.g., rituximab, ocrelizumab) within 6 months of first administration of study drug”
> “10. Has received agents that modulate T cells (e.g., abatacept, alemtuzumab) within 3 months of first administration of study drug”
> “11. Has received JAK inhibitors (e.g., baricitinib, tofacitinib) or TYK2 inhibitors within 4 weeks of first administration of study drug”
> “12. History of lack of clinical response to any therapeutic agent targeted to IL-12, IL-17 or IL-23 (e.g., ustekinumab, risankizumab, secukinumab, ixekizumab) at approved doses after at least 3 months of treatment”
> “13. History of lack of clinical response, in the Investigator’s opinion, to 2 or more biologic therapies at approved doses after at least 3 months of treatment”
> “14. Has received any investigational agent, within 30 days or 5 half-lives (whichever is longer) of any study drug or is currently enrolled in an investigational study”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.4-4"></a>

###### Exclusion criteria on QTcF, cardiovascular disease, infections, and laboratory values in the protocol

> “16. Patients with QTcF >450 msec (males) or >470 msec (females) at screening”
> “17. Unstable cardiovascular disease, defined as a recent clinical deterioration (e.g., unstable angina, rapid atrial fibrillation) or a cardiac hospitalization within the last 3 months”
> “18. Active herpes viral infection, including herpes simplex 1 and 2 and herpes zoster identified on examination and/or medical history within 2 months of administration of study drug”
> “19. Patients with hepatitis C virus (HCV), or hepatitis B virus (HBV) or human immunodeficiency virus (HIV) or active or inadequately treated latent tuberculosis (TB) infection at screening”
> “20. Has any of the following lab abnormalities:”
> “Absolute neutrophil count <1.5 X 10^9/L”
> “Hemoglobin <9 g/dL”
> “AST/ALT ≥2 x upper limit of normal (ULN)”
> “Albumin <3 g/dL”
> “Total bilirubin ≥2 x ULN (patients with a history of Gilbert’s syndrome are not eligible)”
> “Glomerular filtration rate <50 (Cockcroft and Gault method)”
> “22. History of serious bacterial, fungal, or viral infections that led to hospitalization and IV antibiotic treatment within 90 days prior to screening, or any recent serious infection requiring antibiotic treatment within 30 days of Study Day 1”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.4-5"></a>

###### Exclusion criteria on corticosteroid-requiring conditions, malignancy, live vaccines, surgery, and mental illness in the protocol

> “21. History of any immune-mediated or inflammatory medical condition for which patient requires current systemic (oral, SC, IM or IV) corticosteroids”
> “23. Known current malignancy or current evaluation for a potential malignancy or history of malignancy within the past 5 years prior to screening, except for adequately treated basal cell skin carcinoma, carcinoma in situ of the cervix and breast ductal carcinoma in situ”
> “24. Live vaccines (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, and bacillus Calmette-Guérin) within 4 weeks of Study Day 1”
> “25. Patient has a known hypersensitivity to any component of the study drug”
> “26. Patient has planned surgery during the study period”
> “27. Any acute or chronic illness/condition or evidence of an unstable clinical condition that in the investigator’s judgement will substantially increase the risk to the patient if he or she participates in the study”
> “28. History of mental illness within the last 5 years, unless the patient fulfills one of the following conditions:”
> “Receiving a fixed regimen of psychiatric medications for at least 6 months before screening, displays no sign of acute mental illness and, in the opinion of the investigator, the patient is able and safe to participate in the study”
> “Has not required or been prescribed any psychiatric medication (including but not limited to antidepressants or anxiolytics) within 12 months before screening and, in the opinion of the investigator, the patient is able and safe to participate in the study”
> “29. Patient who, for any reason, is deemed by the investigator to be inappropriate for this study or is unable to comply with the study protocol”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.4-6"></a>

###### Body mass index added to the weight criterion in the EU Clinical Trials Register

> “Total body weight >40 kg (88 lb), BMI > 18 kg/m2”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="topic-3.1.4.4-7"></a>

###### Eligibility criteria summarized in the supplementary material of the published article

> “Eligible patients were adults with plaque psoriasis between the ages of 18-75 years with a total body weight >40 kg (88 lb), a diagnosis of plaque psoriasis for ≥6 months, body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) ≥12 and static Physician’s Global Assessment (sPGA) score ≥3 at baseline.”
> “Key patient exclusion criteria included presence of unstable medical conditions, active viral infections, active or untreated latent tuberculosis, or current malignancy.”
> “Patients who had been previously unresponsive to agents targeting IL-12, IL-23, or IL-17, patients who had failed more than 2 biologics, or patients who had received any investigational treatment within 30 days or 5 half-lives of treatment with study drug were excluded from the study.”

Source: [Blauvelt et al. (2025b)](https://data.mendeley.com/public-files/datasets/zs5xvkwpym/files/d4eed96a-ef9b-421e-91a5-551459647784/file_downloaded)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Dose groups, randomization, administration, and placebo matching in the published article

> “On day 1, eligible patients were randomized equally into 1 of 6 treatment groups (ESK-001 10 mg once daily [QD], 20 mg QD, 40 mg QD, 20 mg twice daily [BID], 40 mg BID, or placebo).”
> “Patients were directed to take study drug tablets orally with or without food.”
> “Placebo tablets were matched for shape, size, and color.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.5-2"></a>

###### Arms and tablet regimens in the ClinicalTrials.gov results

| Arm | Arm description in the results |
| --- | --- |
| ESK-001 10 mg QD | “ESK-001 10mg tablet once a day” |
| ESK-001 20 mg QD | “ESK-001 20mg tablet once a day” |
| ESK-001 40 mg QD | “ESK-001 40mg tablet once a day” |
| ESK-001 20 mg BID | “ESK-001 20mg tablet twice a day” |
| ESK-001 40 mg BID | “ESK-001 40mg tablet twice a day” |
| Placebo | “Placebo tablet” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="topic-3.1.4.5-3"></a>

###### Randomization ratio across five dose levels and placebo in the protocol

> “Patients fulfilling all eligibility criteria will be randomized in a 1:1:1:1:1:1 manner to receive oral doses of ESK-001 at one of 5 dose levels”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using PASI 75 Response as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary, secondary, and exploratory efficacy end points in the published article

> “The primary efficacy end point was the proportion of patients achieving ≥75% reduction from baseline Psoriasis Area and Severity Index (PASI) at 12 weeks between ESK-001 dose groups and placebo.”
> “The secondary efficacy end points measured at week 12 included proportions of patients achieving PASI-50, 90, or 100; proportion of patients achieving a static Physician's Global Assessment (sPGA) score of “0” (“clear skin”) or “1” (“minimal disease”); and changes from baseline in % body surface area compared to placebo.”
> “End points assessing patient-reported outcomes at week 12 compared to placebo included the secondary end point of change from baseline in Dermatology Life Quality Index (DLQI) and the exploratory end point of change from baseline in pruritus numerical rating scale score for worst or on-average severity of itch over the prior 24 hours.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.6.1-2"></a>

###### Safety and pharmacokinetic outcomes in the published article

> “Safety outcomes included the incidence of treatment-emergent adverse events (TEAEs), serious adverse events, laboratory test results, and electrocardiogram parameters.”
> “AEs were coded according to the Medical Dictionary for Regulatory Activities, version 25.0.”
> “Key parameters, including Cmax (maximum (or peak) serum concentration), Ctrough (concentration reached by a drug immediately before the next dose is administered), and Tmax (time of peak plasma concentration), were assessed using population PK modeling and noncompartmental analysis, providing a characterization of ESK-001's PK profile and variability within the study population.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.6.1-3"></a>

###### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Outcome type | Outcome measure | Measure description | Time frame |
| --- | --- | --- | --- |
| Primary | “To Compare the Psoriasis Area and Severity Index (PASI-75) Between Doses of ESK-001 and Placebo” | “Proportion of patients with moderate to severe psoriasis achieving ≥75% reduction in PASI score” | “12 weeks” |
| Secondary | “To Assess the Safety and Tolerability of ESK-001 Dose in Moderate to Severe Psoriasis Patients” | “Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). See Adverse Events section.” | “12 weeks” |
| Secondary | “To Assess the Response Rate in Static Physician's Global Assessment (sPGA) Score” | “Proportion of patients achieving an sPGA score of "0" ("cleared") or "1" ("minimal")” | “12 weeks” |
| Secondary | “To Characterize the Pharmacokinetics (PK) of ESK-001” | “Plasma concentrations and PK parameters of ESK-001.” | “14 weeks” |

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

<a id="topic-3.1.4.6.1-4"></a>

###### Pharmacokinetic outcome measures at registration, October 2022, superseded in June 2024

> “Plasma concentrations and PK parameters including steady-state maximum observed concentration (Cmax) for ESK-001 at Week 8”
> “Plasma concentrations and PK parameters including steady-state trough observed plasma concentration (Ctrough) for ESK-001 at Week 8”

Source: [ClinicalTrials.gov NCT05600036 version 1](https://clinicaltrials.gov/study/NCT05600036?tab=history&a=1)

<a id="topic-3.1.4.6.1-5"></a>

###### Primary and secondary end points in the EU Clinical Trials Register

> “Proportion of patients with moderate to severe psoriasis achieving ≥75% reduction in PASI score at 12 weeks between doses of ESK-001 and placebo”
> “Proportion of patients achieving PASI-75 at 12 weeks compared among the ESK-001 treatments”
> “Change from baseline in %BSA after 12 weeks of ESK-001 treatment compared with placebo.”
> “Change from baseline in DLQI at Week 12 in ESK-001 compared with placebo”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="topic-3.1.4.6.1-6"></a>

###### Exploratory end points in the protocol

> “Change from baseline in NRS score after 12 weeks of ESK-001 treatment compared with placebo”
> “Change from baseline in EQ-5D at Week 12 in ESK-001 compared with placebo”
> “Change from baseline in transcriptomic and proteomic expression in response to ESK-001 treatment”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.6.1-7"></a>

###### PASI and sPGA scoring and the timepoint of the PASI-based end points in the protocol

> “The PASI system derives a score for the severity of psoriatic lesions by evaluating erythema, induration, and scaling in each of 4 body regions, as detailed in Appendix A. The primary and secondary endpoints are based on the PASI response at the end of treatment (12-week timepoint).”
> “The PASI is a grading system used for the evaluation of the severity of psoriatic lesions and their response to treatment. The PASI produces a numeric score that can range from 0 to 72.”
> “The Physician Global Assessment (PGA) is used to determine the subject’s psoriasis lesions overall at a given time point.”
> “0 = Cleared, except for residual discoloration”
> “1 = Minimal - majority of lesions have individual scores for I + E + S / 3 that averages 1”
> “5 = Severe - majority of lesions have individual scores for I + E + S / 3 that averages 5”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.6.1-8"></a>

###### Responder definitions for DLQI and pruritus NRS in the statistical analysis plan

> “The primary endpoint is the proportion of subjects achieving >=75% reduction in PASI score (PASI-75) at Week 12.”
> “The two questions collected in NRS questionnaire will be assessed separated as the average itch within the past 24 hours and the worst itch within the past 24 hours.”
> “Additionally, a responder analysis will be conducted for DLQI where a responder is defined as the subject who achieved a post-baseline score of 0 or 1.”
> “A responder analysis will also be conducted for NRS questionnaire where a responder is defined as a subject who has achieved a post-baseline itch score of < 4.”

Source: [Alumis STRIDE statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/SAP_001.pdf)

<a id="topic-3.1.4.6.1-9"></a>

###### Regulatory guidance on dose-finding designs and on the duration needed to show short-term efficacy

> “The dose-finding studies should be randomised, and placebo-controlled using parallel group design.”
> “The studies should characterise the most beneficial part of the dose-response curve and use at least 3 dosages to establish the optimal dose compared to placebo.”
> “A duration of 8 to 12 weeks (4 weeks for a potent topically applied corticosteroid) is generally sufficient to show short-term efficacy, except for drugs with slow onset of action, where longer study duration may be needed.”

Source: [EMA psoriasis clinical investigation guideline (2004)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Sample size calculation in the published article

> “The sample size was determined based on the primary efficacy end point. Calculations were based on a 1:1:1:1:1:1 randomization ratio and provided at least 99% power to detect an absolute difference in the PASI-75 response rate of at least 50% in an active group compared to placebo.”
> “A sample size of 35 patients per dose group was estimated with a two-sided, two-sample t-test at a significance level of 0.05.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.7.1-2"></a>

###### Planned enrollment and sample size assumptions in the protocol

> “Approximately 210 patients will be randomly assigned to one of the 6 study arms (35 patients per arm).”
> “The Sponsor may choose, based on the evolving data (e.g., safety) from ESK-001 studies, to enroll up to 50 additional patients.”
> “Calculations are based on a 1:1:1:1:1:1 randomization ratio (ESK-001 doses 1-5 vs. placebo) and will provide at least 99% power to detect 50% increase in the PASI-75 response rate in an active arm (i.e., 60% response rate) compared to the placebo assuming the response rate is 10% in the placebo arm.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.7.1-3"></a>

###### Planned enrollment in the EU Clinical Trials Register

> “F.4.1 In the member state 30”
> “F.4.2.1 In the EEA 60”
> “F.4.2.2 In the whole clinical trial 210”

Source: [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)

<a id="topic-3.1.4.7.1-4"></a>

###### Estimated enrollment at registration in the ClinicalTrials.gov record

> “Enrollment 210 [Estimated]”

Source: [ClinicalTrials.gov NCT05600036 version 1](https://clinicaltrials.gov/study/NCT05600036?tab=history&a=1)

<a id="topic-3.1.4.7.1-5"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 228”

Source: [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)

<a id="topic-3.1.4.7.1-6"></a>

###### Participants per arm in the intent-to-treat, modified intent-to-treat, and safety analysis sets of the published article

| Analysis set (table) | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
| --- | --- | --- | --- | --- | --- | --- |
| Intent-to-treat (Table I) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 40)” | “(N = 39)” | “(N = 39)” |
| Modified intent-to-treat (Table II) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 39)” | “(N = 39)” | “(N = 39)” |
| Safety (Table III) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 39)” | “(N = 39)” | “(N = 39)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

| Analysis set (table) | Pooled ESK-001 column header |
| --- | --- |
| Intent-to-treat (Table I) | “ESK-001 pooled (N = 190)” |
| Safety (Table III) | “ESK-001 pooled (N = 189)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Efficacy and safety analysis populations, statistical tests, and missing-data handling in the published article

> “All efficacy analyses were based on the modified intent-to-treat population, which included randomized patients who received at least 1 dose of study drug with analyses conducted according to the randomized treatment.”
> “All efficacy responder-type end points were assessed with the Cochran-Mantel-Haenszel test and adjusted for stratification factors.”
> “A nonresponder imputation was applied to responder analyses in which patients who dropped out of the study before week 12 were considered as nonresponders at the week 12 visit.”
> “Safety analyses included all patients who received at least 1 dose of either ESK-001 or placebo.”
> “Subjects were analyzed according to the actual treatment received for safety analyses.”
> “Baseline in this study was defined as the last available data on or prior to the time of the first dose of study drug.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.7.2-2"></a>

###### Analysis sets named in the table captions and notes of the published article

> “Demographic and baseline characteristics of STRIDE study (ITT analysis set)”
> “Summary of efficacy outcomes at Week 12 of STRIDE study (mITT analysis set)”
> “The modified intent-to-treat (mITT) analysis set includes all randomized patients who received ≥1 dose analyzed based on their randomized treatment. For patients with missing data at week 12, a nonresponder imputation (NRI) was applied for all responder end points.”
> “P values were calculated by comparing the proportion in each active arm vs placebo using the Cochrane-Mantel-Haenszel test adjusted for randomization stratification factors.”
> “Summary of TEAEs in STRIDE study (safety analysis set)”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.7.2-3"></a>

###### Analysis populations, stratification factors, multiplicity, and treatment-emergent period in the statistical analysis plan

> “Modified Intent-to-Treat (mITT) Population: All randomized subjects who received at least one dose of study drug, with analyses conducted according to the assigned treatment. This will be the analysis population used for the primary efficacy analysis at Week 12.”
> “Intent-to-treat (ITT) Population: All randomized subjects, regardless of whether they receive study drug, with analyses conducted according to the assigned treatment.”
> “Per-protocol (PP) Population: All subjects in the ITT population who have received at least one dose of study drug as assigned, have both baseline and at least one post-baseline PASI score, and have no important protocol deviations (IPD) which may affect key primary and secondary efficacy endpoints in the treatment period.”
> “Safety Analysis Population: All randomized subjects who receive at least one dose of study drug with analyses conducted by actual treatment received.”
> “PK Analysis Population: All randomized subjects who receive at least 1 dose of ESK-001 and have at least one non-missing PK concentration with analysis conducted by actual treatment received.”
> “Prior use of biologics or JAK inhibitors (yes/no)”
> “Geographic region (North America /rest of world (ROW))”
> “No adjustments for multiplicity control will be performed in this study.”
> “The treatment emergent period is defined as first dose through the end of study for subjects who complete the full treatment period of 12 weeks.”
> “If a subject discontinues study drug early, then the treatment emergent period will be first dose through four weeks after last dose.”
> “Since the EQ-5D-5L value sets used to calculate the index score are country-specific and there currently are none available for Czech Republic where some subjects are enrolled in this study, the value set for Poland will be used instead as the closest Eastern European country with available scoring instrument.”

Source: [Alumis STRIDE statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/SAP_001.pdf)

<a id="topic-3.1.4.7.2-4"></a>

###### Intent-to-treat efficacy analysis planned in the protocol

> “Efficacy analyses will be based on the intent-to-treat (ITT) approach. All patients randomized (ITT population) will be included in the analysis, and subjects will be analyzed according to their randomized treatment.”
> “Unless otherwise noted, analyses of efficacy outcome measures will be stratified by prior use of biologics and geographic region.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-3.1.4.7.2-5"></a>

###### Analysis population for each outcome measure in the ClinicalTrials.gov results

| Outcome measure | Analysis population description |
| --- | --- |
| PASI-75 (primary) | “Analysis Population Description All Randomized and Treated Participants” |
| Safety and tolerability | “Analysis Population Description Safety Analysis Set” |
| sPGA response | “Analysis Population Description mITT population” |
| Pharmacokinetics | “Analysis Population Description PK Analysis Set” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Randomized, dosed, completed, and discontinued participants in the published article

> “Of the 228 patients randomized to placebo or 1 of 5 ESK-001 doses, a total of 227 patients were dosed in this phase 2 study”
> “A total of 204 patients (89.5%) completed the study.”
> “Overall, study discontinuation was similar between treatment groups, with 18 (9%) patients in ESK-001 groups and 5 (13%) patients in the placebo group discontinuing”
> “Five patients (2.6%) discontinued ESK-001 due to an AE.”
> “Withdrawal of consent was the most common reason for discontinuation of treatment.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.1-2"></a>

###### Participant flow by arm with reasons for not completing in the ClinicalTrials.gov results

| Participant flow, overall study | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
| --- | --- | --- | --- | --- | --- | --- |
| Started | “38” | “36” | “36” | “40” | “39” | “39” |
| Completed | “33” | “36” | “30” | “37” | “33” | “35” |
| Not completed | “5” | “0” | “6” | “3” | “6” | “4” |
| Reason: adverse event | “0” | “0” | “2” | “0” | “1” | “1” |
| Reason: discontinued prior to dosing due to the blood sample logistics | “0” | “0” | “0” | “1” | “0” | “0” |
| Reason: lost to follow-up | “0” | “0” | “2” | “1” | “1” | “0” |
| Reason: protocol violation | “0” | “0” | “0” | “0” | “2” | “0” |
| Reason: subject can't continue with week 16 visit | “0” | “0” | “1” | “0” | “0” | “0” |
| Reason: terminated from the study due to sponsor requirements | “0” | “0” | “0” | “1” | “0” | “0” |
| Reason: withdrawal by subject | “5” | “0” | “1” | “0” | “2” | “3” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Demographic and baseline disease characteristics by arm in the intent-to-treat set

| Characteristic | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 40 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 | ESK-001 pooled, N = 190 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Mean age, years (SD) | “49 (11.7)” | “49 (12.7)” | “44 (12.0)” | “48 (12.5)” | “50 (10.4)” | “48 (14.2)” | “48 (12.4)” |
| Male, n (%) | “31 (82)” | “24 (67)” | “24 (67)” | “23 (58)” | “26 (67)” | “26 (67)” | “123 (65)” |
| Female, n (%) | “7 (18)” | “12 (33)” | “12 (33)” | “17 (43)” | “13 (33)” | “13 (33)” | “67 (35)” |
| Race, American Indian or Alaska Native, n (%) | “0 (0)” | “0 (0)” | “1 (3)” | “0 (0)” | “1 (3)” | “0 (0)” | “2 (1)” |
| Race, Asian, n (%) | “4 (11)” | “1 (3)” | “2 (6)” | “2 (5)” | “2 (5)” | “2 (5)” | “9 (5)” |
| Race, Black or African American, n (%) | “3 (8)” | “4 (11)” | “0 (0)” | “1 (3)” | “1 (3)” | “1 (3)” | “7 (4)” |
| Race, Native Hawaiian or Other Pacific Islander, n (%) | “0 (0)” | “1 (3)” | “0 (0)” | “2 (5)” | “0 (0)” | “0 (0)” | “3 (2)” |
| Race, White, n (%) | “27 (71)” | “30 (83)” | “31 (86)” | “34 (85)” | “33 (85)” | “33 (85)” | “161 (85)” |
| Race, other, n (%) | “4 (11)” | “0 (0)” | “2 (6)” | “1 (3)” | “2 (5)” | “1 (3)” | “6 (3)” |
| Race, not reported, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” | “2 (5)” | “2 (1)” |
| Ethnicity, Hispanic or Latino, n (%) | “13 (34)” | “7 (19)” | “14 (39)” | “7 (18)” | “13 (33)” | “11 (28)” | “52 (27)” |
| Ethnicity, not Hispanic or Latino, n (%) | “24 (63)” | “29 (81)” | “21 (58)” | “33 (83)” | “26 (67)” | “28 (72)” | “137 (72)” |
| Ethnicity, not reported, n (%) | “1 (3)” | “0 (0)” | “1 (3)” | “0 (0)” | “0 (0)” | “0 (0)” | “1 (1)” |
| Mean weight, kg (SD) | “94 (21.4)” | “92 (21.3)” | “103 (39.1)” | “95 (24.7)” | “88 (19.1)” | “91 (20.9)” | “94 (26.1)” |
| Mean BMI, kg/m2 (SD) | “32 (6.8)” | “31 (5.9)” | “35 (12.1)” | “32 (7.4)” | “30 (6.4)” | “32 (7.1)” | “32 (8.1)” |
| Mean duration of psoriasis, years (SD) | “20 (11.6)” | “19 (13.4)” | “17 (8.3)” | “22 (12.2)” | “17 (12.4)” | “22 (15.5)” | “19 (12.7)” |
| Prior treatment with biologics or JAK inhibitors, n (%) | “13 (34)” | “13 (36)” | “14 (39)” | “16 (40)” | “13 (33)” | “13 (33)” | “69 (36)” |
| Mean PASI score (SD) | “18 (4.5)” | “17 (3.9)” | “19 (6.6)” | “18 (6.5)” | “17 (6.5)” | “17 (4.9)” | “18 (5.8)” |
| sPGA score 3 (moderate), n (%) | “22 (58)” | “24 (67)” | “17 (47)” | “23 (58)” | “25 (64)” | “23 (59)” | “112 (59)” |
| sPGA score 4 (marked), n (%) | “15 (40)” | “9 (25)” | “17 (47)” | “16 (40)” | “14 (36)” | “16 (41)” | “72 (38)” |
| sPGA score 5 (severe), n (%) | “1 (3)” | “3 (8)” | “2 (6)” | “1 (3)” | “0 (0)” | “0 (0)” | “6 (3)” |
| Mean BSA, % (SD) | “23 (12.1)” | “21 (12.2)” | “20 (12.6)” | “21 (15.0)” | “20 (12.9)” | “22 (15.1)” | “21 (13.5)” |
| Mean DLQI score (SD) | “10 (7.2)” | “10 (5.4)” | “9 (7.6)” | “10 (7.2)” | “10 (6.4)” | “11 (6.8)” | “10 (6.7)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.2-2"></a>

###### Balance across arms and overall prior biologic or JAK inhibitor exposure in the published article

> “Baseline demographics and disease characteristics were generally well-balanced across treatment groups (Table I) and reflected the moderate-to-severe psoriasis population.”
> “Overall, 82 patients (36%) had prior biologics/JAK inhibitor exposure.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.2-3"></a>

###### Age categories by arm in the ClinicalTrials.gov results

| Age category, participants | Placebo, n = 38 | ESK-001 10 mg QD, n = 36 | ESK-001 20 mg QD, n = 36 | ESK-001 20 mg BID, n = 40 | ESK-001 40 mg QD, n = 39 | ESK-001 40 mg BID, n = 39 | Total, n = 228 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 18 years or younger | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| Between 18 and 65 years | “35” | “33” | “33” | “35” | “37” | “33” | “206” |
| 65 years or older | “3” | “3” | “3” | “5” | “2” | “6” | “22” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### PASI 75, PASI 90, PASI 100, sPGA 0/1, sPGA 0, and BSA results at week 12 by dose in the modified intent-to-treat set

| Week 12 end point | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 |
| --- | --- | --- | --- | --- | --- | --- |
| PASI-75, n (%) | “0 (0)” | “7 (19)” | “12 (33)” | “22 (56)” | “22 (56)” | “25 (64)” |
| PASI-75, P value vs placebo | “-” | “0.0025” | “0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
| PASI-75, difference vs placebo, % (95% CI) | “-” | “19 (−3, 41)” | “33 (11, 54)” | “56 (37, 73)” | “56 (37, 73)” | “64 (46, 79)” |
| PASI-90, n (%) | “0 (0)” | “0 (0)” | “4 (11)” | “10 (26)” | “10 (26)” | “15 (39)” |
| PASI-90, P value vs placebo | “-” | “-” | “.0322” | “.0007” | “.0005” | “<.0001” |
| PASI-90, difference vs placebo, % (95% CI) | “-” | “-” | “11 (−12,34)” | “26 (4, 46)” | “26 (4, 46)” | “39 (17, 58)” |
| PASI-100, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “4 (10)” | “3 (8)” | “6 (15)” |
| PASI-100, P value vs placebo | “-” | “-” | “-” | “.0396” | “.0712” | “.0127” |
| PASI-100, difference vs placebo, % (95% CI) | “-” | “-” | “-” | “10 (−12, 32)” | “8 (−15, 30)” | “15 (−7, 37)” |
| sPGA-0/1, n (%) | “3 (8)” | “6 (17)” | “14 (39)” | “19 (49)” | “21 (54)” | “23 (59)” |
| sPGA-0/1, P value vs placebo | “-” | “.1965” | “.0012” | “<.0001” | “<.0001” | “<.0001” |
| sPGA-0/1, difference vs placebo, % (95% CI) | “-” | “9 (−14, 32)” | “31 (8, 51)” | “41 (20, 60)” | “46 (26, 65)” | “51 (31, 69)” |
| sPGA-0, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “4 (10)” | “4 (10)” | “9 (23)” |
| sPGA-0, P value vs placebo | “-” | “-” | “-” | “.0396” | “.0333” | “.0017” |
| sPGA-0, difference vs placebo, % (95% CI) | “-” | “-” | “-” | “10 (−12, 32)” | “10 (−12,32)” | “23 (1, 44)” |
| Mean BSA change from baseline (SD) | “−3 (6.8)” | “−7 (7.8)” | “−7 (8.1)” | “−14 (12.9)” | “−15 (14.2)” | “−14 (12.1)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.3-2"></a>

###### Primary end point, dose-dependent response, and key secondary end points in the published article

> “ESK-001 demonstrated both clinically meaningful and statistically significant dose-dependent improvements in psoriasis skin severity and quality of life”
> “A dose-dependent effect was observed across all end points, with maximal ESK-001 efficacy observed in the highest dose arm (40 mg BID).”
> “More patients achieved PASI-75 in each of the ESK-001 dose arms compared with placebo: 64% in the 40 mg BID dose arm vs 0% in the placebo group (P < .0001) at week 12, meeting the primary end point.”
> “Likewise, all key secondary end points were met in the 20 mg BID, 40 mg QD, and 40 mg BID dose arms.”
> “In patients receiving ESK-001 40 mg BID, 39% (P < .0001) and 15% (P = .0127) achieved PASI-90 and PASI-100, respectively (placebo, 0%).”
> “Furthermore, 59% (P < .0001) and 23% (P = .0017) achieved sPGA-0/1 and sPGA-0, respectively (placebo, 8% and 0%, respectively).”
> “Clinical responses to ESK-001 were robust and increased over time in all ESK-001 dose arms.”
> “In the 3 highest dose groups, clinically meaningful improvements in the primary and all secondary end points were achieved, including PASI, sPGA, DLQI, pruritus, and % body surface area involvement (P < .001).”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.3-3"></a>

###### Maintenance of PASI 75 and PASI 90 responses during the 4 weeks off treatment, and response trajectories at week 12

> “During the 4 weeks off ESK-001 in the safety follow-up period between week 12 and week 16, 83% and 85% of patients in the 40 mg BID dose arm maintained their PASI-75 and PASI-90 responses, respectively.”
> “Clinical responses increased over time, with response trajectories suggesting maximal efficacy not yet achieved at the time of the primary end point (week 12) as noted across other treatments for psoriasis.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.3-4"></a>

###### PASI 75 response rates with 95% confidence intervals in the ClinicalTrials.gov results

| Week 12 outcome | Placebo, n = 38 | ESK-001 10 mg QD, n = 36 | ESK-001 20 mg QD, n = 36 | ESK-001 20 mg BID, n = 39 | ESK-001 40 mg QD, n = 39 | ESK-001 40 mg BID, n = 39 |
| --- | --- | --- | --- | --- | --- | --- |
| PASI-75, percentage (95% CI) | “0 (0.0 to 9.3)” | “19.4 (8.2 to 36.0)” | “33.3 (18.6 to 51.0)” | “56.4 (36.6 to 72.2)” | “56.4 (39.6 to 72.2)” | “64.1 (47.2 to 78.8)” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="topic-3.1.4.8.3-5"></a>

###### Plasma ESK-001 concentrations by dose in the ClinicalTrials.gov results

> “To Characterize the Pharmacokinetics (PK) of ESK-001 Type: Secondary | Time Frame: 14 weeks Description Plasma concentrations and PK parameters of ESK-001.”
> “Mean (Standard Deviation) | Unit of Measure: ng/ml”

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

| Plasma ESK-001 concentration, ng/ml | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
| --- | --- | --- | --- | --- | --- | --- |
| Mean (SD) | “2.9(10.5)” | “11.9(12.4)” | “33.0(49.9)” | “63.9(44.8)” | “50.7(44.8)” | “174.0(125.0)” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="topic-3.1.4.8.3-6"></a>

###### Dose-proportional pharmacokinetics, exposure-response, and trough coverage of the IC90 in the published article

> “PK findings demonstrated dose-dependent linear kinetics.”
> “A positive correlation between ESK-001 exposure and PASI was observed, with patients achieving PASI-90 and PASI-100 having higher mean exposures compared to patients achieving PASI-75”
> “ESK-001 demonstrated a dose-dependent increase in TYK2 inhibition, with the 40 mg BID dose achieving continuous IC90 coverage at trough levels over 24 hours, a key characteristic demonstrating optimized efficacy outcomes.”
> “The observed trough exposure levels (Ctrough = 182 ng/mL) exceeded the in vitro human whole blood IC90 for phosphorylated signal transducer and activator of transcription inhibition (144 ng/mL) throughout the dosing period, indicating sustained and continued TYK2 inhibition over time.”
> “Additionally, the PK findings were consistent with results from studies in healthy volunteers, demonstrating favorable, dose-dependent linear kinetics with minimal variability.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.3-7"></a>

###### Blood SIGLEC1 and lesional skin biomarker results in the published article

> “Transcriptomic analysis confirmed that maximal inhibition of TYK2 occurred with the 40 mg BID dose, as measured by SIGLEC1 via blood RNA-seq, a novel TYK2-sensitive pharmacodynamic biomarker”
> “RNA-seq analyses in skin showed a reduction in key disease biomarkers (including IL-23, IL-17F, and β-defensin in lesional skin following 12 weeks of treatment with ESK-001), with expression levels of IL-17F and IL-23A normalizing to the levels found in nonlesional skin after treatment with 40 mg BID dose”
> “Optional skin punch biopsies were collected from a subset of patients with approximately 5-12 patient samples collected per dose group, consisting of paired lesional and nonlesional samples at baseline, and a lesional sample at week 12.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.3-8"></a>

###### Exploratory exposure-response analysis and selection of the 40 mg twice-daily dose for phase 3

> “Data from 121 healthy subjects and 185 subjects with PsO.”
> “Cavg of ESK-001 was categorized into four exposure groups or bins (Bin 1 = placebo, Bin 2-4 = tertiles of exposure from low to high; number of subjects is about equal for each bin).”
> “STRIDE Week 12 Cavg probability distribution by exposure bins showed that 40 mg BID had substantially higher exposures overall and thus, would be expected to have the strongest efficacy.”
> “The exploratory E-R analyses demonstrated an exposure-dependent increase in key efficacy endpoints PASI-75, sPGA 0/1, and %BSA change responses.”
> “Maximal therapeutic response was achieved at 40 mg BID dose, which maintained a safety profile comparable to lower tested doses. Hence, 40 mg BID dose was selected for the upcoming Phase III studies in subjects with moderate-to-severe plaque PsO.”

Source: [Ucpinar et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv2024_pstr_poppk-er_final.pdf)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

###### DLQI 0/1, DLQI 4-point decrease, and pruritus NRS results at week 12 by dose in the modified intent-to-treat set

| Week 12 patient-reported outcome | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 |
| --- | --- | --- | --- | --- | --- | --- |
| DLQI-0/1, n (%) | “7 (18)” | “10 (28)” | “12 (33)” | “20 (51)” | “19 (48)” | “25 (64)” |
| DLQI-0/1, P value vs placebo | “-” | “.2807” | “.1159” | “.0016” | “.0045” | “<.0001” |
| DLQI-0/1, difference vs placebo, % (95% CI) | “-” | “9 (−10, 29)” | “15 (−5, 35)” | “33 (13, 53)” | “30 (10, 50)” | “46 (26, 65)” |
| DLQI 4-point decrease, n (%) | “7 (19)” | “18 (51)” | “18 (51)” | “25 (64)” | “26 (70)” | “24 (65)” |
| DLQI 4-point decrease, P value vs placebo | “-” | “.0032” | “.0032” | “.0001” | “<.0001” | “<.0001” |
| DLQI 4-point decrease, difference vs placebo, % (95% CI) | “-” | “33 (12, 53)” | “33 (12, 53)” | “45 (26, 65)” | “51 (32, 71)” | “46 (26, 66)” |
| Mean change from baseline in average pruritus NRS (SD) | “−1 (3)” | “−2 (3)” | “−3 (3)” | “−4 (3)” | “−4 (3)” | “−5 (3)” |
| Mean change from baseline in worst pruritus NRS (SD) | “−1 (3)” | “−3 (3)” | “−3 (4)” | “−4 (3)” | “−5 (3)” | “−5 (3)” |
| Average pruritus NRS score <4, n (%) | “11 (29)” | “17 (47)” | “21 (58)” | “27 (69)” | “27 (69)” | “28 (72)” |
| Worst pruritus NRS score <4, n (%) | “10 (26)” | “17 (47)” | “18 (50)” | “26 (67)” | “27 (69)” | “29 (74)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.4-2"></a>

###### DLQI 0/1 and average pruritus NRS improvement with 40 mg twice daily in the published article

> “Improvements in skin severity end points were accompanied by dose-dependent improvements in patient-reported outcomes, as demonstrated by changes in DLQI and pruritus, with 64% of patients who received ESK-001 40 mg BID achieving a DLQI of 0/1 versus 18% with placebo (P < .0001).”
> “Additionally, the average pruritus numerical rating scale score improved by 5 points with ESK-001 40 mg BID versus 1 point with placebo at week 12 (P < .0001) (Table II).”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.4-3"></a>

###### Median change in average and worst pruritus NRS at week 12 by dose in the congress poster

| Week 12 pruritus NRS change from baseline, median (IQR) | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 |
| --- | --- | --- | --- | --- | --- | --- |
| Average pruritus NRS | “0.0 (-3.0, 1.0)” | “-2.0 (-3.0, 0.0)” | “-2.5 (-6.0, 0.0)” | “-3.0 (-5.0, -2.0)” | “-5.0 (-6.0, -3.0)” | “-4.0 (-8.0, -3.0)” |
| Worst pruritus NRS | “-0.5 (-2.0, 1.0)” | “-2.0 (-4.0, -1.0)” | “-2.5 (-5.0, 1.0)” | “-4.0 (-6.0, -1.0)” | “-5.0 (-7.0, -3.0)” | “-5.0 (-7.0, -3.0)” |

Source: [Blauvelt et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/eadv_2024_pstr-pro_ole.pdf)

<a id="topic-3.1.4.8.4-4"></a>

###### DLQI reductions of at least 4, 5, and 6 points with 40 mg twice daily and pruritus NRS of 3 or less in the congress poster

> “Largest clinically meaningful reductions in DLQI at highest ESK-001 dose (40 mg BID) in STRIDE study.”
> “62% had ≥4 point reduction, 54% had ≥5 point reduction, 51% had ≥6 point reduction.”
> “Significantly more patients achieved pruritus NRS ≤3 when treated with three highest ESK-001 doses compared to placebo (p<0.001 vs placebo).”

Source: [Blauvelt et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/eadv_2024_pstr-pro_ole.pdf)

<a id="topic-3.1.4.8.4-5"></a>

###### EQ-5D results

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Treatment-emergent adverse events by dose in the safety analysis set

| Outcome, n (%) | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 | ESK-001 pooled, N = 189 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| TEAEs | “15 (39.5)” | “19 (52.8)” | “14 (38.9)” | “18 (46.2)” | “19 (48.7)” | “25 (64.1)” | “95 (50.3)” |
| TEAEs leading to treatment discontinuation | “0 (0.0)” | “0 (0.0)” | “2 (5.6)” | “0 (0.0)” | “2 (5.1)” | “1 (2.6)” | “5 (2.6)” |
| TEAEs grade 3 or higher | “0 (0.0)” | “3 (8.3)” | “1 (2.8)” | “3 (7.7)” | “3 (7.7)” | “0 (0.0)” | “10 (5.3)” |
| TEAEs related to study drug | “5 (13.2)” | “3 (8.3)” | “3 (8.3)” | “5 (12.8)” | “7 (17.9)” | “9 (23.1)” | “27 (14.3)” |
| Headache | “2 (5.3)” | “0 (0.0)” | “2 (5.6)” | “3 (7.7)” | “4 (10.3)” | “3 (7.7)” | “12 (6.3)” |
| Upper respiratory tract infection | “0 (0.0)” | “2 (5.6)” | “2 (5.6)” | “1 (2.6)” | “2 (5.1)” | “3 (7.7)” | “10 (5.3)” |
| Nasopharyngitis | “3 (7.9)” | “2 (5.6)” | “0 (0.0)” | “1 (2.6)” | “1 (2.6)” | “3 (7.7)” | “7 (3.7)” |
| SAEs | “0 (0.0)” | “1 (2.8)” | “0 (0.0)” | “3 (7.7)” | “1 (2.6)” | “0 (0.0)” | “5 (2.6)” |
| Deaths | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

> “TEAEs leading to treatment discontinuation in 5 patients included eczema (20 mg QD), arthralgia (20 mg QD), blood triglyceride increased (40 mg QD), dermatitis contact (40 mg QD), and urticaria (40 mg BID).”
> “TEAEs reported by 3 or more patients in any treatment group.”
> “All events of headache were grade 1 (mild) or grade 2 (moderate) in severity and most were resolved by the end of the study.”
> “All events of upper respiratory tract infection and nasopharyngitis were grade 1 (mild) or grade 2 (moderate) in severity and all were resolved by the end of the study.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.5-2"></a>

###### Overall tolerability, common adverse events, and absence of tuberculosis, herpes zoster, opportunistic infections, and oral ulcers in the published article

> “ESK-001 was generally safe and well-tolerated in adult patients with moderate-to-severe psoriasis following 12 weeks of treatment and 4 weeks off treatment, with no dose-limiting safety findings and a study drug discontinuation rate of 2.6% due to AEs”
> “There were no deaths in this study.”
> “Overall, the most common AEs (occurring in >5% of patients in any treatment group) were headache (6.3%), upper respiratory tract infections (5.3%), and nasopharyngitis (3.7%).”
> “Rates of acne and folliculitis were 2.1% and 1.6%, respectively, with no dose dependency (data on file).”
> “AEs were reported in 40% and in 39% to 64% of the patients in the placebo group and active-drug groups, respectively, with the highest percentage in the 40 mg BID dose group.”
> “TEAEs related to study drug occurred in 23% of subjects receiving 40 mg BID dose, 14.3% of subjects in pooled ESK-001 groups, and 13.2% of placebo subjects.”
> “Across all groups, the majority of TEAEs were mild or moderate and resolved.”
> “There were no cases of tuberculosis, herpes zoster, opportunistic infections, or oral ulcers.”
> “In addition, laboratory and electrocardiogram findings showed no meaningful changes during 12 weeks of ESK-001 treatment”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.5-3"></a>

###### Serious adverse events by arm, with the gastrointestinal event in the 20 mg twice-daily arm reported as enterocolitis, enteritis, or colitis and enteritis

> “SAEs: lower limb fracture (10 mg QD), tibia fracture (20 mg BID), coronary artery occlusion (20 mg BID), enterocolitis (20 mg BID), dermatitis contact (40 mg QD); all assessed by investigators as unrelated to a study drug.”
> “Five serious adverse events were reported and none were considered by the investigator to be related to study drug: 2 cases of limb fracture from trauma, contact dermatitis following exposure to a known allergen, an incidental asymptomatic computed tomography scan finding of coronary artery occlusion successfully treated with cardiac catheterization, and enteritis (etiology unknown) which resolved with no study drug discontinuation.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

| Serious adverse event, affected / at risk (%) | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
| --- | --- | --- | --- | --- | --- | --- |
| Total | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “3/39 (7.69%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |
| Coronary artery occlusion | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Colitis | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Enteritis | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Lower limb fracture | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Tibia fracture | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Dermatitis contact | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

> “SAEs (all unrelated): Lower limb fracture (10mg QD), tibia fracture (20mg BID), coronary artery occlusion (20mg BID), colitis and enteritis in one subject (20mg BID), dermatitis contact (40mg QD).”

Source: [Papp et al. (2024)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_2_for_website_aad_pres_vf.pdf)

<a id="topic-3.1.4.8.5-4"></a>

###### Other adverse events reported in at least 5% of participants in any arm in the ClinicalTrials.gov results

> “Adverse Event data was collected from Screening through end of study (Week 16).”
> “5% Frequency Threshold for Reporting Other Adverse Events”

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

| Other (not serious) adverse event, affected / at risk (%) | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
| --- | --- | --- | --- | --- | --- | --- |
| Total | “9/38 (23.68%)” | “8/36 (22.22%)” | “4/36 (11.11%)” | “18/39 (46.15%)” | “11/39 (28.21%)” | “18/39 (46.15%)” |
| Diarrhea | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “2/39 (5.13%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |
| Dyspepsia | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “2/39 (5.13%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Nausea | “1/38 (2.63%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “2/39 (5.13%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Pyrexia | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “2/39 (5.13%)” |
| Upper respiratory tract infection | “0/38 (0.00%)” | “2/36 (5.56%)” | “2/36 (5.56%)” | “1/39 (2.56%)” | “2/39 (5.13%)” | “3/39 (7.69%)” |
| Nasopharyngitis | “3/38 (7.89%)” | “2/36 (5.56%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “1/39 (2.56%)” | “3/39 (7.69%)” |
| COVID-19 | “3/38 (7.89%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “1/39 (2.56%)” |
| Diabetes mellitus | “0/38 (0.00%)” | “2/36 (5.56%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Headache | “2/38 (5.26%)” | “0/36 (0.00%)” | “2/36 (5.56%)” | “3/39 (7.69%)” | “4/39 (10.26%)” | “3/39 (7.69%)” |
| Dizziness | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “2/39 (5.13%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |
| Cough | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “2/39 (5.13%)” | “0/39 (0.00%)” | “2/39 (5.13%)” |
| Acne | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “2/39 (5.13%)” | “2/39 (5.13%)” |
| Dermatitis acneiform | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “0/39 (0.00%)” | “2/39 (5.13%)” |

Source: [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)

<a id="topic-3.1.4.8.5-5"></a>

###### Absence of dose-dependent safety signals and of JAK inhibitor-associated adverse events in the discussion of the published article

> “No dose-dependent safety signals were identified, and the overall safety profile of ESK-001 was consistent with long-term safety analyses up to 4 years reported for deucravacitinib, another TYK2 inhibitor, with no new safety findings.”
> “Of note, the safety profile of ESK-001 did not demonstrate any AEs associated with JAK inhibitor safety findings, such as serious infections, increased mortality, malignancy, major adverse cardiovascular events, and thrombosis.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="topic-3.1.4.8.5-6"></a>

###### Absence of MACE, serious infections, treatment-related thromboses, and laboratory or ECG trends in the congress presentation

> “Note: no MACE, serious infections, treatment related thromboses or concerning lab/ECG trends were observed.”

Source: [Papp et al. (2024)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_2_for_website_aad_pres_vf.pdf)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

- The authors cite the small sample size per treatment group and the 16-week study duration, and the exclusion of participants who were previously nonresponders to IL-17, IL-12, or IL-23 targeted therapies. The protocol also excluded participants with lack of response to 2 or more biologic therapies.
- The primary endpoint was assessed at week 12, when, according to the authors, response trajectories suggested maximal efficacy had not yet been achieved.
- The statistical analysis plan states that no adjustments for multiplicity were performed.
- The analysis population for efficacy differs by source: the protocol planned intent-to-treat analyses, the article used the modified intent-to-treat population, and the ClinicalTrials.gov results describe the PASI 75 population as all randomized and treated participants. The 20 mg BID arm has 40 participants in the intent-to-treat set and 39 in the modified intent-to-treat and safety sets.
- The number of sites is 30 in the article, 53 in the ClinicalTrials.gov record, and approximately 65 planned in the protocol.
- The serious gastrointestinal event in the 20 mg BID arm is reported as enterocolitis (article table footnote), enteritis of unknown etiology (article text), colitis and enteritis as separate terms (ClinicalTrials.gov results), and colitis and enteritis in one subject (congress presentation).
- The article reports 5 participants (2.6%) discontinuing envudeucitinib due to an AE; the ClinicalTrials.gov participant flow lists an adverse event as the reason for not completing the study for 2 (20 mg QD), 1 (40 mg QD), and 1 (40 mg BID) participants.
- The DLQI decrease of at least 4 points with 40 mg BID is 65% in the article and 62% in the patient-reported outcomes poster.
- Acne and folliculitis rates are cited as data on file, skin biopsies were optional and collected from approximately 5 to 12 participants per dose group, and the report holds no EQ-5D results.

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext); [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036); [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results); [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf); [Alumis STRIDE statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/SAP_001.pdf); [Blauvelt et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/eadv_2024_pstr-pro_ole.pdf); [Papp et al. (2024)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_2_for_website_aad_pres_vf.pdf)

<a id="topic-3.1.4.9-2"></a>

###### Limitations stated by the authors: sample size, duration, and exclusion of prior nonresponders to IL-17, IL-12, or IL-23 therapies

> “Limitations of this phase 2 study include small sample size per treatment group and 16-week study duration.”
> “Considering the pathway modulated by TYK2 inhibition, patients who were previously nonresponders to IL-17/IL-12/IL-23 targeted therapies were excluded in this phase 2 study.”

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)

<a id="heading-3.1.5"></a>

#### 3.1.5 STRIDE Open-label Extension

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Objective of the 52-week analysis

> “To assess long-term safety and efficacy of envudeucitinib throughout 52 weeks in the ongoing phase 2 open-label extension in patients who completed STRIDE.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.1-2"></a>

###### Purpose of the open-label extension in the ClinicalTrials.gov record

> “This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.”
> “A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Study start, completion, and record dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-01-17”
> “Primary Completion (Estimated) 2027-12-01”
> “Study Completion (Estimated) 2027-12-31”
> “First Posted 2023-02-22”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.2-2"></a>

###### Completion dates estimated at registration, February 2023, superseded in July 2026

> “Primary Completion 2026-12-01 [Estimated]”
> “Study Completion 2026-12-30 [Estimated]”

Source: [ClinicalTrials.gov NCT05739435 version 1](https://clinicaltrials.gov/study/NCT05739435?tab=history&a=1)

<a id="topic-3.1.5.2-3"></a>

###### Recruitment status and last update in the ClinicalTrials.gov record

> “Last Update Posted 2026-07-28 Active, not recruiting No longer looking for participants”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.2-4"></a>

###### Countries of trial sites in the ClinicalTrials.gov record

> “This study has 38 locations”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

| Country | A site listed for the country in the record |
| --- | --- |
| United States | “Rogers, Arkansas, United States, 72758” |
| Canada | “Surrey, British Columbia, Canada, V3V 0C6” |

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.2-5"></a>

###### North American sites and date of first entry into the open-label extension

> “This study was conducted at North American sites only.”
> “Of note, the first patient entered OLE on 17 January 2023.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : None (Open Label)”
> “Patients have the option to remain on study until ESK-001 is commercially available.”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.3-2"></a>

###### Ongoing phase 2 extension with enrollment within 28 days of the STRIDE end-of-study visit

> “The OLE is an ongoing phase 2 study (NCT05739435) to assess the safety and efficacy of envudeucitinib in adults with moderate-to-severe plaque psoriasis who completed STRIDE.”
> “Patients were eligible for the OLE regardless of treatment response in STRIDE and were enrolled at the time of or within 28 days following the STRIDE end-of-study visit.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.3-3"></a>

###### Protocol amendment of January 2024 moving all participants to 40 mg twice daily

> “During the study, data from STRIDE3 and interim OLE data indicated that the 40-mg BID dose offered the most robust benefit/risk profile compared to the QD regimen. The findings prompted a protocol amendment on 2 January 2024 to transition all patients in the study to the 40-mg BID dose (between weeks 40 and 64).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.3-4"></a>

###### Visit and pharmacokinetic sampling schedule

> “Patients were assessed for safety and efficacy at study visit day 1, weeks 2, 4, 8, 12, 16, and every 12 weeks thereafter. Pharmacokinetic (PK) samples were collected throughout the 52 weeks on day 1, weeks 4, 16, and every 6 months thereafter.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.3-5"></a>

###### Rollover after the STRIDE week 16 visit and timing of the switch to twice-daily dosing

> “Eligible patients rolled over to the OLE study following completion of the STRIDE end-of-study visit at Week 16. Upon clear identification of the most beneficial dose, 40-mg QD patients switched to the 40-mg BID arm between Weeks 40 and 64.”

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Inclusion and exclusion criteria in the ClinicalTrials.gov record

> “Must have completed a prior ESK-001 study”
> “Men and Women must use highly effective methods of contraception for the entirety of the study”
> “Exclusion Criteria: Pregnancy Received a prohibited concomitant medication”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.4-2"></a>

###### Eligibility criteria and prohibited treatments in the supplementary material

> “Eligible patients were adult males or nonpregnant females who completed the envudeucitinib Phase 2 STRIDE study and consented to participate in the OLE study.”
> “Patients were excluded from the study if, after the last dose of envudeucitinib in the STRIDE study and prior to entering the OLE, they developed a new acute or chronic illness/condition or evidence of an unstable existing clinical condition that could have increased their safety risk, or if they received a prohibited concomitant medication.”
> “Prohibited treatments were those medications used for treatment of plaque psoriasis, including but not limited to systemic corticosteroids; topical medications that could affect psoriasis evaluation; phototherapy; therapeutic agents targeting IL12/23, IL-23, or IL-17; TYK2 inhibitors; or any investigational agents.”

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Allocation to 40 mg once or twice daily by STRIDE dose arm

> “At the time of enrollment, patients were assigned to 40-mg QD or 40-mg BID”
> “Patients receiving 10-mg QD or 20-mg QD in STRIDE entered the 40-mg QD OLE arm, while those on 20-mg or 40-mg BID in STRIDE entered the 40-mg BID OLE arm; STRIDE patients on placebo and 40-mg QD were allocated to either OLE dose arm”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.5-2"></a>

###### Numbers allocated to each extension arm from each STRIDE arm

> “All OLE patients enrolled from the STRIDE 10 mg QD (n=30) and 20 mg QD (n=26) arms entered the 40-mg QD OLE arm; all OLE enrolled patients from the STRIDE 20 mg BID (n=29) and 40mg BID (n=27) arms entered the OLE 40-mg BID arm.”
> “Patients from the STRIDE placebo and 40-mg QD arms were allocated as follows: OLE 40-mg QD arm included 9 and 17 patients from STRIDE 40-mg QD and placebo arms, respectively; OLE 40 mg BID included 17 and 9 patients from STRIDE 40-mg QD and placebo arms, respectively”

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="topic-3.1.5.5-3"></a>

###### Arms and interventions in the ClinicalTrials.gov record

> “Experimental: envudeucitinib Dose Level 1 envudeucitinib administered as an oral tablet”
> “Experimental: envudeucitinib Dose Level 2 envudeucitinib administered as an oral tablet”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Treatment-emergent and Serious Adverse Events as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary and secondary endpoints in the publication

> “The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). The secondary endpoints were as follows: change from baseline in Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), body surface area (%BSA), and pruritus Numerical Rating Scale (NRS) to assess long-term efficacy; change from baseline in Dermatology Life Quality Index (DLQI) to assess the change in quality of life (QoL); and envudeucitinib plasma concentrations and PK parameters. Safety assessments also included vital signs, clinical laboratory assessments, and electrocardiograms (ECGs).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.6.1-2"></a>

###### Primary and secondary outcomes in the ClinicalTrials.gov record

| Outcome | Outcome measure | Measure description and time frame |
| --- | --- | --- |
| Primary | “To assess the safety and tolerability of long-term ESK-001 treatment” | “Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) Approximately 3 years” |
| Secondary | “To assess the long-term efficacy of ESK-001” | “Change from baseline in Psoriasis Area and Severity Index (PASI) over time Approximately 3 years” |
| Secondary | “To assess the change in quality of life (QoL) with long-term ESK-001 administration” | “Change from baseline in Dermatology Life Quality Index (DLQI) over time Approximately 3 years” |
| Secondary | “To assess the pharmacokinetics (PK) of ESK-001 (ctrough)” | “Plasma concentrations and PK parameters including steady-state trough observed plasma concentration (Ctrough) for ESK-001 2 years” |

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.6.1-3"></a>

###### Regulatory guidance on one-year exposure in the safety database

> “Therefore, some patients should be treated with the drug for 12 months.”
> “100 patients exposed for a minimum of one-year is considered to be acceptable to include as part of the safety data base.”

Source: [ICH E1 population exposure guideline (1995)](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-1-population-exposure-extent-population-exposure-assess-clinical-safety-step-5_en.pdf)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 165”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.7.1-2"></a>

###### Enrollment estimated at registration, February 2023, superseded in May 2024

> “Masking None (Open Label) Allocation Randomized Enrollment 210 [Estimated]”

Source: [ClinicalTrials.gov NCT05739435 version 1](https://clinicaltrials.gov/study/NCT05739435?tab=history&a=1)

<a id="topic-3.1.5.7.1-3"></a>

###### Sample size based on STRIDE completers without a power calculation

> “Formal power calculations were not performed to determine the sample size. The number of patients included in this study was based on the number of patients who completed STRIDE, qualified for, and chose to enroll in this study.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Modified intent-to-treat, safety, and pharmacokinetic populations and modified non-responder imputation

> “All efficacy analyses were based on the modified intent-to-treat (mITT) analysis population, which included all patients who received at least 1 dose of study drug according to the assigned treatment. For efficacy analyses, baseline was defined as the patients' values obtained on Day 1 of STRIDE. A modified non-responder imputation (mNRI) was applied for responder-type analyses where patients who discontinued the study due to adverse events (AEs) or inadequate response were treated as non-responders and patients who discontinued for all other reasons had their last observation carried forward. The safety analysis population included all patients who received at least 1 dose of study drug analyzed according to the actual treatment received. The PK analysis population included patients who received at least 1 dose of envudeucitinib and had at least one PK concentration measurement.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.7.2-2"></a>

###### Composition of the 40 mg once-daily and overall 40 mg twice-daily groups in the safety and efficacy tables

> “Envudeucitinib 40-mg QD data presented is for all patients who were dosed with 40-mg QD up to the time of discontinuation from envudeucitinib treatment or switch to 40-mg BID. Envudeucitinib 40-mg BID data presented is for all patients reaching week 52, including patients who were randomized to envudeucitinib 40-mg BID from the start of OLE and who switched from 40-mg QD to 40-mg BID.”
> “The week 28 data is presented for original envudeucitinib 40-mg QD. These patients then switched to 40-mg BID after week 28. The week 52 data is presented for the original and overall envudeucitinib 40-mg BID cohorts. Overall envudeucitinib 40-mg BID includes those who switched from 40-mg QD to 40-mg BID, and patients who were originally assigned to envudeucitinib 40-mg BID.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.7.2-3"></a>

###### Analysis sets by arm, ITT population

| Analysis set | Original 40 mg QD (N = 82) | Original 40 mg BID (N = 83) | 40 mg QD to 40 mg BID (N = 65) | Overall 40 mg BID (N = 148) | Overall (N = 165) |
| --- | --- | --- | --- | --- | --- |
| ITT population | “82” | “83” | “65” | “148” | “165” |
| mITT population | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |
| Safety analysis set | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |
| PK analysis set | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="topic-3.1.5.7.2-4"></a>

###### Post-hoc treat-to-target analyses and mixed model for percent change in PASI

> “Achievement of treat-to-target thresholds at Week 12 of STRIDE and Week 52 of OLE was performed as a post-hoc analysis. All p-values presented are nominal.”
> “LS Means and 95% confidence interval (CI) of percent change from baseline of PASI total score was based on a mixed model repeated measures (MMRM) analysis.”

Source: [Armstrong et al. (2025c)](https://www.alumis.com/file.cfm/613/docs/2025_fall_clinical_dermatology_conference.pdf)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Rollover from STRIDE: randomized, completing, ineligible, and declining participants

> “95% of Eligible STRIDE Subjects Continued in OLE Study”
> “228 Randomized Phase 2 STRIDE Subjects”
> “204 Subjects Completing STRIDE”
> “30 Ineligible and not participating in OLE”
> “25: OLE Not initiated in Czech Republic”
> “5: Did not meet OLE inclusion criteria”
> “9 Eligible for OLE but chose not to participate”

Source: [Blauvelt et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv_late_breaker_presentation_final.pdf)

<a id="topic-3.1.5.8.1-2"></a>

###### Enrollment of 165 participants and one participant not dosed

> “A total of 165 patients were enrolled in this OLE study. One enrolled patient was diagnosed with coronary artery occlusion at week 16 of STRIDE3 (at day 1 of the OLE) prior to dosing in OLE and, therefore, came off study.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.1-3"></a>

###### Participants ongoing and discontinuations at the 52-week data cut-off

> “Treatment was ongoing for 126 patients (76.4%) of the 165 patients enrolled in the OLE at the cut-off date for the 52-week data analyses”
> “Overall, most study discontinuations were due to withdrawal by patient (7.9%) or lost to follow-up (6.1%)”
> “One patient discontinued from study due to pregnancy and 1 due to partner's pregnancy. Six patients (3.7%) discontinued envudeucitinib due to an AE (Table II). Out of these patients, 1 discontinued envudeucitinib due to an AE of osteomyelitis, but had not discontinued the study at the time of the cut-off date.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.1-4"></a>

###### Disposition by arm, ITT population

| Disposition | Original 40 mg QD (N = 82) | Original 40 mg BID (N = 83) | 40 mg QD to 40 mg BID (N = 65) | Overall 40 mg BID (N = 148) | Overall (N = 165) |
| --- | --- | --- | --- | --- | --- |
| Patients ongoing in study, n (%) | “0 (0)” | “66 (79.5)” | “60 (92.3)” | “126 (85.1)” | “126 (76.4)” |
| Patients who switched to 40 mg BID, n (%) | “65 (79.3)” | “-” | “-” | “-” | “65 (39.4)” |
| Discontinued: withdrawal by subject | “6 (7.3)” | “3 (3.6)” | “4 (6.2)” | “7 (4.7)” | “13 (7.9)” |
| Discontinued: lost to follow-up | “3 (3.7)” | “6 (7.2)” | “1 (1.5)” | “7 (4.7)” | “10 (6.1)” |
| Discontinued: inadequate response | “6 (7.3)” | “1 (1.2)” | “0 (0)” | “1 (0.7)” | “7 (4.2)” |
| Discontinued: adverse event | “1 (1.2)” | “4 (4.8)” | “0 (0)” | “4 (2.7)” | “5 (3.0)” |
| Discontinued: pregnancy | “1 (1.2)” | “0 (0)” | “0 (0)” | “0 (0)” | “1 (0.6)” |
| Discontinued: protocol deviation | “0 (0)” | “1 (1.2)” | “0 (0)” | “1 (0.7)” | “1 (0.6)” |
| Discontinued: death | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” |

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="topic-3.1.5.8.1-5"></a>

###### Basis of the disposition counts, data date, and the participant not dosed

> “The numbers and percentages of patients discontinued from the study are summarized based on the treatment that the patients were receiving at the time of discontinuation. The numbers and percentages of patients ongoing in the study are summarized based on the treatment that the patients were receiving at the time of data cut.”
> “Data from 18 November 2024 is included.”
> “Patient did not receive dose due to incidental finding of coronary artery occlusion on the last day of STRIDE Phase 2 (Week 16)/Day 1 of OLE. The patient was successfully treated by stent placement procedure. The patient received envudeucitinib 20 mg BID during STRIDE and was originally assigned to receive envudeucitinib 40 mg BID in OLE, although did not receive treatment.”

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Demographics and prior treatment, ITT population

> “Patient demographics and baseline characteristics were comparable to a general moderate-to-severe psoriasis population (ITT), with the majority of patients being male (70.9%) and white (80.6%); 47.9% were previously treated with biologics and 2.4% with Janus kinase inhibitors (JAKi). The mean age was 49.2 years and the average disease duration was 19.8 years (Table I).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.2-2"></a>

###### Demographic and baseline characteristics by original dose assignment, ITT population

| Characteristic | Original 40 mg QD (N = 82) | Original 40 mg BID (N = 83) | Overall (N = 165) |
| --- | --- | --- | --- |
| Age (y), mean (SD) | “47.5 (12.7)” | “50.8 (12.1)” | “49.2 (12.4)” |
| Male, n (%) | “56 (68.3)” | “61 (73.5)” | “117 (70.9)” |
| Female, n (%) | “26 (31.7)” | “22 (26.5)” | “48 (29.1)” |
| Race: Asian, n (%) | “7 (8.5)” | “4 (4.8)” | “11 (6.7)” |
| Race: Black or African American, n (%) | “5 (6.1)” | “1 (1.2)” | “6 (3.6)” |
| Race: Native Hawaiian or Other Pacific Islander, n (%) | “1 (1.2)” | “2 (2.4)” | “3 (1.8)” |
| Race: White, n (%) | “63 (76.8)” | “70 (84.3)” | “133 (80.6)” |
| Race: Other, n (%) | “6 (7.3)” | “5 (6.0)” | “11 (6.7)” |
| Ethnicity: Hispanic or Latino, n (%) | “26 (31.7)” | “25 (30.1)” | “51 (30.9)” |
| Weight (kg), mean (SD) | “98.1 (28.5)” | “94.0 (23.2)” | “96.0 (26.0)” |
| BMI (kg/m2), mean (SD) | “33.1 (8.8)” | “31.7 (7.4)” | “32.4 (8.1)” |
| Duration of psoriasis (y), mean (SD) | “17.2 (10.9)” | “22.3 (14.3)” | “19.8 (13.0)” |
| Prior treatment with biologics, n (%) | “37 (45.1)” | “42 (50.6)” | “79 (47.9)” |
| Prior treatment with JAKi, n (%) | “1 (1.2)” | “3 (3.6)” | “4 (2.4)” |
| PASI, mean (SD) | “10.2 (7.2)” | “6.8 (7.0)” | “8.5 (7.2)” |
| sPGA score 0, n (%) | “1 (1.2)” | “5 (6.0)” | “6 (3.6)” |
| sPGA score 1, n (%) | “10 (12.2)” | “26 (31.3)” | “36 (21.8)” |
| sPGA score 2, n (%) | “19 (23.2)” | “19 (22.9)” | “38 (23.0)” |
| sPGA score 3, n (%) | “39 (47.6)” | “23 (27.7)” | “62 (37.6)” |
| sPGA score 4, n (%) | “12 (14.6)” | “7 (8.4)” | “19 (11.5)” |
| BSA involvement (%), mean (SD) | “12.9 (13.4)” | “8.7 (11.1)” | “10.8 (12.5)” |
| DLQI, mean (SD) | “5.8 (5.8)” | “4.5 (4.8)” | “5.2 (5.3)” |
| Average pruritus NRS score, mean (SD) | “4.6 (3.0)” | “4.0 (3.1)” | “4.3 (3.1)” |

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Week 52 response rates stated for 40 mg twice daily in the abstract and text, mITT population

> “After 52 weeks of treatment with envudeucitinib 40-mg twice daily, 78% of patients achieved Psoriasis Area and Severity Index (PASI)-75, 61% achieved PASI-90, 39% achieved PASI-100, and 39% achieved sPGA-0.”
> “An increased sPGA response was also observed with 40-mg BID, with 61% of patients reaching sPGA-0/1 at week 52 and 39% reaching sPGA-0 (Fig 1, B, Table III).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.3-2"></a>

###### Week 28 and week 52 skin responses by original and overall 40 mg twice-daily groups, mITT population, mNRI

| Endpoint | Week 28, original 40 mg QD (N = 80) | Week 52, original 40 mg BID (N = 80) | Week 52, overall 40 mg BID (N = 144) |
| --- | --- | --- | --- |
| PASI-75, n (%) | “54 (67.5)” | “62 (77.5)” | “112 (77.8)” |
| PASI-75, 95% CI | “56.1, 77.6” | “66.8, 86.1” | “70.1, 84.3” |
| PASI-90, n (%) | “36 (45.0)” | “49 (61.3)” | “90 (62.5)” |
| PASI-90, 95% CI | “33.8, 56.5” | “49.7, 71.9” | “54.1, 70.4” |
| PASI-100, n (%) | “15 (18.8)” | “31 (38.8)” | “47 (32.6)” |
| PASI-100, 95% CI | “10.9, 29.0” | “28.1, 50.3” | “25.1, 40.9” |
| sPGA-0/1, n (%) | “41 (51.3)” | “49 (61.3)” | “86 (59.7)” |
| sPGA-0/1, 95% CI | “39.8, 62.6” | “49.7, 71.9” | “51.2, 67.8” |
| sPGA-0, n (%) | “15 (18.8)” | “31 (38.8)” | “47 (32.6)” |
| sPGA-0, 95% CI | “10.9, 29.0” | “28.1, 50.3” | “25.1, 40.9” |

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.3-3"></a>

###### Imputation method of the efficacy table

> “All data are based on an mNRI imputation methodology. Non-response was imputed for patients who discontinued due to inadequate response or adverse events, and LOCF if discontinued for all other reasons.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.3-4"></a>

###### Maintenance of STRIDE week 12 PASI-75 response and continued improvement at week 52, 40 mg twice daily

> “Of the PASI-75 responders at week 12 in STRIDE who entered the OLE, 80% of patients in the OLE 40-mg BID arm maintained their PASI-75 response at week 52.”
> “Moreover, of the patients who did not achieve PASI-100 at week 12 in STRIDE, 62% in the OLE 40-mg BID arm showed continued improvement in PASI response at OLE week 52”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.3-5"></a>

###### Improvement in PASI response category from STRIDE week 12 to extension week 52, 40 mg twice daily, mITT population

| Responder status at week 12 of STRIDE | N | Improvement to PASI-75, n (%) | Improvement to PASI-90, n (%) | Improvement to PASI-100, n (%) | Any improvement, n (%) |
| --- | --- | --- | --- | --- | --- |
| Below PASI-75 | “38” | “7 (18.4)” | “8 (21.1)” | “12 (31.6)” | “27 (71.1)” |
| PASI-75 and below PASI-90 | “24” | “----” | “4 (16.7)” | “10 (41.7)” | “14 (58.3)” |
| PASI-90 and below PASI-100 | “11” | “----” | “----” | “4 (36.4)” | “4 (36.4)” |
| Total | “73” | “----” | “----” | “----” | “45 (61.6)” |

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="topic-3.1.5.8.3-6"></a>

###### Discontinuations among week 52 nonresponders in the original 40 mg twice-daily group

> “Of the 18 non-responders at Week 52, 11 discontinued study early.”

Source: [Blauvelt et al. (2025a)](https://www.alumis.com/file.cfm/18/docs/aad2025_blauvelt_et_al_esk-001_52w_ole_vf.pdf)

<a id="topic-3.1.5.8.3-7"></a>

###### Week 52 compared with extension week 12 in the original 40 mg twice-daily group, mNRI, n = 80

> “These data demonstrated that patients receiving 40 mg twice daily dosing of ESK-001 achieved long-term sustained or increasing clinical responses through Week 52 compared to Week 12 (using modified non-responder imputation, n=80) as measured by PASI 90 (61.3% vs. 52.4%), PASI 100 (38.8% vs. 26.8%), and sPGA 0 (38.8% vs. 32.9%).”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

<a id="topic-3.1.5.8.3-8"></a>

###### Week 28 PASI and sPGA responses with 40 mg twice daily, mNRI, March 2024 data cut

> “PASI-75, PASI-90, and PASI-100 responses (mNRI) with 40 mg BID at Week 28 of 83%, 63%, and 31%, respectively”
> “sPGA 0/1 and 0 responses (mNRI) with 40 mg BID at Week 28 of 68% and 35%, respectively”
> “Data as of March 1, 2024”

Source: [Blauvelt et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv_late_breaker_presentation_final.pdf)

<a id="topic-3.1.5.8.3-9"></a>

###### Treat-to-target thresholds at week 52 with 40 mg twice daily, post-hoc analysis

> “At Week 52, 60% of patients on envudeucitinib 40 mg BID achieved BSA ≤1%”
> “Nearly 90% PASI improvement from baseline at 52 weeks with envudeucitinib 40 mg BID”

Source: [Armstrong et al. (2025c)](https://www.alumis.com/file.cfm/613/docs/2025_fall_clinical_dermatology_conference.pdf)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### DLQI and pruritus responses at week 52 stated in the text, 40 mg twice daily

> “Improvements in signs and symptoms were accompanied by dose-dependent improvements in QoL, as measured by DLQI and pruritus NRS (Table III). In the 40-mg BID arm at week 52, 61% of patients achieved DLQI-0/1 and approximately 80% of patients achieved itch symptom control at week 52 (NRS <4). Post-hoc analysis showed that 62% of patients in the 40-mg BID overall group achieved ≥4 point improvement from baseline in worst pruritus NRS score at week 52, with onset of improvement shown as early as week 4.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.4-2"></a>

###### Week 28 and week 52 patient-reported outcomes by original and overall 40 mg twice-daily groups, mITT population, mNRI

| Endpoint | Week 28, original 40 mg QD (N = 80) | Week 52, original 40 mg BID (N = 80) | Week 52, overall 40 mg BID (N = 144) |
| --- | --- | --- | --- |
| DLQI 0/1, n (%) | “41 (51.3)” | “49 (61.3)” | “87 (60.4)” |
| DLQI 0/1, 95% CI | “39.8, 62.6” | “49.7, 71.9” | “51.9, 68.5” |
| DLQI 4-point decrease, n (%) | “49 (61.3)” | “55 (68.8)” | “103 (71.5)” |
| DLQI 4-point decrease, 95% CI | “49.7, 71.9” | “57.4, 78.7” | “63.4, 78.7” |
| Average pruritus NRS score below 4, n (%) | “54 (67.5)” | “65 (81.3)” | “115 (79.9)” |
| Average pruritus NRS score below 4, 95% CI | “56.1, 77.6” | “71.0, 89.1” | “72.4, 86.1” |
| Worst pruritus NRS score below 4, n (%) | “51 (63.8)” | “63 (78.8)” | “112 (77.8)” |
| Worst pruritus NRS score below 4, 95% CI | “52.2, 74.2” | “68.2, 87.1” | “70.1, 84.3” |
| Improvement in worst pruritus NRS score of at least 4, post-hoc, n (%) | “44 (55.0)” | “47 (58.8)” | “89 (61.8)” |
| Improvement in worst pruritus NRS score of at least 4, post-hoc, 95% CI | “43.5, 66.2” | “47.2, 69.6” | “53.3, 69.8” |

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.4-3"></a>

###### Itch control and DLQI at week 52 stated in the company release, original 40 mg twice-daily group

> “At Week 52, patients maintained robust clinical improvements in control of itch (NRS≤4, 81.3%) and quality-of-life (DLQI0/1, 61.3%).”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

<a id="topic-3.1.5.8.4-4"></a>

###### Minimal or no impact on quality of life at weeks 12 and 52 with 40 mg twice daily

> “At Week 12 and 52, >60% of patients on envudeucitinib 40 mg BID reported minimal or no impact on QoL”

Source: [Armstrong et al. (2025c)](https://www.alumis.com/file.cfm/613/docs/2025_fall_clinical_dermatology_conference.pdf)

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Adverse events with exposure-adjusted incidence rates through week 52, safety analysis population

| Event, n (%) [EAIR] | Original 40 mg QD (N = 82) | Overall 40 mg BID (N = 147) | Overall (N = 164) |
| --- | --- | --- | --- |
| Patients with at least 1 TEAE | “50 (61.0) [122.76]” | “73 (49.7) [102.33]” | “108 (65.9) [108.18]” |
| Patients with TEAE leading to study drug discontinuation | “1 (1.2) [1.55]” | “5 (3.4) [4.19]” | “6 (3.7) [3.26]” |
| Patients with TEAE grade 3 or higher | “3 (3.7) [4.66]” | “6 (4.1) [5.12]” | “8 (4.9) [4.42]” |
| Upper respiratory tract infection | “3 (3.7) [4.71]” | “13 (8.8) [11.66]” | “16 (9.8) [9.20]” |
| Nasopharyngitis | “10 (12.2) [16.88]” | “6 (4.1) [5.15]” | “14 (8.5) [8.09]” |
| COVID-19 | “3 (3.7) [4.74]” | “8 (5.4) [6.88]” | “11 (6.7) [6.17]” |
| Headache | “5 (6.1) [8.28]” | “5 (3.4) [4.28]” | “10 (6.1) [5.71]” |
| Patients with at least 1 treatment-emergent SAE | “2 (2.4) [3.10]” | “4 (2.7) [3.39]” | “6 (3.7) [3.29]” |
| Patients with SAEs related to study drug | “2 (2.4) [3.10]” | “2 (1.4) [1.67]” | “4 (2.4) [2.17]” |
| Patients with TEAE leading to death | “0 (0) [-]” | “0 (0) [-]” | “0 (0) [-]” |

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-2"></a>

###### Adverse events leading to discontinuation, frequency threshold, and severity of the most frequent events

> “TEAEs leading to drug discontinuation in 6 patients included dyspepsia, hypersensitivity, osteomyelitis, pruritus, renal cell carcinoma (envudeucitinib 40-mg BID), and non-small cell lung cancer (envudeucitinib 40-mg QD).”
> “TEAEs reported by 5% or more patients in any treatment group.”
> “All events of upper respiratory tract infection, nasopharyngitis, COVID-19, and headache were grade 1 (mild) or grade 2 (moderate) in severity.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-3"></a>

###### Overall tolerability, severity, acne, and folliculitis

> “Treatment with envudeucitinib over 52 weeks in the OLE was generally safe and well-tolerated with no deaths and a low rate of study drug discontinuation due to AEs (3.7%) (Table II). The overall number of patients with at least 1 TEAE was 65.9%, with the majority of TEAEs being mild or moderate in severity (23.8% and 37.2%, respectively).”
> “Rates of acne and folliculitis were low at 3.0% and 2.4%, respectively, all being mild or moderate in severity and self-limited.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-4"></a>

###### Comparison of the once-daily and twice-daily arms, including related adverse events

> “Comparison of the 40-mg QD arm and the 40-mg BID arm showed no dose-dependent effects on the overall frequency of AEs, nor on the numbers of most frequent TEAEs.”
> “TEAEs considered related to the study drug occurred in 14.6% of patients in the 40-mg QD arm compared to 10.2% in the 40-mg BID arm, while SAEs related to the study drug occurred in 2 patients in each group (2.4% and 1.4%, respectively).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-5"></a>

###### Treatment-related adverse events with exposure-adjusted incidence rates, September 2024 data cut

> “Subjects with TEAE related to study drug 12 (15) 20.19 15 (10) 13.83 26 (16) 15.70”
> “Safety data displayed are based on 06 SEP 2024 data cut of ongoing OLE study.”

Source: [Blauvelt et al. (2025a)](https://www.alumis.com/file.cfm/18/docs/aad2025_blauvelt_et_al_esk-001_52w_ole_vf.pdf)

<a id="topic-3.1.5.8.5-6"></a>

###### Serious adverse events: four considered related and two considered unrelated

> “The overall frequency of patients with at least 1 SAE was 3.7% (n = 6) (Table II). Four SAEs reported in 4 patients were considered related to study drug by the investigator: peritonsillar abscess (40-mg BID), non-small cell lung cancer in a patient with a strong family history (3 first-degree relatives) and genetic subtype consistent with familial lung cancer (40-mg QD), clear-cell type renal cell carcinoma incidentally identified during the course of evaluation for urolithiasis (40-mg BID), and arthritis in a patient with history of prior inflammatory arthritic event (40-mg QD). Separately, 1 patient with multiple co-morbidities, including diabetes, long-standing foot ulcer, and recurrent episodes of lower limb cellulitis, had SAEs of sepsis, septic shock, and cellulitis (40-mg BID), and 1 patient with positive medical history had a SAE of asthma exacerbation, all considered unrelated to study drug (after switch from 40-mg QD to 40-mg BID).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-7"></a>

###### Laboratory values, lipids, cytopenia, rhabdomyolysis, and tuberculosis

> “Laboratory assessments did not show any clinically significant abnormalities, including no episodes of acute liver or renal dysfunction, nor identified any liver, renal, or hematological trends of concern. Throughout 52 weeks of envudeucitinib treatment, mean lab values remained stable and within normal limits across both dose arms”
> “Consistent with the co-morbidities associated with psoriasis and high BMI of the study population, the day 1 lipid panel values were at the upper limit of normal and remained stable throughout the 52 weeks”
> “There were no AEs of cytopenia or rhabdomyolysis, and no cases of tuberculosis.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-8"></a>

###### Herpes zoster, electrocardiograms, and thromboembolic events

> “There were 2 cases of herpes zoster, neither of which resulted in envudeucitinib treatment interruption or study discontinuation, and both cases completely resolved (1 with and 1 without antiviral treatment).”
> “There were neither significant changes in ECG findings during 52 weeks of envudeucitinib treatment, nor were thromboembolic events reported.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

- The authors state that this was an open-label study with limited sample size and no placebo or active comparator.
- No formal power calculation was performed; the sample consisted of STRIDE completers who qualified and chose to enroll. The extension was not initiated in the Czech Republic, which made 25 STRIDE completers ineligible, and the study was conducted at North American sites only.
- Dose assignment followed the STRIDE arm for participants from the 10 mg QD and 20 mg QD arms (40 mg QD) and the 20 mg BID and 40 mg BID arms (40 mg BID); participants from the placebo and 40 mg QD arms were allocated to either dose. The ClinicalTrials.gov record lists the allocation as randomized.
- A protocol amendment on 2 January 2024 moved all participants to 40 mg BID between weeks 40 and 64, so the overall 40 mg BID group (N = 148, intent-to-treat) includes 65 participants who switched from 40 mg QD.
- Efficacy baseline was STRIDE Day 1, and participants entered the extension with a mean PASI of 8.5. Responder analyses used modified nonresponder imputation, carrying the last observation forward for discontinuations other than for AEs or inadequate response.
- Week 52 PASI 100 with 40 mg BID is 39% in the article text, 31 of 80 (38.8%) in the original 40 mg BID group, and 47 of 144 (32.6%) in the overall 40 mg BID group. Itch control in the original 40 mg BID group is reported as “NRS≤4, 81.3%” in a press release and as average pruritus NRS below 4 in 65 participants (81.3%) in the article table.
- Data cutoffs differ: the supplement includes data from 18 November 2024, and a congress poster by Blauvelt et al. displays safety data from the 06 SEP 2024 data cut. The treat-to-target analyses and the analysis of an improvement of at least 4 points in worst pruritus NRS are post hoc.
- The study is ongoing; 126 participants (76.4%) were continuing treatment at the 52-week data cut-off, and study completion is estimated for 2027-12-31.

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext); [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded); [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435); [Blauvelt et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv_late_breaker_presentation_final.pdf); [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm); [Blauvelt et al. (2025a)](https://www.alumis.com/file.cfm/18/docs/aad2025_blauvelt_et_al_esk-001_52w_ole_vf.pdf); [Armstrong et al. (2025c)](https://www.alumis.com/file.cfm/613/docs/2025_fall_clinical_dermatology_conference.pdf)

<a id="topic-3.1.5.9-2"></a>

###### Open-label design, sample size, and absence of a control group as stated by the authors

> “This was an open-label study with limited sample size and no control.”
> “However, important limitations of this open-label study should be acknowledged, including the lack of placebo or active comparator and the relatively small sample size.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

Additional sources: [Noot et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41161603/)

<a id="heading-3.1.6"></a>

#### 3.1.6 ACTRN12621000011886

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Aims of the first-in-human and multiple-dose studies

> “The aim of the studies was to assess the safety, tolerability, PK, pharmacodynamics (PD), and the effect of a high‐calorie breakfast of single and multiple oral doses of ESK‐001 in healthy adult participants.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.1-2"></a>

###### Dose-finding purpose of the wide dose range

> “The wide dose ranges chosen in this study aimed to identify the safest and most tolerable dose while achieving maximum PD target engagement and to support dose selection for phase II studies.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Study period and site of the first-in-human study in the publication

> “This was a first‐in‐human, phase I, single‐center, randomized, double‐blinded, placebo‐controlled, single (SAD) and multiple ascending dose (MAD) study of oral ESK‐001 administration in healthy participants (ACTRN12621000011886), conducted between January 21, 2021 and February 24, 2022 at a facility in Adelaide (Australia).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.2-2"></a>

###### Registration, enrollment, and data collection dates in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Date submitted | “26/11/2020” |
| Date registered | “11/01/2021” |
| Type of registration | “Prospectively registered” |
| Recruitment status | “Completed” |
| Date of first participant enrolment, anticipated | “29/01/2021” |
| Date of first participant enrolment, actual | “17/02/2021” |
| Date of last participant enrolment, anticipated | “17/11/2021” |
| Date of last participant enrolment, actual | “19/01/2022” |
| Date of last data collection, anticipated | “30/11/2021” |
| Date of last data collection, actual | “4/02/2022” |
| Date last updated | “14/06/2022” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.2-3"></a>

###### Recruitment state and principal investigator site in Adelaide, Australia, in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Recruitment state(s) | “SA” |
| Principal investigator | “Prof Sepehr Shakib” |
| Principal investigator address | “CMAX Clinical Research Pty Ltd Level 5, 18 a North Terrace Adelaide, SA, 5000 Australia” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.2-4"></a>

###### Results documents and data sharing in the ANZCTR record

> “No documents have been uploaded by study researchers.”

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

| Field | Quoted record |
| --- | --- |
| Will the study consider sharing individual participant data? | “No” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Study type, allocation, control, and phase in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Health condition(s) studied | “Psoriasis” |
| Study type | “Interventional” |
| Purpose of the study | “Treatment” |
| Allocation to intervention | “Randomised controlled trial” |
| Control group | “Placebo” |
| Phase | “Phase 1” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.3-2"></a>

###### Secondary sponsor, funding, and ethics approval in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Funding source category | “Commercial sector/Industry” |
| Secondary sponsor name | “Avance Clinical Pty Ltd” |
| Ethics committee name | “Bellberry Human Research Ethics Committee” |
| Ethics approval date | “10/12/2020” |
| Ethics approval number | “2020-11-1116” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.3-3"></a>

###### Regulatory framework of the Australian study

> “The study adhered to the applicable regulations of the Australian Therapeutic Goods Administration under the Clinical Trial Notification scheme, the principles of the Declaration of Helsinki, the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 (R2) Good Clinical Practice – Scientific Guideline, and the National Health and Medical Research Council National Statement on Ethical Conduct in Human Research.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.3-4"></a>

###### Blinding and randomization procedures

> “The Sponsor, Principal Investigator, clinical study personnel, and study participants were blinded to treatment.”
> “Any analysis of PK and PD data prior to unblinding was performed by the unblinded bioanalytical laboratory and pharmacokineticist at Avance Biometrics who had no responsibility for data monitoring and management in the study.”
> “The data were reblinded before being provided to any study personnel who were to remain blind.”
> “Randomization was prepared by unblinded statisticians using SAS Version 9.4 (or higher), provided to pharmacy staff involved in study drug dispensing, and maintained in a restricted access area.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.3-5"></a>

###### Single ascending dose part: confinement, escalation, and 3:1 randomization

> “In the SAD part, the screening period from Day −28 to −2 was followed by admission of the participants to the facility from Day −1 to 3 (Day 4 for Cohort 25 mg) with dose administration on Day 1 and final safety assessments on Day 7 ± 2.”
> “Dose escalation was based on the safety and PK results of the previous dose cohort.”
> “Participants were randomized to six cohorts (planned cohort size: 8 participants) to receive a single oral dose of ESK‐001 or placebo (3:1) in fasted conditions.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.3-6"></a>

###### Food effect cohort: two periods separated by a washout

> “Eight participants were allocated to the food effect (FE) cohort and were admitted to the facility from Day −1 to 8, with the first study drug administration on Day 1 (Period 1), followed by a 5‐day washout period and second dose administration on Day 6 (Period 2).”
> “Final safety assessments occurred on Day 12 ± 2.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.3-7"></a>

###### Single ascending dose cohorts in the congress poster's design schematic

> “ESK-001: liquid formulation”
> “Cohorts 1 to 5: fasted, active (n=6), placebo (n=2)”
> “Part A from Study ACTRN12621000011886”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Age, body mass index, and health criteria in the published report

> “Eligible participants included adult men and women, aged 18–55 years (SAD/MAD) or 18–60 years (MD), with a BMI of 18.0–32.0 kg/m2, body weight ≥50 kg (SAD/MAD), and medically healthy as determined by physical examination, vital signs, conventional 12‐lead electrocardiogram (ECG), and routine laboratory parameters.”
> “Women were of nonchildbearing potential or had a negative pregnancy test if childbearing potential and were not lactating.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.4-2"></a>

###### Key inclusion criteria and age limits in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Body mass index and weight | “Body mass index greater than or equal to 18.0 and less than or equal to 32.0 kg/m2, with a body weight greater than or equal to 50 kg at screening.” |
| Smoking | “Be nonsmokers (including tobacco, e-cigarettes and marijuana) for at least 3 months prior to first study drug administration and have a negative test for cotinine at the Screening visit and at check-in on Day -1.” |
| Health status | “Medically healthy without clinically significant abnormalities at the screening visit, at check-in on Day -1 and pre-dose on Day 1” |
| Electrocardiogram | “Conventional 12-lead ECG recording in triplicate consistent with normal cardiac conduction and function” |
| Minimum age | “18 Years” |
| Maximum age | “55 Years” |
| Sex | “Both males and females” |
| Healthy volunteers | “Yes” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.4-3"></a>

###### Key exclusion criteria in the ANZCTR record

| Criterion | Quoted record |
| --- | --- |
| Significant disease | “History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be clinically relevant.” |
| Current infection | “Current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications.” |
| Malignancy | “Any history of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma).” |
| Immunosuppression | “Presence of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.” |
| Immunosuppressive or immunomodulating medications | “Use of or plans to use systemic immunosuppressive (e.g., corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon) during the study or within 3 months prior to the first study drug administration.” |
| Skin findings | “Presence or evidence of recent sunburn, scar tissue, tattoo (more than 25% of body area), open sore, or branding that, in the opinion of the Investigator, would interfere with interpretation of skin adverse reaction assessments.” |
| Liver function tests | “Liver function test results elevated more than 1.5-fold above the upper limit of normal (ULN) for gamma glutamyl transferase [GGT], bilirubin (total, conjugated and unconjugated) or alkaline phosphatase (ALP) or elevated 2.0-fold above ULN for aspartate aminotransferase (AST) or alanine aminotransferase (ALT).” |
| Viral infection | “Positive test results for active human immunodeficiency virus (HIV-1 and HIV-2), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the screening visit.” |
| Tuberculosis | “History of active, latent or inadequately treated tuberculosis infection.” |
| Conditions affecting drug disposition | “Presence or having sequelae of gastrointestinal, liver (including Gilbert’s syndrome), kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.” |
| Renal function | “Estimated creatinine clearance (CrCl) < 60 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.” |
| Concomitant medication | “Use of any systemically absorbed prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 10 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration, except occasional use of paracetamol (up to a maximum of 4 doses per day of 500-mg paracetamol, and no more than 3g per week).” |
| Interferon hypersensitivity | “Known hypersensitivity to interferon alfa or any component of the product (Part B only).” |
| Vaccination | “Use of any vaccinations within 30 days prior to the first study drug administration.” |
| Other investigational trials | “Participation in another investigational clinical trial within 60 days (or 5 half-lives, of the investigational agent) (whichever is longer) prior to the first study drug administration.” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Liquid formulation and matching placebo

> “The active treatment was a liquid formulation of ESK‐001 (Batch number: JR‐C200609006‐FPF20001), while placebo contained the same excipients as the active treatment, with denatonium benzoate (Batch number: R086X0) instead of ESK‐001.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.5-2"></a>

###### Planned and actual single ascending dose levels and starting dose basis

> “Planned dose levels were in the range of 5–150 mg; actual dose levels were 5, 10, 17.5, 25, 50, and 100 mg.”
> “The starting dose was determined based on preclinical data and allometric scaling in accordance with FDA guidance.”
> “Dose escalation was based on the observed safety, pharmacokinetics data, and in vitro TYK2 pharmacodynamic marker levels.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.5-3"></a>

###### Food effect cohort dose of 25 mg fasted and after a high-calorie meal

> “The dose of the study drug was 25 mg (a dose well‐tolerated in a previous cohort) and was administered once fasted and once followed by ingestion of a high‐calorie standard FDA meal (800–1000 kcal).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.5-4"></a>

###### Single ascending dose, food effect, and multiple ascending dose regimens in the ANZCTR record

> “Enrolled participants will be assigned to one of Cohort 1, 2, 3, 4, 5 or 6 will receive a single dose of FTP-637 solution (or placebo) between the dose levels; 5 to 150mg.”
> “Participants will be dosed in the morning following an overnight fast of 10 hours, and will continue to fast for a further 4 hours post dose.”
> “Food effect, cohort 11, receive open label FTP-637 (no placebo) on 2 occasions, once fasted once fed.”
> “The 2 dosing occasions will be separated by 5 days.”
> “Enrolled participants will be assigned to one of Cohort 7, 8, 9, 10 will receive a 7 doses of FTP-637 solution (or placebo) once / twice daily for 7 days.”
> “Dose levels to be evaluated will be in the range of 5 to 150 mg.”
> “Part B participants will be dosed with a meal, preferably at the end of the meal but it may occur during the meal to remain within the required dosing interval.”

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.5-5"></a>

###### Placebo solution in the ANZCTR record

> “A solution containing, Citric Monohydrate, Sodium Citrate Dihydrate, Hypromellose, Betadex Sulfobutyl Ether Sodium, Deionized water, and a bittering agent, Denatonium Benzoate, will be used as the placebo.”

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Primary and secondary outcomes in the ANZCTR record

| Outcome | Quoted record |
| --- | --- |
| Primary outcome 1 | “Safety and tolerability of single and 7-day repeat oral doses of FTP-637 as assessed by Adverse Events (assessed accordingly to Common Terminology Criteria for Adverse Events), Physical Examination (change in examination findings), change in weight (digital scale), Vital signs (Blood pressure and heat rate measured using a digital BP monitor), ECG (12 and 5 lead), and Clinical Laboratory parameters (blood biochemistry, hematology and coagulation, and urinalysis).” |
| Secondary outcome 1 | “Pharmacokinetics (PK) of FTP-637 in plasma following administration of single and 7-day repeat oral doses in healthy adult volunteers.” |
| Secondary outcome 2 | “Pharmacokinetics (PK) of FTP-637 as assessed by urine and faeces analysis after a single oral dose in healthy adult volunteers..” |
| Secondary outcome 3 | “Pharmacodynamics (PD) of biomarker changes relevant to the TYK2 pathway associated with administration of FTP-637 in healthy adult volunteers (Part B only). Outcome measured by collection of blood samples.” |
| Secondary outcome 4 | “Exploratory: Effect of FTP-637 on QT interval corrected using the Fridericia method (QTcF) and other ECG parameters, including exposure-related changes in QTcF” |
| Secondary outcome 5 | “Exploratory: Pharmacodynamics (PD) of biomarker changes in Lymphocyte count in plasma, associated with administration of FTP-637 in healthy adult volunteers (Part B only).” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.6.1-2"></a>

###### Adverse event recording period and adverse events expected with TYK2 inhibitors in the ANZCTR record

> “Adverse events will be recorded from the time that a subject signs consent until the final follow up visit.”
> “Adverse events will be assessed by study investigators.”
> “Adverse events known to be associated with tyrosine kinase 2 inhibitors include nasopharyngitis, headache, diarrhea, upper respiratory tract infection, acne and nausea.”

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.6.1-3"></a>

###### Safety assessments in the published report

> “Safety assessments included: (1) recording of treatment‐emergent adverse events (TEAEs) including serious TEAEs, TEAEs leading to death, and TEAEs leading to study drug and/or study discontinuation; (2) clinical laboratory parameters; (3) vital signs; (4) body weight (SAD/MAD); (5) ECG parameters; and (6) physical examinations.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.6.1-4"></a>

###### Pharmacokinetic sampling and urine and feces collection in the single ascending dose part

> “Blood and urine samples were collected predose and at several timepoints postdose.”
> “In the SAD part, urine samples were only collected for the Cohort 50 mg.”
> “Feces were also collected in the SAD/MAD study but not analyzed.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Target and final sample size in the ANZCTR record

| Field | Quoted record |
| --- | --- |
| Sample size, target | “96” |
| Sample size, final | “87” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.7.1-2"></a>

###### Participants enrolled in the single and multiple ascending dose parts

> “Ninety‐one participants were enrolled in the SAD/MAD study: 53 in the SAD part (Figure 2) and 38 in the MAD part (Figure S1).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.7.1-3"></a>

###### Absence of a formal sample size calculation

> “No formal sample size calculation was performed.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Safety analysis set

> “The safety analysis was based on all randomized participants who received at least 1 dose of the study drug and had at least 1 postdose safety assessment, and was conducted by actual treatment received.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.7.2-2"></a>

###### Dose proportionality and food effect analyses

> “Dose proportionality was assessed using the power model with linear regression method.”
> “The FE was determined by comparing the PK of ESK‐001 in fed and fasted conditions.”
> “Natural log‐transformed maximum concentration (C max) and area under curve (AUC) were analyzed by an analysis of variance (ANOVA) using PROC MIXED in SAS with treatment, period, and sequence as a fixed effect and participant as a random effect.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Incomplete recruitment of two cohorts during the COVID-19 pandemic

> “Due to the COVID‐19 global pandemic, it was not possible to recruit 8 participants for cohorts 17.5 and 100 mg.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.1-2"></a>

###### Withdrawal of two food effect cohort participants

> “Two participants of the FE cohort discontinued the study drug and study due to TEAEs (see Safety and Tolerability results), that were indicative of a possible COVID‐19 infection, requiring isolation and withdrawal from the study.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Race, ethnicity, sex, and body mass index in the single ascending dose part

> “Most participants were white, not Hispanic or Latin, male in the cohorts receiving ESK‐001 and female in the pooled placebo cohorts (Table S1).”
> “The mean BMI ranged from 21.7 to 26.6 kg/m2.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Absorption, half-life, dose proportionality, and volume of distribution after single doses

> “Following single doses of 5 to 100 mg, ESK‐001 was rapidly absorbed with a median time to C max (T max) of 0.8–1.1 h and showed linear PK characteristics with low variability across the dose cohorts (Figure 3a, Table 1).”
> “The mean terminal half‐life (t ½) was 7.5– 9.3 h and was consistent across the different dose levels.”
> “The AUC from time zero to infinite time (AUC0–inf) and C max increased in a near dose‐proportional manner at doses of 5– 100 mg, and C max plateaued at doses of 50 mg and above, indicating that absorption of ESK‐001 was slowing down at higher doses.”
> “The mean apparent distribution volume during the terminal phase (Vz/F) was high, ranging from 103 to 186 L.”
> “A similar PK profile was observed following multiple doses in the MAD part (Figure S2, Table S3).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.3-2"></a>

###### Plasma pharmacokinetic parameters by single ascending dose and food effect cohort

| Parameter | 5 mg fasted | 10 mg fasted | 17.5 mg fasted | 25 mg fasted | 50 mg fasted | 100 mg fasted | Food effect cohort, 25 mg fasted | Food effect cohort, 25 mg fed |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants | “5 mg Fasted (N = 6)” | “10 mg Fasted (N = 6)” | “17.5 mg Fasted (N = 4)” | “25 mg Fasted (N = 5)” | “50 mg Fasted (N = 5)” | “100 mg Fasted (N = 5)” | “FE cohort 25 mg Fasted (N = 6)” | “FE cohort 25 mg Fed (N = 6)” |
| Cmax, ng/mL | “38.6 (22)” | “93.0 (28)” | “217 (19)” | “253 (21)” | “603 (24)” | “949 (15)” | “272 (13)” | “131 (22)” |
| Tmax, h | “0.75 (0.75–2.00)” | “0.88 (0.75–4.00)” | “1.13 (0.75–2.00)” | “1.00 (1.00–1.50)” | “1.00 (0.50–1.50)” | “1.00 (0.75–6.00)” | “0.75 (0.50–1.00)” | “4.00 (4.00–6.00)” |
| AUC0–t, h*ng/mL | “326 (29)” | “794 (24)” | “1896 (5)” | “2110 (18)” | “4097 (24)” | “11,092 (14)” | “1829 (13)” | “1802 (20)” |
| AUC0–inf, h*ng/mL | “336 (28)” | “816 (26)” | “1925 (5)” | “2138 (18)” | “4137 (24)” | “11,286 (14)” | “1850 (14)” | “1833 (20)” |
| AUC0–24h, h*ng/mL | “283 (26)” | “675 (18)” | “1662 (4)” | “1873 (20)” | “3678 (21)” | “9379 (14)” | “1642 (13)” | “1550 (20)” |
| t½, h | “8.66 (22)” | “9.26 (18)” | “7.85 (19)” | “7.97 (11)” | “7.48 (10)” | “8.11 (13)” | “7.60 (17)” | “7.91 (14)” |
| CL/F, L/h | “14.9 (36)” | “12.3 (21)” | “9.1 (5)” | “11.7 (17)” | “12.1 (23)” | “8.9 (13)” | “13.5 (13)” | “13.6 (21)” |
| Vz/F, L | “186 (20)” | “164 (13)” | “103 (18)” | “134 (27)” | “130 (14)” | “104 (20)” | “148 (19)” | “156 (28)” |

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

> “Note: All data are reported as geometric mean (CV%) except T max, which was reported as median (minimum–maximum).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.3-3"></a>

###### Urinary excretion of unchanged drug after a single 50 mg dose and multiple doses

> “Urinary excretion of ESK‐001 was minimal following single 50 mg and multiple‐dose administration of ESK‐001, with mean percentage of unchanged drug excreted (%Fe) (coefficient of variation [CV%]) ranging from 0.42% (58%) to 0.93% (49%), and geometric mean renal clearance of unchanged drug from the plasma (CLr) (CV%) ranging from 53.4 (77%) to 101 mL/h (53%).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.3-4"></a>

###### Food effect with the liquid formulation at 25 mg

> “The AUC0–inf was similar under fed and fasted dose administration of 25 mg ESK‐001 (Table 1).”
> “However, C max was reduced by ~50% and median T max increased from 0.75 h to 4 h under fed conditions, indicating that food slowed the absorption of ESK‐001.”
> “Although food slowed the absorption of ESK‐001, data suggest that ESK‐001 may be administered with or without food, as the bioavailability (AUC0–inf) of ESK‐001 was similar under fed and fasted conditions.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.3-5"></a>

###### Pharmacodynamic results of the multiple ascending dose part

> “PD parameters were also assessed in the MAD part of the SAD/MAD study but are not discussed in this article.”
> “Similar results on biomarker changes were observed in the MAD part of the SAD/MAD study (data not shown).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Treatment-emergent adverse events by single ascending dose cohort

| Event | 5 mg fasted (N = 6) | 10 mg fasted (N = 6) | 17.5 mg fasted (N = 4) | 25 mg fasted (N = 6) | 50 mg fasted (N = 6) | 100 mg fasted (N = 5) | Food effect cohort, 25 mg fasted (N = 7) | Food effect cohort, 25 mg fed (N = 7) | Total active (N = 41) | Pooled placebo (N = 12) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participant with at least 1 TEAE | “3 (50.0) [7]” | “3 (50.0) [4]” | “3 (75.0) [8]” | “4 (66.6) [8]” | “6 (100.0) [18]” | “5 (100.0) [22]” | “4 (57.1) [14]” | “4 (57.1) [15]” | “32 (78.0) [96]” | “5 (41.6) [9]” |
| Mild | “3 (50.0) [6]” | “3 (50.0) [4]” | “3 (75.0) [8]” | “4 (66.6) [8]” | “6 (100.0) [18]” | “5 (100.0) [20]” | “4 (57.1) [13]” | “4 (57.1) [13]” | “32 (78.0) [90]” | “5 (41.6) [9]” |
| Moderate | “1 (16.6) [1]” | “0” | “0” | “0” | “0” | “2 (40.0) [2]” | “1 (14.2) [1]” | “2 (28.5) [2]” | “6 (14.6) [6]” | “0” |
| Severe | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| TEAEs considered related to the study drug | “1 (16.6) [2]” | “0” | “3 (75.0) [5]” | “4 (66.6) [6]” | “4 (66.6) [8]” | “5 (100.0) [20]” | “4 (57.1) [5]” | “4 (57.1) [9]” | “25 (60.9) [55]” | “2 (16.6) [3]” |
| TEAEs leading to study drug discontinuation | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “1 (14.2) [1]” | “1 (2.4) [1]” | “0” |
| Any serious TEAE | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| Headache | “0” | “2 (33.3) [2]” | “0” | “2 (33.3) [3]” | “5 (83.3) [5]” | “5 (100.0) [5]” | “3 (42.8) [3]” | “3 (42.8) [6]” | “20 (48.7) [24]” | “3 (25.0) [3]” |
| Dizziness | “0” | “0” | “1 (25.0) [1]” | “0” | “0” | “1 (20.0) [1]” | “0” | “2 (28.5) [2]” | “4 (9.7) [4]” | “0” |
| Fatigue | “0” | “0” | “3 (75.0) [4]” | “0” | “0” | “1 (20.0) [1]” | “0” | “0” | “4 (9.7) [5]” | “1 (8.3) [1]” |
| Nausea | “0” | “0” | “0” | “1 (16.6) [1]” | “2 (33.3) [2]” | “5 (100) [5]” | “1 (14.2) [1]” | “1 (14.2) [1]” | “10 (24.3) [10]” | “0” |
| Catheter site bruise | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “2 (16.6) [2]” |

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

> “Note: All values are n (%) [number of reported TEAEs].”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.5-2"></a>

###### Incidence, severity, relatedness, and discontinuations in the single ascending dose part

> “In the SAD part, 37 (69.8%) participants experienced 105 TEAEs; 32 (78.0%) participants receiving ESK‐001 experienced 96 TEAEs and 5 (41.6%) participants receiving placebo experienced 9 TEAEs.”
> “Most TEAEs (94.3%) were mild in severity and a few moderate in severity (all following administration of ESK‐001).”
> “There were no dose‐related trends in the incidence and severity of TEAEs.”
> “Two participants in the FE cohort discontinued the study drug and study due to TEAEs indicative of a possible COVID‐19 infection, one after 1 dose (fed) in Period 1 due to upper respiratory tract infection, and one after 1 dose (fasted) in Period 1 due to sinus congestion, cough, and sneezing, all mild in severity and not related to study drug.”
> “The most common TEAE (reported in ≥30% of the participants in any group) by preferred term was a headache.”
> “In the cohorts receiving ESK‐001, most TEAEs were considered related to the study drug by the investigator; 25 (61.0%) participants receiving ESK‐001 experienced 55 TEAEs considered related to the study drug.”
> “Two (16.6%) participants receiving placebo experienced 3 TEAEs considered related to placebo.”
> “There were no apparent treatment or dose‐related trends in the clinical laboratory results and no TEAEs arising from abnormalities in clinical laboratory results.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.5-3"></a>

###### Safety in the multiple ascending dose part

> “For the MAD part, a similar safety profile as for the SAD part was observed (Table S6).”
> “One participant receiving ESK‐001 (Cohort 10 mg q.d fasted) discontinued the study drug and study after 1 dose due to TEAEs of nausea and vomiting, both mild in severity and both considered related to study drug.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.5-4"></a>

###### Deaths, serious and severe events, vital signs, and electrocardiograms across both phase 1 studies

> “Overall, there were no deaths, serious TEAEs, nor severe TEAEs reported in either the SAD/MAD or MD studies”
> “No clinically relevant changes were observed in vital signs, ECGs, and physical examination findings.”
> “Additionally, there were no MACE, malignancies, venous thromboembolisms, or adverse trends in laboratory parameters observed, which are commonly associated with non‐selective JAK inhibitors.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.8.5-5"></a>

###### Cardiac conduction and concentration-QTc analysis

> “Per cardiodynamic analyses, ESK‐001 had no clinically relevant effect on cardiac conduction (i.e., the PR and QRS intervals).”
> “Based on the concentration‐QTc analysis, an effect on the placebo‐corrected change from baseline QTcF (QT interval corrected using Fridericia's method) exceeding 10 ms can be excluded within the observed range of ESK‐001 plasma concentrations up to ~ 1000 ng/mL (data not shown).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

- The authors note that the study provided short-term exposure data, so chronic effects such as cumulative toxicity were not captured.
- The multiple ascending dose part is reported in supplementary figures and tables, and its biomarker results and the concentration-QTc results are reported as data not shown.
- Participants were healthy adults dosed with a liquid formulation of ESK-001.
- Because of the COVID-19 pandemic, the 17.5 mg and 100 mg cohorts could not be filled to the planned 8 participants (N = 4 and N = 5 in the pharmacokinetic table), and 2 food effect cohort participants withdrew with TEAEs indicative of a possible COVID-19 infection.
- The article and the registry differ: the article reports 91 participants enrolled and a study conducted between January 21, 2021 and February 24, 2022; the ANZCTR record gives a final sample size of 87, a first enrolment on 17/02/2021, and a last data collection on 4/02/2022.
- No formal sample size calculation was performed. Feces were collected but not analyzed, and urine was collected only for the 50 mg cohort of the single ascending dose part.
- The ANZCTR record states that no documents have been uploaded by study researchers and answers No to whether the study will consider sharing individual participant data.

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/); [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-3.1.6.9-2"></a>

###### Short-term exposure in both phase 1 studies

> “Some study limitations should be taken into consideration, including that both the SAD/MAD study and the MD study provided short‐term exposure data, and hence, chronic effects (eg, cumulative toxicity) were not captured (as mentioned above).”
> “However, long‐term safety studies are needed to further evaluate the safety of ESK‐001.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.6.9-3"></a>

###### Multiple ascending dose part reported only in the supplement

> “As this article focuses on the tablet formulation, details of the MAD part are not discussed in detail.”
> “Study details of the MAD part are described in Appendix S1.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7"></a>

#### 3.1.7 ESK-001-003

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Brief summary in the ClinicalTrials.gov record

> “Brief Summary Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants”

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.1-2"></a>

###### Pharmacokinetic and pharmacodynamic assessment for dose selection

> “Assessment of the PK/PD relationship on Day 14 (Figure 5) was performed to allow the selection of a suitable dose range for future clinical studies in patients with immune‐mediated diseases.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Study period and single site in Glendale, United States, in the published report

> “This was a phase I, single‐center, randomized, double‐blinded (with Sponsor unblinded), placebo‐controlled, parallel‐group, MD study of oral ESK‐001 immediate release tablet administration in healthy participants (NCT05431634), conducted from April 15, 2022 to September 20, 2022 at a facility in Glendale (US).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.2-2"></a>

###### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-05-12”
> “Primary Completion (Actual) 2022-12-01”
> “Study Completion (Actual) 2022-12-31”
> “First Submitted 2022-06-09”
> “First Posted 2022-06-24”

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.2-3"></a>

###### Site in the ClinicalTrials.gov record

> “This study has 1 location”
> “Glendale, California, United States, 91206”

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.2-4"></a>

###### Recruitment and results status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2023-05-09” |

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Official title and design details in the ClinicalTrials.gov record

> “A Blinded, Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 Tablets Administered Over 14days to Healthy Participants”

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

| Field | Quoted record |
| --- | --- |
| Other study ID numbers | “ESK-001-003” |
| Conditions | “Safety and Tolerability” |
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “Double (ParticipantInvestigator)” |

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.3-2"></a>

###### Blinding, confinement, and 14-day dosing schedule

> “The Principal Investigator, clinical study personnel, and study participants were blinded to treatment with the Sponsor unblinded.”
> “Following the screening period from Day −29 to −2, participants were admitted to the facility from Day −1 to 16 for a 14‐day course of the study drug with first dose administration on Day 1, and returned 5–7 days after the last dose for final safety assessments.”
> “Randomization utilized a randomization code and restricted access area maintenance.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.3-3"></a>

###### Regulatory framework of the United States study

> “The study adhered to the 21 Code of Federal Regulation guideline, the principles of the Declaration of Helsinki, the ICH E6 (R2) Good Clinical Practice – Scientific Guideline, the requirements of national drug and data protection laws, in particular, the Health Insurance Portability and Accountability Act of 1996.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Inclusion and exclusion criteria in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Inclusion: age | “Participant is a man or woman between the ages of 18 and 60years, inclusive, at the Screening Visit” |
| Inclusion: health status | “Participant is healthy as determined by medical history, physical examination, vital signs, and routine laboratory parameters” |
| Inclusion: other | “Other inclusions as specified in the protocol” |
| Exclusion: prior exposure | “Participant has a prior exposure to ESK-001” |
| Exclusion: hypersensitivity | “Participant has a history of hypersensitivity to any of the ingredients of ESK-001” |
| Exclusion: other | “Other exclusions as specified in the protocol” |
| Ages eligible for study | “18 Years to 60 Years (Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Tablet strengths and matching placebo

> “The study products included ESK‐001 30 mg tablet (Batch number: 25089), ESK‐001 10 mg tablet (Batch number: 25087), and matching placebos (30 mg tablet [Batch number: 25206], 10 mg tablet [Batch number: 25204]).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.5-2"></a>

###### Six dose regimens and the basis for dose and fasting conditions

> “Doses were 20 mg once daily (q.d.) fasted, 20 mg once every 12 h (Q12) fasted, 40 mg Q12 fasted, 10 mg q.d. fasted, 30 mg Q12 nonfasted, and 60 mg q.d. nonfasted.”
> “The dose levels were determined based on the SAD/MAD study results and relative bioavailability study data of the tablet vs. liquid formulation.”
> “The fasting requirement was adjusted for the last two cohorts, based on data from the FE cohort.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.5-3"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Arm description | Intervention |
| --- | --- | --- |
| “Placebo Comparator: Placebo” | “Placebo for ESK-001” | “Other: Placebo” |
| “Experimental: Experimental Drug ESK-001” | “Experimental Drug ESK-001” | “Multiple doses of ESK-001” |

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Adverse Event Incidence as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Measure description | Time frame |
| --- | --- | --- | --- |
| Primary | “Incidence of Adverse Events (AEs)” | “Safety and tolerability” | “Up to 14 days” |
| Primary | “Incidence of Serious Adverse Events (SAEs)” | “Safety and tolerability” | “Up to 14 days” |
| Secondary | “The area under plasma concentration-time curve from time zero extrapolated to last measurable concentration (AUCt) for ESK001 on Day 1 and Day 14” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “The area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) for ESK001 on Day1 and Day 14” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “The observed maximum plasma concentration (Cmax) for ESK001 on Day 1 and Day 14.” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “The time to reach the observed maximum plasma concentration (tmax) for ESK001 on Day 1 and Day 14.” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “Apparent plasma elimination half-life (t½λz) for ESK001 on Day 1 and Day 14” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “Apparent clearance CL(Clearance)/F for ESK001 on Day 1” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “The accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) for ESK001 on Day 14” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “The accumulation ratio for Cmax (RAC Cmax) for ESK001 on Day 14.” | “Pharmacokinetics” | “Up to 14 days” |
| Secondary | “Cytokine induction of pSTAT expression and downstream cytokine production as a measure of tyk2 pathway inhibition by ESK001” | “Pharmacodynamics” | “14 days after first dose” |

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.6.1-2"></a>

###### Pharmacodynamic assessments: pSTAT1 flow cytometry and whole-blood RNA sequencing

> “The effect of ESK‐001 on exploratory PD and biomarker parameters was evaluated in the whole blood of healthy participants from the MD study.”
> “Flow cytometry analysis of pSTAT1 (phosphorylated signal transducer and activator of transcription 1) expression in T cells in IFNα‐stimulated whole blood and RNA sequencing of unstimulated whole blood was performed.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.6.1-3"></a>

###### Definitions of percentage pSTAT1 inhibition and the type I interferon and SIGLEC1 signatures

> “The percentage inhibition of pSTAT1 was calculated for each participant for each timepoint as the percentage change from baseline (Day 1 predose).”
> “RNA sequencing was performed to analyze type I IFN gene and SIGLEC1 signature, which were defined as the median transcript expression of the Dx Terity panel genes HERC5, RSAD2, IFI27, and IFIT1, and SIGLEC1, respectively.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.6.1-4"></a>

###### Urine collection and pharmacokinetic-pharmacodynamic sampling in the multiple-dose study

> “Urine was collected from all MD cohorts but only cohorts 20 mg q.d., 60 mg q.d., and 40 mg Q12 were analyzed.”
> “Parallel collection of PK samples alongside PD sampling enabled the determination of the ESK‐001 PK/PD relationship.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Planned cohort size and participants enrolled per cohort

> “Participants were randomized to six cohorts (planned cohort size: 8 participants) to receive ESK‐001 or placebo (3:1), with 49 participants (36 for ESK‐001 and 13 for placebo) enrolled per Sponsor's decision.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.7.1-2"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 49”

Source: [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.7.1-3"></a>

###### Enrollment estimated at registration, June 2022, superseded in May 2023

> “Enrollment 48 [Estimated]”

Source: [ClinicalTrials.gov NCT05431634 version 1](https://clinicaltrials.gov/study/NCT05431634?tab=history&a=1)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

###### Steady-state assessment and software for pharmacokinetic and statistical analyses

> “Plasma ESK‐001 steady state was assessed by calculating the 90% confidence interval (CI) of the slope of the linear regression of loge (concentration at the end of a dose interval [C trough]) vs. time in the MD study.”
> “The PK analyses were conducted using Phoenix WinNonlin Version 8.3 or higher, and all statistical analyses were performed using SAS Version 9.4 (SAS Institute, Cary, North Carolina, USA).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.7.2-2"></a>

###### Data included in the pharmacokinetic-pharmacodynamic analysis

> “All available individual PD TYK2 inhibition data points (across all valid cohorts, doses, and timepoints) with matching PK measurements were included in the assessment.”
> “Individual PD results were plotted against their respective exposure (in μM) on a semi‐log scale graph and best‐fit curve (log inhibitor vs. response, four parameters) was generated in GraphPad Prism.”
> “Per protocol, PD samples were to be collected on Day 14, but for some participants, the PD samples were collected on Day 13.”
> “N = 6 participants, except for Cohort 30 mg Q12 Day 14 (N = 5).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.7.2-3"></a>

###### Exclusion of placebo participants with unexpected plasma concentrations

> “In the MD study, five participants receiving a placebo showed sparse unexpected ESK‐001 plasma concentrations but were excluded as per Sponsor's request.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

###### Randomization and discontinuations in the multiple-dose study

> “In the MD study, 49 participants were randomized to study treatment (Figure 2).”
> “Five participants discontinued the study.”
> “Two participants discontinued the study drug and study due to TEAEs (see Safety and Tolerability results).”
> “One participant receiving ESK‐001 (Cohort 20 mg q.d. fasted) discontinued the study drug and study after the sixth dose due to psychotic behavior.”
> “Additionally, two participants receiving placebo discontinued the study drug and study due to withdrawal by participant (both for personal reasons, non‐safety‐related); one (Cohort 40 mg Q12 fasted) after the second dose on Day 10, and another (Cohort 30 mg Q12 nonfasted) after the first dose on Day 3.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Race, ethnicity, sex, and body mass index in the multiple-dose study

> “Most participants were white and not Hispanic or Latin (Table S1).”
> “Overall, sex was balanced between cohorts receiving ESK‐001.”
> “The mean BMI ranged from 24.0 to 26.8 kg/m2.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Absorption, half-life, dose proportionality, steady state, and accumulation with the tablet

> “ESK‐001 was rapidly absorbed into the systemic circulation with a median T max of 1.5–3.1 h on Day 1 following a single dose, and 1.1–2.2 h on Day 14 following multiple q.d. or Q12 doses (Figure 3b, Table 1).”
> “The mean t½ after the last dose on Day 14 ranged from 7.6 to 12.4 h across all q.d. or Q12 doses and no trend with dose or dose regimen was observed.”
> “Similarly, no trend with dose was observed for geometric mean apparent steady‐state volume of distribution (Vss/F) and mean apparent total plasma clearance (CL/F).”
> “After multiple q.d. doses and after the first dose administration of Q12 doses, AUC from time zero to time tau (AUC0–tau) appeared to increase in a dose‐proportional manner (slope estimates [95% CI] were 0.934 [0.62;1.25] and 0.992 [0.49, 1.49], respectively), although 95% CIs were wide.”
> “No definitive conclusion could be derived on dose proportionality for q.d. doses on Day 1 and for Q12 doses on Day 14.”
> “Steady state was achieved by Day 3 following q.d. and Q12 multiple doses.”
> “Following multiple q.d. doses, accumulation ratios (R ac) based on C max and AUC0–tau showed no to minimal accumulation of ESK‐001 (mean R ac C max ranged from 0.71 to 1.41 and mean R ac AUC from 0.80 to 1.39).”
> “Following multiple Q12 doses, there was an ~ 2‐fold accumulation of ESK‐001 (mean R ac C max ranged from 1.74 to 2.17 and mean R ac AUC from 1.74 to 2.42).”
> “The C trough levels at the highest ESK‐001 dose of 40 mg Q12 were maintained above the in vitro human whole blood (HWB) 90% pSTAT inhibitory concentration (IC90) threshold (Figure 3c).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-2"></a>

###### Plasma pharmacokinetic parameters by multiple-dose cohort on days 1 and 14

> “Summary of plasma PK parameters of ESK‐001 following administration of single and multiple doses.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

| Cohort and day (N = 6 per cohort) | Cmax, ng/mL | Ctrough, ng/mL | Tmax, h | AUC0–tau, h*ng/mL | t½, h | CL/F, L/h | Rac Cmax | Rac AUCtau |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 10 mg q.d. fasted, day 1 | “88.2 (42.7)” | “‐” | “2.02 (1.01–2.04)” | “630.8 (41.1)” | “‐” | “‐” | “‐” | “‐” |
| 10 mg q.d. fasted, day 14 | “99.5 (40.9)” | “11.8 (48.2)” | “1.60 (0.50–2.24)” | “795.8 (37.2)” | “9.22 (22.8)” | “12.6 (37.2)” | “1.13 (21.0)” | “1.26 (12.4)” |
| 20 mg q.d. fasted, day 1 | “171.4 (26.7)” | “‐” | “1.53 (0.51–2.07)” | “1338.0 (14.9)” | “‐” | “‐” | “‐” | “‐” |
| 20 mg q.d. fasted, day 14 | “132.0 (93.3)” | “15.1 (65.6)” | “2.10 (1.02–2.16)” | “1102.0 (71.4)” | “9.18 (36.7)” | “18.2 (71.4)” | “0.71 (80.2)” | “0.80 (79.9)” |
| 20 mg Q12 fasted, day 1 | “132.2 (20.9)” | “‐” | “2.01 (0.51–2.05)” | “793.1 (24.1)” | “‐” | “‐” | “‐” | “‐” |
| 20 mg Q12 fasted, day 14 | “287.1 (20.0)” | “108.7 (27.7)” | “2.06 (0.50–2.14)” | “1920.0 (17.3)” | “9.61 (7.6)” | “10.4 (17.3)” | “2.17 (32.7)” | “2.42 (25.6)” |
| 30 mg Q12 nonfasted, day 1 | “182.0 (46.6)” | “‐” | “2.09 (2.06–2.19)” | “1206.0 (38.7)” | “‐” | “‐” | “‐” | “‐” |
| 30 mg Q12 nonfasted, day 14 | “282.7 (24.0)” | “54.2 (306.4)” | “2.20 (2.12–4.19)” | “1878.0 (31.4)” | “7.60 (14.5)” | “16.0 (31.4)” | “1.74 (25.8)” | “1.74 (10.0)” |
| 60 mg q.d. nonfasted, day 1 | “356.7 (48.6)” | “‐” | “3.12 (1.13–4.07)” | “2934.0 (30.7)” | “‐” | “‐” | “‐” | “‐” |
| 60 mg q.d. nonfasted, day 14 | “503.8 (40.3)” | “45.5 (61.8)” | “2.09 (2.03–2.12)” | “4074.0 (33.7)” | “9.56 (20.2)” | “14.7 (33.7)” | “1.41 (34.4)” | “1.39 (30.5)” |
| 40 mg Q12 fasted, day 1 | “249.6 (25.9)” | “‐” | “2.06 (1.01–4.01)” | “1574.0 (25.4)” | “‐” | “‐” | “‐” | “‐” |
| 40 mg Q12 fasted, day 14 | “437.4 (49.0)” | “226.3 (31.3)” | “1.08 (1.04–2.13)” | “3246.0 (50.2)” | “12.41 (29.8)” | “12.3 (50.2)” | “1.75 (61.9)” | “2.06 (51.2)” |

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-3"></a>

###### Urinary excretion of unchanged drug in the multiple-dose study

> “Only a small amount of unchanged ESK‐001 was eliminated in urine.”
> “The mean %Fe (CV%) and CLr (CV%) were comparable for Cohort 60 mg q.d. (nonfasted) (0.43% [94.7%] and 63.8 mL/h [66.8%], respectively) and Cohort 40 mg Q12 (fasted) (0.37% [55.8%] and 46 mL/h [115.2%], respectively).”
> “Due to one outlier participant with very high %Fe (45.4%) and CLr (24.3 L/h) compared with the other participants in the same treatment group, the mean %Fe and CLr for the Cohort 20 mg q.d. (fasted) were higher (1.12% [935.9%] and 203.7 mL/h [4430.3%], respectively) than for the Cohorts 60 mg q.d. (nonfasted) and 40 mg Q12 (fasted).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-4"></a>

###### Elimination route in the congress poster's summary of the multiple-dose study

> “The primary elimination route was through liver metabolism, with <1% renal excretion.”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="topic-3.1.7.8.3-5"></a>

###### Inhibition of IFNα-induced pSTAT1 in T cells by dose

> “In the MD study, IFNα‐induced pSTAT1 expression was analyzed in T cells from whole blood as a measure of TYK2 inhibition and confirmed robust pharmacologic activity of ESK‐001 with a clear dose‐dependent effect (Figure 4a).”
> “Maximal TYK2 pathway inhibition was achieved within 2–4 h for all doses >10 mg q.d., with dose‐dependent differences observable at later timepoints following the last dose.”
> “At the highest daily dose of 80 mg (administered as 40 mg Q12), maximal levels of TYK2 inhibition were achieved within 2–4 h and maintained throughout the Q12 dose interval.”
> “At the lowest total daily dose of 10 mg q.d., a partial TYK2 inhibition profile was achieved, with TYK2 inhibition peaking at <50% inhibition within 2–4 h and quickly returning to baseline TYK2 activity with minimal inhibition measured at 12 and 24 h.”
> “All dose levels returned toward normal TYK2 activity 24–48 h after the last dose on Day 14.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-6"></a>

###### Type I interferon gene signature and SIGLEC1 expression

> “The mRNA transcriptomics analysis showed clear dose‐dependent inhibition of type I IFN gene signature on Day 14 with full inhibition at higher doses, which was concordant with pSTAT1 functional assay results (4b).”
> “Similarly, clear dose‐dependent inhibition of expression of SIGLEC1 (sialic acid binding Ig like lectin 1), a novel TYK2‐responsive biomarker, was observed (Figure 4c).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-7"></a>

###### Downstream cytokine inhibition in the congress poster

> “Downstream pathway inhibition of IFNα induced CXCL10 and IL-12/IL-18 induced IFNγ production.”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="topic-3.1.7.8.3-8"></a>

###### Pharmacokinetic-pharmacodynamic relationship at the highest and lowest doses

> “At the highest dose of 40 mg Q12, peak (2–4 h after the last dose) and trough (12 h after the last dose) samples showed maximal TYK2 inhibition, which aligned with PK exposures at or above the in vitro HWB pSTAT IC90 threshold and was maintained throughout the treatment period (Figure 5c).”
> “As expected at the lowest dose (10 mg q.d.), ESK‐001 demonstrated only a partial profile of TYK2 inhibition with limited TYK2 inhibition achieved at peak timepoints (2–4 h after the last dose), which was not maintained at trough timepoints (24 h after the last dose) (Figure 5b).”
> “ESK‐001 demonstrated a strong PK/PD relationship, with high predictability, low variability, and a clear sigmoidal exposure–response relationship with TYK2 inhibition.”
> “Higher levels of drug exposure above the IC90 guide point did not result in additional pharmacological effects.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.3-9"></a>

###### Dose range selected for the STRIDE phase 2 study

> “The PK/PD relationship was used to select the dose range of 10 mg q.d. to 40 mg Q12 for ESK‐001 treatment in phase II studies, including the STRIDE phase II study in plaque psoriasis (NCT05600036).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Treatment-emergent adverse events by multiple-dose cohort

| Event | 10 mg q.d. fasted (N = 6) | 20 mg q.d. fasted (N = 6) | 20 mg Q12 fasted (N = 6) | 30 mg Q12 nonfasted (N = 6) | 60 mg q.d. nonfasted (N = 6) | 40 mg Q12 fasted (N = 6) | Total active (N = 36) | Pooled placebo (N = 13) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participant with at least 1 TEAE | “3 (50.0) [7]” | “5 (83.3) [11]” | “5 (83.3) [14]” | “5 (83.3) [10]” | “4 (66.7) [16]” | “5 (83.3) [14]” | “27 (75.0) [72]” | “11 (84.6) [19]” |
| Mild | “3 (50.0) [6]” | “5 (83.3) [10]” | “5 (83.3) [14]” | “5 (83.3) [9]” | “4 (66.7) [11]” | “5 (83.3) [14]” | “27 (75.0) [64]” | “11 (84.6) [18]” |
| Moderate | “1 (16.7) [1]” | “1 (16.7) [1]” | “0” | “1 (16.7) [1]” | “3 (50.0) [5]” | “0” | “6 (16.7) [8]” | “1 (7.7) [1]” |
| Severe | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| TEAEs considered related to the study drug | “1 (16.7) [2]” | “2 (33.3) [4]” | “1 (16.7) [1]” | “3 (50.0) [3]” | “4 (66.7) [11]” | “4 (66.7) [8]” | “15 (41.7) [29]” | “1 (7.7) [1]” |
| TEAEs leading to study drug discontinuation | “0” | “0” | “0” | “1 (16.7) [1]” | “0” | “0” | “1 (2.8) [1]” | “1 (7.7) [1]” |
| Any serious TEAE | “0” | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| Erythema | “2 (33.3) [2]” | “5 (83.3) [6]” | “5 (83.3) [5]” | “4 (66.7) [5]” | “2 (33.3) [2]” | “2 (33.3) [2]” | “20 (55.6) [22]” | “9 (69.2) [11]” |
| Headache | “0” | “3 (50.0) [5]” | “2 (33.3) [2]” | “1 (16.7) [1]” | “4 (66.7) [9]” | “4 (66.7) [8]” | “14 (38.9) [25]” | “1 (7.7) [1]” |
| Gastrointestinal disorders | “0” | “0” | “1 (16.7) [1]” | “1 (16.7) [1]” | “2 (33.3) [2]” | “1 (16.7) [1]” | “5 (13.9) [5]” | “1 (7.7) [1]” |
| Psychiatric disorders | “1 (16.7) [1]” | “0” | “0” | “0” | “0” | “1 (16.7) [1]” | “2 (5.6) [2]” | “1 (7.7) [1]” |
| Dysmenorrhoea | “0” | “0” | “1 (16.7) [1]” | “0” | “0” | “0” | “1 (2.8) [1]” | “2 (15.4) [2]” |

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

> “Events occurring in >1 participant per cohort or pooled placebo group by SOC and PT are reported.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.5-2"></a>

###### Incidence, severity, relatedness, discontinuations, and laboratory findings in the multiple-dose study

> “Thirty‐eight (77.6%) participants experienced 91 TEAEs; 27 (75.0%) participants receiving ESK‐001 experienced 72 TEAEs and 11 (84.6%) participants receiving placebo experienced 19 TEAEs.”
> “Most TEAEs (90.1%) were mild in severity; all other TEAEs were moderate in severity.”
> “There was no dose‐dependent increase in the number of TEAEs or meaningful change in the severity levels observed.”
> “The frequency of headaches appeared to increase with increasing dose of ESK‐001; however, most headaches (80.8%) were observed to be mild in severity across all dose levels and resolved without sequalae.”
> “Two participants discontinued the study drug and study due to TEAEs; one participant receiving ESK‐001 (Cohort 30 mg Q12 nonfasted) due to rash morbilliform (considered study drug‐related), and one receiving placebo (Cohort 60 mg q.d. nonfasted) due to COVID‐19 (considered not study drug‐related); both TEAEs were mild in severity.”
> “The most common TEAEs (reported in ≥30% of the participants in any group) by preferred term were erythema and headache.”
> “Events of erythema were secondary to skin taping for a sample collection procedure.”
> “Fifteen (41.7%) participants receiving ESK‐001 experienced 29 TEAEs considered related to the study drug and 1 (7.7%) participant receiving a placebo experienced a TEAE considered related to placebo.”
> “Minor fluctuations occurred in coagulation, clinical chemistry, and urinalysis parameters, but without treatment‐related trends.”
> “Two participants reported an abnormal clinically meaningful laboratory value; one for Strep A2 rapid screen on Day 8, and one for SARS‐CoV‐2 RNA on Day 9.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-3.1.7.8.5-3"></a>

###### Deaths, serious events, and adverse events of special interest in the congress poster's safety summary

> “ESK-001 was generally well tolerated across cohorts. No deaths or serious treatment-emergent adverse events (TEAEs) were observed.”
> “No major adverse cardiovascular events, malignancies, venous thromboembolism events or adverse trends in laboratory parameters occurred.”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

- The authors advise caution in interpreting the dose proportionality analysis because of the small number of participants, the limited q.d. and Q12 dose range, and the wide 95% CIs; no definitive conclusion could be derived for q.d. doses on Day 1 and Q12 doses on Day 14.
- Participants were 49 healthy adults (36 envudeucitinib, 13 placebo) treated for 14 days at one site.
- The last two cohorts (30 mg Q12 and 60 mg q.d.) were dosed nonfasted, while the other cohorts were dosed fasted.
- The Sponsor was unblinded, and five placebo participants with unexpected ESK-001 plasma concentrations were excluded at the Sponsor's request.
- Some pharmacodynamic samples were collected on Day 13 instead of Day 14, and urine was analyzed for only 3 of the 6 cohorts, with one outlier participant raising the 20 mg q.d. means.
- Erythema, the most common TEAE with headache, was secondary to skin taping for a sample collection procedure.
- The article describes a parallel-group study conducted from April 15, 2022 to September 20, 2022; the ClinicalTrials.gov record lists sequential assignment, a start on 2022-05-12, and completion on 2022-12-31, and reads “No Results Posted”.

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/); [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)

<a id="topic-3.1.7.9-2"></a>

###### Small sample and limited dose range for the dose proportionality analysis

> “Furthermore, in the MD study, the results of statistical analysis of the dose proportionality should be cautiously interpreted in light of the small number of participants included in the analysis, the limited q.d. and Q12 dose range examined, and the wide 95% CI around the estimated slopes.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="heading-3.1.8"></a>

#### 3.1.8 Asian Ethnic Bridging Study

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Primary and secondary objectives

> “Primary objective: To evaluate the pharmacokinetics (PK) of ESK-001 in Japanese, Chinese, and Caucasian healthy participants following single and multiple doses.”
> “Secondary objective: To assess the safety and tolerability of ESK-001 in Japanese, Chinese, and Caucasian healthy participants following single and multiple doses.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

No evidence found.

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Sequential periods and blood sampling in the Japanese and Chinese cohorts

> “3 sequential treatment periods (Period 1: 20 mg single dose on Day 1; Period 2: 40 mg single dose on Day 6; Period 3: 40 mg BID for 7 days), each separated by 5-day washout periods.”
> “Blood samples collected on Days 1 and 2 for Period 1, on Days 6 and 7 for Period 2, and from Day 11 to Day 19 for Period 3.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-3.1.8.3-2"></a>

###### Caucasian reference cohort given the expected therapeutic dose only

> “1 treatment period (40 mg BID for 7 days).”
> “Note: Several previous ESK-001 studies (ClinPharm, STRIDE) have provided Caucasian data.”
> “Therefore, Cohort 3 was directly given the expected therapeutic dose (ie, 40 mg BID).”
> “Blood samples collected from Day 1 to Day 9.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Ancestry required for each cohort

> “Enrolled participants of Japanese and Chinese ancestry in Cohort 1 and Cohort 2, respectively.”
> “Enrolled participants of Caucasian ancestry.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Fed-state dosing in the Asian cohorts and fasted-state dosing in the Caucasian cohort on day 7 of twice-daily dosing

> “Note: Japanese & Chinese BID Day 7 PK profile is fed state and Caucasian BID Day 7 PK profile is fasted state dosing data.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

###### Noncompartmental analysis of the parent drug and its main metabolite

> “PK parameters were calculated from concentrations of ESK-001 (and its main metabolite) in plasma using noncompartmental analysis methods.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-3.1.8.6.1-2"></a>

###### Definitions of the steady-state pharmacokinetic parameters

> “Cmax,ss = maximum plasma concentration on Day 7 at steady state; AUC0-τ, ss = area under the concentration-time curve for the dosing interval at steady state; Tmax,ss= time needed to reach Cmax postdose on Day 7 at steady state; t1/2,ss = terminal elimination half-life on Day 7 at steady state; CL/F = apparent clearance; Vd/F = volume of distribution; BWCmax = body weight normalized Cmax; BWAUC = body weight normalized AUC; Rac = accumulation ratio; MRCmax = metabolite to parent ratio based on Cmax; MRAUC = metabolite to parent ratio based on AUC”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Single-center open-label enrollment of 24 participants in three cohorts

> “This Phase I, single-center, open-label study enrolled a total of 24 healthy participants (8 per cohort) into 1 of 3 cohorts.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

###### Descriptive statistics and external Caucasian data in the single-dose plots

> “The descriptive statistics shown are not log-transformed.”
> “Note: In 20 mg & 40 mg single dose graphs, Caucasian data was plotted with the data from another study (ie, ESK-001-003 20 mg QD/40 mg BID multiple dosing study).”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

<a id="topic-3.1.8.8.1-1"></a>

###### Reason for the single discontinuation due to a treatment-emergent adverse event

> “Moderate headache that resolved with routine treatment (paracetamol) within 4 days of discontinuation of ESK-001”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Demographics by ethnic cohort

| Characteristic | Cohort 1: Japanese (n=8) | Cohort 2: Chinese (n=8) | Cohort 3: Caucasian (n=8) | Overall (n=24) |
| --- | --- | --- | --- | --- |
| Age (years), mean (SD) | “42.6 (9.3)” | “38.4 (8.2)” | “45.5 (11.8)” | “42.2 (9.9)” |
| Sex, female/male, n (%) | “1 (12.5)/7 (87.5)” | “0 (0.0)/8 (100.0)” | “5 (62.5)/3 (37.5)” | “6 (25.0)/18 (75.0)” |
| Hispanic or Latino, n (%) | “0 (0.0)” | “0 (0.0)” | “2 (25.0)” | “2 (8.3)” |
| Not Hispanic or Latino, n (%) | “8 (100.0)” | “8 (100.0)” | “6 (75.0)” | “22 (91.7)” |
| Height (cm), mean (SD) | “170.2 (8.2)” | “170.0 (3.0)” | “168.6 (7.7)” | “169.6 (6.4)” |
| Weight (kg), mean (SD) | “66.4 (10.2)” | “72.6 (9.7)” | “80.4 (8.1)” | “73.1 (10.7)” |

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Steady-state pharmacokinetics of the parent drug and main metabolite on day 7 of 40 mg twice daily, by ethnic cohort

> “PK evaluation of ESK-001 and its main metabolite following 7th day of BID 40 mg oral administration of ESK-001”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

| Parameter | Cohort 1: Japanese (n=8) | Cohort 2: Chinese (n=8) | Cohort 3: Caucasian (n=8) |
| --- | --- | --- | --- |
| Cmax,ss (ng/mL), geometric mean (CV%) | “502 (25.1)” | “586 (24.3)” | “531 (11.1)” |
| AUC0-τ,ss (hr*ng/mL), geometric mean (CV%) | “3,410 (22.7)” | “4,580 (18.3)” | “3,530 (9.5)” |
| Tmax,ss (hr), median (min, max) | “2.8 (2.0, 4.0)” | “3.0 (1.0, 6.0)” | “1.0 (1.0, 2.0)” |
| t1/2,ss (hr), geometric mean (CV%) | “7.6 (20.4)” | “8.4 (13.4)” | “9.1 (17.0)” |
| CL/F (L/hr), geometric mean (CV%) | “10.8 (22.7)” | “8.0 (18.3)” | “10.4 (9.5)” |
| Vd/F (L), geometric mean (CV%) | “118.0 (35.9)” | “97.4 (26.5)” | “138.0 (17.7)” |
| BWCmax (ng/mL/mg/kg), geometric mean (CV%) | “895 (32.5)” | “1,140 (14.3)” | “1,140 (12.6)” |
| BWAUC0-τ,ss (hr*ng/mL/mg/kg), geometric mean (CV%) | “6,080 (26.9)” | “8,950 (9.8)” | “7,540 (11.4)” |
| Rac, geometric mean (CV%) | “2.10 (96.3)” | “2.48 (38.0)” | “2.09 (34.7)” |
| MRCmax main metabolite, geometric mean (CV%) | “2.65 (33.6)” | “2.91 (23.1)” | “2.60 (24.9)” |
| MRAUC main metabolite, geometric mean (CV%) | “3.56 (30.3)” | “3.69 (24.9)” | “3.73 (15.8)” |

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-3.1.8.8.3-2"></a>

###### Comparability of absorption, exposure, elimination, and food effect across ethnicities

> “PK profiles of ESK-001 were similar across different ethnicities”
> “Rapid absorption, steady elimination, and dose-proportional exposure across all ethnicities.”
> “Food slightly delayed Tmax but did not significantly affect exposure.”
> “In general, plasma exposures (as Cmax and AUC) of ESK-001 and its main metabolite were comparable across ethnicities, as were elimination half-lives (t1/2), clearance (CL/F), and volume of distribution (Vd/F).”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-3.1.8.8.3-3"></a>

###### Conclusion on dosing in Asian populations

> “No clinically relevant differences in PK parameters, safety, or tolerability were observed across ethnicities, supporting the conclusion that the same therapeutic dosing regimen can be safely used for psoriasis treatment in Asian populations.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Treatment-emergent adverse events by dose period and ethnic cohort

| Event | 20 mg, Japanese (n=8) | 20 mg, Chinese (n=8) | 40 mg, Japanese (n=8) | 40 mg, Chinese (n=8) | 40 mg BID, Japanese (n=8) | 40 mg BID, Chinese (n=8) | 40 mg BID, Caucasian (n=8) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Any TEAE, n (%) | “1 (12.5)” | “2 (25.0)” | “5 (62.5)” | “1 (12.5)” | “4 (50.0)” | “5 (62.5)” | “6 (75.0)” |
| At least 1 TEAE Grade 2, n (%) | “0 (0.0)” | “1 (12.5)” | “0 (0.0)” | “1 (12.5)” | “1 (12.5)” | “0 (0.0)” | “4 (50.0)” |
| At least 1 TEAE Grade ≥3, n (%) | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| TEAE related to study medication | “1 (12.5)” | “1 (12.5)” | “5 (62.5)” | “1 (12.5)” | “4 (50.0)” | “4 (50.0)” | “6 (75.0)” |
| TEAEs leading to study discontinuation | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (12.5)” |
| TEAEs leading to study medication discontinuation | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (12.5)” |

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-3.1.8.8.5-2"></a>

###### Tolerability, severity, and most common events by ethnic cohort

> “Safety profiles of ESK-001 were similar across different ethnicities”
> “ESK-001 was generally well tolerated at all evaluated doses.”
> “Most treatment-emergent adverse events (TEAEs) were mild, with some instances of moderate TEAEs.”
> “TEAEs related to ESK-001 were generally limited to expected TEAEs also observed during earlier clinical studies with ESK-001.”
> “Headache (Cohort 1: n=6; Cohort 2: n=3; Cohort 3: n=6)”
> “Somnolence (Cohort 1: n=4; Cohort 2: n=0; Cohort 3: n=0)”
> “Dizziness (Cohort 1: n=1; Cohort 2: n=2; Cohort 3: n=1”
> “No severe, life-threatening, or fatal TEAEs.”
> “No serious TEAEs or deaths.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

- The only source is one congress poster; no registry record, study location, or study dates are quoted, and the poster states no limitations.
- The study was single-center and open-label, with 24 healthy participants (8 per cohort).
- The Caucasian cohort received only 40 mg BID, and the Caucasian single-dose curves were plotted with data from another study (ESK-001-003).
- Day 7 pharmacokinetic profiles of the twice-daily regimen were obtained in the fed state for the Japanese and Chinese cohorts and in the fasted state for the Caucasian cohort.
- The cohorts differed in sex (female/male: 1/7, 0/8, and 5/3) and mean weight (66.4, 72.6, and 80.4 kg), and the results are descriptive statistics that are not log-transformed.

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="heading-3.1.9"></a>

#### 3.1.9 ESK-001-019

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

###### Brief summary in the ClinicalTrials.gov record

> “This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

###### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2024-06-21”
> “Primary Completion (Actual) 2024-08-31”
> “Study Completion (Actual) 2024-08-31”
> “First Submitted 2025-12-10”
> “First Posted 2026-01-30”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="topic-3.1.9.2-2"></a>

###### Site in Daytona Beach, Florida, in the ClinicalTrials.gov record

> “This study has 1 location”
> “Daytona Beach, Florida, United States, 32117”
> “Fortrea CRU”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="topic-3.1.9.2-3"></a>

###### Recruitment and results status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2026-01-30” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Official title and design details in the ClinicalTrials.gov record

> “A Phase 1, Partially Blinded, Randomized, Crossover Study to Evaluate the Pharmacokinetics and QT/QTc Interval of ESK-001 Compared to Placebo and Moxifloxacin in Healthy Subjects”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

| Field | Quoted record |
| --- | --- |
| Other study ID numbers | “ESK-001-019” |
| Conditions | “Healthy Volunteer” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Triple (ParticipantInvestigatorOutcomes Assessor)” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="topic-3.1.9.3-2"></a>

###### Four treatment sequences, blinding, and central electrocardiogram reading

> “Masking Description: All subjects will be randomized to 1 of 4 treatment sequences; each subject will receive all 4 treatments. Treatments 1 through 3 will be blinded; Treatment 4 will be given open label. The central ECG laboratory will be blinded to treatment assignment”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Age and body size | “Healthy male and female subjects aged between 18 and 55 years, inclusive. Body mass index between ≥18.0 and ≤32.0 kg/m2, inclusive, and a minimum body weight of 45 kg.” |
| Consent | “Able to comprehend and willing to sign an ICF and to abide by the study restrictions.” |
| Health status | “In good health, determined by no clinically significant findings from medical history, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations, and from the physical examination at screening or check-in, as assessed by the investigator (or designee).” |
| Electrolytes | “Serum sodium, potassium, calcium, and magnesium levels are within the normal range at screening and check-in-” |
| Ages eligible for study | “18 Years to 55 Years (Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="topic-3.1.9.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Viral infection | “Positive hepatitis panel and/or positive human immunodeficiency virus test, hepatitis B surface antigen, or hepatitis C antibodies.” |
| Liver enzymes | “Alanine aminotransferase or aspartate aminotransferase >1.5 times the upper limit of normal, at screening or check-in.” |
| Hypersensitivity | “History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).” |
| Recent surgery | “Surgery within the past three months prior to the first study drug administration determined by the principal investigator to be clinically relevant.” |
| Gastrointestinal surgery | “History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).” |
| Gilbert's syndrome or cholecystectomy | “History of Gilbert's syndrome or cholecystectomy surgery.” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Arm description |
| --- | --- |
| “Experimental: Treatment 1: (Therapeutic dose)” | “1 oral dose of ESK-001” |
| “Experimental: Treatment 2: (Supratherapeutic dose)” | “1 oral dose of ESK-001” |
| “Placebo Comparator: Treatment 3: ESK-001-matched placebo” | “ESK-001-matched placebo” |
| “Active Comparator: Treatment 4: (positive control)” | “Moxifloxacin 400 mg tablet” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Placebo-adjusted Change in QTcF as the Primary Endpoint

<a id="topic-3.1.9.6.1-1"></a>

###### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Change from baseline in placebo-adjusted QTcF (∆∆QTcF)” | “24 hours” |
| Secondary | “Change from baseline in ECG parameter ΔHR” | “24 hours” |
| Secondary | “Change from baseline in ECG parameter Δ PR interval” | “24 hours” |
| Secondary | “Change from baseline in ECG parameter ΔQRS duration” | “24 hours” |
| Secondary | “Change from baseline in ECG parameter ΔQTc interval” | “24 hours” |
| Secondary | “Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation” | “Up to 22 Days” |
| Secondary | “Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations” | “Up to 22 Days” |
| Secondary | “Composite of pharmacokinetic (PK) parameter Vz/F for ESK-001 and metabolites” | “24 hours” |
| Secondary | “Composite of pharmacokinetic (PK) parameter Cmax for ESK-001 and metabolites” | “24 hours” |
| Secondary | “Composite of pharmacokinetic (PK) parameter tmax for ESK-001 and metabolites” | “24 hours” |
| Secondary | “Composite of pharmacokinetic (PK) parameter CL/F for ESK-001 and metabolites” | “24 hours” |

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 52”

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

No evidence found.

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary

- The study is known only from its ClinicalTrials.gov record, which reads “No Results Posted”; the report holds no QTcF, ECG, pharmacokinetic, or safety result.
- The record was first submitted on 2025-12-10, after the actual study completion date of 2024-08-31.
- The record describes the therapeutic and supratherapeutic arms each as one oral dose of ESK-001 without stating the dose.
- The study gave single doses to 52 healthy participants aged 18 to 55 years at one site, with the moxifloxacin positive control given open label.

Source: [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)

<a id="heading-3.1.10"></a>

#### 3.1.10 ESK-001-022

<a id="heading-3.1.10.1"></a>

##### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

###### Brief summary in the ClinicalTrials.gov record

> “This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.”

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.2"></a>

##### 3.1.10.2 Location and Study Date

<a id="topic-3.1.10.2-1"></a>

###### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-04-29”
> “Primary Completion (Actual) 2026-03-24”
> “Study Completion (Actual) 2026-03-24”
> “First Posted 2025-05-01”

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="topic-3.1.10.2-2"></a>

###### Completion dates estimated at registration, April 2025, superseded in May 2026

> “Primary Completion 2025-12 [Estimated]”
> “Study Completion 2025-12 [Estimated]”

Source: [ClinicalTrials.gov NCT06952634 version 1](https://clinicaltrials.gov/study/NCT06952634?tab=history&a=1)

<a id="topic-3.1.10.2-3"></a>

###### Sites in California, Florida, and Tennessee in the ClinicalTrials.gov record

> “This study has 4 locations”

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

| Site | Quoted record |
| --- | --- |
| California | “Lake Forest, California, United States, 92630” |
| Florida | “Miami Lakes, Florida, United States, 33104” |
| Florida | “Orlando, Florida, United States, 32809” |
| Tennessee | “Knoxville, Tennessee, United States, 37920” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="topic-3.1.10.2-4"></a>

###### Recruitment and results status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2026-05-12” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.3"></a>

##### 3.1.10.3 Study Design

<a id="topic-3.1.10.3-1"></a>

###### Official title and design details in the ClinicalTrials.gov record

> “A Phase 1, Open Label, Single Dose Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of ESK001”

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

| Field | Quoted record |
| --- | --- |
| Other study ID numbers | “ESK-001-022” |
| Conditions | “Hepatic Impairment” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.4"></a>

##### 3.1.10.4 Eligibility Criteria

<a id="topic-3.1.10.4-1"></a>

###### Key inclusion and exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Inclusion, all participants | “Body mass index between 18.0 and 40.0 kg/m2” |
| Inclusion, hepatic impairment | “Diagnosis of chronic (> 6 months), stable hepatic impairment with no clinically significant changes within 30 days prior to dosing, as determined by medical history” |
| Exclusion, all participants | “Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg), or uncontrolled treated/untreated hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg), or resting pulse rate < 45 or > 100 bpm.” |
| Exclusion, healthy volunteers | “Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.” |
| Exclusion, healthy volunteers | “Positive hepatitis panel and/or positive human immunodeficiency virus test.” |
| Exclusion, hepatic impairment | “History of any uncontrolled or unstable renal, hematological, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator or designee, within 6 months prior to screening.” |
| Exclusion, hepatic impairment | “History or current diagnosis of uncontrolled or significant cardiac disease indicative of a significant risk of safety for participation in the study.” |
| Exclusion, hepatic impairment | “Liver function tests outside the appropriate reference ranges that are not consistent with hepatic dysfunction, as determined by the investigator or designee.” |
| Exclusion, hepatic impairment | “QTcF > 480 ms for males or > 490 ms for females at screening or check-in, as confirmed from the mean of the original value and 2 repeats.” |
| Ages eligible for study | “18 Years to 75 Years (Adult, Older Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.5"></a>

##### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Arm description |
| --- | --- |
| “Experimental: Healthy Volunteer” | “Up to 24 healthy volunteer participants will receive a single dose of ESK-001” |
| “Experimental: Mild Hepatic Impairment” | “8 participants with mild hepatic impairment will receive a single dose of ESK-001” |
| “Experimental: Moderate Hepatic Impairment” | “8 participants with moderate hepatic impairment will receive a single dose of ESK-001” |
| “Experimental: Severe Hepatic Impairment” | “8 participants with severe hepatic impairment will receive a single dose of ESK-001” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.6"></a>

##### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

###### 3.1.10.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.10.6.1-1"></a>

###### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Maximum observed plasma concentration (Cmax)” | “48 hours” |
| Primary | “Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]” | “48 hours” |
| Primary | “Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]” | “48 hours” |
| Secondary | “Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation” | “48 hours” |
| Secondary | “Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations” | “48 hours” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.7"></a>

##### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

###### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.10.7.1-1"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 32”

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="topic-3.1.10.7.1-2"></a>

###### Enrollment estimated at registration, April 2025, superseded in May 2026

> “Enrollment 48 [Estimated]”

Source: [ClinicalTrials.gov NCT06952634 version 1](https://clinicaltrials.gov/study/NCT06952634?tab=history&a=1)

<a id="heading-3.1.10.7.2"></a>

###### 3.1.10.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.10.8"></a>

##### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

###### 3.1.10.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.10.8.2"></a>

###### 3.1.10.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.10.8.3"></a>

###### 3.1.10.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.10.8.4"></a>

###### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.10.8.5"></a>

###### 3.1.10.8.5 Safety Results

No evidence found.

<a id="heading-3.1.10.9"></a>

##### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

###### Summary

- The hepatic impairment study has no posted results, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
- The design is open-label and non-randomized, with one dose of ESK-001 of unstated strength and a 48-hour outcome time frame.
- Actual enrollment was 32 participants, against 48 estimated at registration and a planned structure of up to 24 healthy volunteers and 8 participants each with mild, moderate, and severe hepatic impairment; the number enrolled in each group is not reported.

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634); [ClinicalTrials.gov NCT06952634 version 1](https://clinicaltrials.gov/study/NCT06952634?tab=history&a=1)

<a id="heading-3.1.11"></a>

#### 3.1.11 ESK-001-023

<a id="heading-3.1.11.1"></a>

##### 3.1.11.1 Objective

<a id="topic-3.1.11.1-1"></a>

###### Brief summary in the ClinicalTrials.gov record

> “This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe renal impairment.”

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.2"></a>

##### 3.1.11.2 Location and Study Date

<a id="topic-3.1.11.2-1"></a>

###### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-04-23”
> “Primary Completion (Actual) 2025-08-01”
> “Study Completion (Actual) 2025-08-01”
> “First Posted 2025-05-08”

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="topic-3.1.11.2-2"></a>

###### Start and completion dates estimated at registration, April 2025, superseded in December 2025

> “Study Start 2025-05-09 [Estimated]”
> “Primary Completion 2025-12 [Estimated]”
> “Study Completion 2025-12 [Estimated]”

Source: [ClinicalTrials.gov NCT06962774 version 1](https://clinicaltrials.gov/study/NCT06962774?tab=history&a=1)

<a id="topic-3.1.11.2-3"></a>

###### Sites in Florida in the ClinicalTrials.gov record

> “This study has 4 locations”

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

| Site | Quoted record |
| --- | --- |
| Florida | “Miami, Florida, United States, 33147” |
| Florida | “Miami Lakes, Florida, United States, 33014” |
| Florida | “Miami Lakes, Florida, United States, 33016” |
| Florida | “Orlando, Florida, United States, 32809” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="topic-3.1.11.2-4"></a>

###### Recruitment and results status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2025-12-10” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.3"></a>

##### 3.1.11.3 Study Design

<a id="topic-3.1.11.3-1"></a>

###### Official title and design details in the ClinicalTrials.gov record

> “A Phase 1, Open-label, Single-dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of ESK-001”

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

| Field | Quoted record |
| --- | --- |
| Other study ID numbers | “ESK-001-023” |
| Conditions | “Renal Impairment” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Single (Participant)” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.4"></a>

##### 3.1.11.4 Eligibility Criteria

<a id="topic-3.1.11.4-1"></a>

###### Key inclusion and exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Inclusion, all participants | “Body mass index between 18.0 and 40.0 kg/m2” |
| Inclusion, renal impairment | “Diagnosis of chronic, stable renal function in the 6 months prior to dosing, as determined by the investigator, based on medical history or eGFR, and not requiring dialysis” |
| Exclusion, all participants | “History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair are allowed).” |
| Exclusion, normal renal function | “-Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.” |
| Exclusion, renal impairment | “History of any uncontrolled or unstable hepatic, hematological, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator or designee, within 6 months prior to screening.” |
| Ages eligible for study | “18 Years to 75 Years (Adult, Older Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.5"></a>

##### 3.1.11.5 Treatment

<a id="topic-3.1.11.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Arm description |
| --- | --- |
| “Experimental: Healthy Volunteer” | “Up to 24 healthy volunteer participants will receive a single dose of ESK-001” |
| “Experimental: Mild Renal Impairment” | “8 participants with mild renal impairment will receive a single dose of ESK-001” |
| “Experimental: Moderate Renal Impairment” | “8 participants with moderate renal impairment will receive a single dose of ESK-001” |
| “Experimental: Severe Renal Impairment” | “8 participants with severe Renal impairment will receive a single dose of ESK-001” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.6"></a>

##### 3.1.11.6 Study Outcomes

<a id="heading-3.1.11.6.1"></a>

###### 3.1.11.6.1 Rationale for Using Pharmacokinetic Parameters and Adverse Event Incidence as the Primary Endpoints

<a id="topic-3.1.11.6.1-1"></a>

###### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Maximum observed plasma concentration (Cmax)” | “48 hours” |
| Primary | “Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation” | “48 hours” |
| Primary | “Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]” | “48 hours” |
| Primary | “Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]” | “48 hours” |
| Secondary | “Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations” | “48 hours” |

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="heading-3.1.11.7"></a>

##### 3.1.11.7 Statistical Analysis Description

<a id="heading-3.1.11.7.1"></a>

###### 3.1.11.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.11.7.1-1"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 16”

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)

<a id="topic-3.1.11.7.1-2"></a>

###### Enrollment estimated at registration, April 2025, superseded in December 2025

> “Enrollment 48 [Estimated]”

Source: [ClinicalTrials.gov NCT06962774 version 1](https://clinicaltrials.gov/study/NCT06962774?tab=history&a=1)

<a id="heading-3.1.11.7.2"></a>

###### 3.1.11.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.11.8"></a>

##### 3.1.11.8 Results

<a id="heading-3.1.11.8.1"></a>

###### 3.1.11.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.11.8.2"></a>

###### 3.1.11.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.11.8.3"></a>

###### 3.1.11.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.11.8.4"></a>

###### 3.1.11.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.11.8.5"></a>

###### 3.1.11.8.5 Safety Results

No evidence found.

<a id="heading-3.1.11.9"></a>

##### 3.1.11.9 Study Limitations

<a id="topic-3.1.11.9-1"></a>

###### Summary

- No pharmacokinetic or adverse event results of the renal impairment study have been posted, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
- Only participants were masked, allocation was non-randomized, and each participant received a single dose with outcomes assessed over 48 hours.
- Enrollment was 16 participants, against 48 estimated at registration, at four sites in Florida; the record plans 8 participants each with mild, moderate, and severe renal impairment but does not report how many were enrolled in each group, and participants requiring dialysis were not eligible.

Source: [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774); [ClinicalTrials.gov NCT06962774 version 1](https://clinicaltrials.gov/study/NCT06962774?tab=history&a=1)

<a id="heading-3.1.12"></a>

#### 3.1.12 ESK-001-002

<a id="heading-3.1.12.1"></a>

##### 3.1.12.1 Objective

<a id="topic-3.1.12.1-1"></a>

###### Official title in the ClinicalTrials.gov record

> “The Relative Bioavailability of an ESK-001 Tablet Versus Liquid Formulation, and the Effect of Food or Gastric Acid Reduction on the Pharmacokinetics of ESK-001 in Healthy Participants”

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-3.1.12.2"></a>

##### 3.1.12.2 Location and Study Date

<a id="topic-3.1.12.2-1"></a>

###### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-03-17”
> “Primary Completion (Actual) 2022-06-30”
> “Study Completion (Actual) 2022-09-20”
> “First Submitted 2022-03-30”
> “First Posted 2022-04-15”

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="topic-3.1.12.2-2"></a>

###### Completion dates estimated at registration, April 2022, superseded in September 2022

> “Primary Completion 2022-04 [Estimated]”
> “Study Completion 2022-04 [Estimated]”

Source: [ClinicalTrials.gov NCT05330858 version 1](https://clinicaltrials.gov/study/NCT05330858?tab=history&a=1)

<a id="topic-3.1.12.2-3"></a>

###### Site in Glendale, California, in the ClinicalTrials.gov record

> “This study has 1 location”
> “Alumis Central Site”

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

| Field | Quoted record |
| --- | --- |
| Location | “Glendale, California, United States, 91206” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="topic-3.1.12.2-4"></a>

###### Recruitment and results status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2023-05-09” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-3.1.12.3"></a>

##### 3.1.12.3 Study Design

<a id="topic-3.1.12.3-1"></a>

###### Design details in the ClinicalTrials.gov record

> “This is a single-center, in-house, open-label, crossover study in 15 healthy participants.”

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

| Field | Quoted record |
| --- | --- |
| Other study ID numbers | “ESK-001-002” |
| Conditions | “Pharmacokinetics” |
| Primary purpose | “Basic Science” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="topic-3.1.12.3-2"></a>

###### Four-period crossover with an 18-day stay in the clinical research unit in the registered description

> “This is a single-center, in-house, open-label, 4-period, partly randomized crossover study in 15 healthy participants. Each participant will receive a single ESK-001 dose on 4 occasions. Eligible participants will be admitted to the clinical research unit (CRU) on the day prior to the first study drug administration (Day 1, Period 1) and remain in the CRU for 18 days.”

Source: [ClinicalTrials.gov NCT05330858 version 1](https://clinicaltrials.gov/study/NCT05330858?tab=history&a=1)

<a id="heading-3.1.12.4"></a>

##### 3.1.12.4 Eligibility Criteria

<a id="topic-3.1.12.4-1"></a>

###### Inclusion and exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Inclusion: age and health | “Healthy Men and woman age 18-60” |
| Inclusion: consent | “Able to provide written informed consent” |
| Inclusion: pregnancy and lactation | “Females can not be pregnant or lactating” |
| Exclusion: prior exposure | “Prior exposure to ESK-001” |
| Exclusion: malignancy | “History of malignancy within the last 10 years” |
| Exclusion: viral infection | “Positive for HIV, Hepatitis B or C” |
| Exclusion: tuberculosis | “History of tuberculosis” |
| Exclusion: alcohol or drugs | “Positive test for alcohol or drugs” |
| Ages eligible for study | “18 Years to 60 Years (Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-3.1.12.5"></a>

##### 3.1.12.5 Treatment

<a id="topic-3.1.12.5-1"></a>

###### Liquid, fasted tablet, fed tablet, and tablet with rabeprazole arms in the ClinicalTrials.gov record

| Arm | Arm description |
| --- | --- |
| “Experimental: ESK-001 Liquid” | “ESK-001 administered as an oral liquid” |
| “Experimental: ESK-001 Tablet Fasted” | “ESK-001 administered as an oral tablet in the fasted state” |
| “Experimental: ESK-001 Tablet Fed” | “ESK-001 administered as an oral tablet in the fed state” |
| “Experimental: ESK-001 and Rabeprazole” | “ESK-001 administered as an oral tablet with rabeprazole” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-3.1.12.6"></a>

##### 3.1.12.6 Study Outcomes

<a id="heading-3.1.12.6.1"></a>

###### 3.1.12.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.12.6.1-1"></a>

###### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Measure description | Time frame |
| --- | --- | --- | --- |
| Primary | “Assess the PK parameters of ESK-001 via time of maximum plasma concentration (Tmax)” | “Relative bioavailability and food effect assessment via collection and comparison of PK plasma samples between dosing arms” | “18 Days” |
| Primary | “Assess the PK parameters of ESK-001 via maximum plasma concentration (Cmax)” | “Relative bioavailability and food effect assessment via collection and comparison of PK plasma samples between dosing arms” | “18 Days” |
| Primary | “Assess the PK parameters of ESK-001 via area under the concentration time curve (AUC)” | “Relative bioavailability and food effect assessment via collection and comparison of PK plasma samples between dosing arms” | “18 Days” |
| Secondary | “Assess the Incidence of Treatment Emergent Adverse Events of ESK-001” | “Collection and review of incidence of adverse events and serious adverse events” | “25 Days” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-3.1.12.7"></a>

##### 3.1.12.7 Statistical Analysis Description

<a id="heading-3.1.12.7.1"></a>

###### 3.1.12.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.12.7.1-1"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 14”

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="topic-3.1.12.7.1-2"></a>

###### Enrollment estimated at registration, April 2022, superseded in May 2023

> “Enrollment 15 [Estimated]”

Source: [ClinicalTrials.gov NCT05330858 version 1](https://clinicaltrials.gov/study/NCT05330858?tab=history&a=1)

<a id="heading-3.1.12.7.2"></a>

###### 3.1.12.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.12.8"></a>

##### 3.1.12.8 Results

<a id="heading-3.1.12.8.1"></a>

###### 3.1.12.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.12.8.2"></a>

###### 3.1.12.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.12.8.3"></a>

###### 3.1.12.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.12.8.4"></a>

###### 3.1.12.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.12.8.5"></a>

###### 3.1.12.8.5 Safety Results

No evidence found.

<a id="heading-3.1.12.9"></a>

##### 3.1.12.9 Study Limitations

<a id="topic-3.1.12.9-1"></a>

###### Summary

- The relative bioavailability, food effect, and gastric acid reduction comparisons (liquid, tablet fasted, tablet fed, and tablet with rabeprazole) have no posted results, and the report holds no published results; the ClinicalTrials.gov record reads “No Results Posted”.
- The study was a single-center, open-label crossover study; the registered description calls it partly randomized and plans 15 healthy participants, and actual enrollment was 14.
- Each participant received a single dose on 4 occasions, so the comparisons rest on single-dose pharmacokinetics in healthy adults aged 18 to 60 years.

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858); [ClinicalTrials.gov NCT05330858 version 1](https://clinicaltrials.gov/study/NCT05330858?tab=history&a=1)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
